Amgen (AMGN) 10-K 24 Feb 14 2013 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2013	Feb. 13, 2014	Jun. 30, 2013
Document and Entity Information [Abstract]	'	'	'
Entity Registrant Name	'AMGEN INC	'	'
Entity Central Index Key	'0000318154	'	'
Document Type	'10-K	'	'
Document Period End Date	31-Dec-13	'	'
Amendment Flag	'false	'	'
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Well-known Seasoned Issuer	'Yes	'	'
Entity Voluntary Filers	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Filer Category	'Large Accelerated Filer	'	'
Entity Public Float	'	'	$74,222,900,950
Entity Common Stock, Shares Outstanding	'	755,007,290	'

Document_and_Entity_Informatio1

Document and Entity Information (Parenthetical)	Jun. 30, 2013
Document and Entity Information [Abstract]	'
Shares of common stock held by directors and executive officers	624,964

Consolidated_Statements_of_Inc

Consolidated Statements of Income (USD $)	12 Months Ended
In Millions, except Per Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Revenues:	'	'	'
Product sales	$18,192	$16,639	$15,295
Other revenues	484	626	287
Total revenues	18,676	17,265	15,582
Operating expenses:	'	'	'
Cost of sales	3,346	3,199	2,708
Research and development	4,083	3,380	3,167
Selling, general and administrative	5,184	4,814	4,499
Other	196	295	896
Total operating expenses	12,809	11,688	11,270
Operating income	5,867	5,577	4,312
Interest expense, net	1,022	1,053	610
Interest and other income, net	420	485	448
Income before income taxes	5,265	5,009	4,150
Provision for income taxes	184	664	467
Net income	$5,081	$4,345	$3,683
Earnings per share:	'	'	'
Basic (in usd per share)	$6.75	$5.61	$4.07
Diluted (in usd per share)	$6.64	$5.52	$4.04
Shares used in the calculation of earnings per share:	'	'	'
Basic (in shares)	753	775	905
Diluted (in shares)	765	787	912

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Income (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Statement of Comprehensive Income [Abstract]	'	'	'
Net income	$5,081	$4,345	$3,683
Other comprehensive income (loss), net of reclassification adjustments and taxes:	'	'	'
Foreign currency translation losses	-80	-9	-1
Effective portion of cash flow hedges	2	-78	40
Net unrealized gains (losses) on available-for-sale securities	-226	63	-15
Other	-3	-1	-6
Other comprehensive income (loss), net of tax	-307	-25	18
Comprehensive income	$4,774	$4,320	$3,701

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Millions, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$3,805	$3,257
Marketable securities	15,596	20,804
Trade receivables, net	2,697	2,518
Inventories	3,019	2,744
Other current assets	2,250	1,886
Total current assets	27,367	31,209
Property, plant and equipment, net	5,349	5,326
Intangible assets, net	13,262	3,968
Goodwill	14,968	12,662
Restricted investments	3,412	0
Other assets	1,767	1,133
Total assets	66,125	54,298
Current liabilities:	'	'
Accounts payable	787	905
Accrued liabilities	4,655	4,791
Current portion of long-term debt	2,505	2,495
Total current liabilities	7,947	8,191
Long-term debt	29,623	24,034
Other noncurrent liabilities	6,459	3,013
Contingencies and commitments	'	'
Stockholders’ equity:	'	'
Common stock and additional paid-in capital; $0.0001 par value; 2,750.0 shares authorized; outstanding — 754.6 shares in 2013 and 756.3 shares in 2012	29,891	29,337
Accumulated deficit	-7,634	-10,423
Accumulated other comprehensive income (loss)	-161	146
Total stockholders’ equity	22,096	19,060
Total liabilities and stockholders’ equity	$66,125	$54,298

Consolidated_Balance_Sheets_Un

Consolidated Balance Sheets (Unaudited) (Parenthetical) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Statement of Financial Position [Abstract]	'	'
Common stock and additional paid-in capital, par value (in usd per share)	$0.00	$0.00
Common stock and additional paid-in capital, shares authorized	2,750,000,000	2,750,000,000
Common stock and additional paid-in capital, shares outstanding	754,600,000	756,300,000

Consolidated_Statements_of_Sto

Consolidated Statements of Stockholders' Equity (USD $)	Total	Number of shares of common stock [Member]	Common stock and additional paid-in capital [Member]	Accumulated deficit [Member]	Accumulated other comprehensive income (loss) [Member]
In Millions, unless otherwise specified	USD ($)		USD ($)	USD ($)	USD ($)
Beginning Balance at Dec. 31, 2010	$23,944	'	$27,299	($3,508)	$153
Beginning Balance, Shares at Dec. 31, 2010	'	932.1	'	'	'
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'	'	'	'
Net income	3,683	'	'	3,683	'
Other comprehensive income (loss), net of tax	18	'	'	'	18
Dividends	-787	'	'	-787	'
Issuance of common stock in connection with the Company’s equity award programs	230	'	230	'	'
Issuance of common stock in connection with the Company’s equity award programs, Shares	'	7.8	'	'	'
Stock-based compensation	337	'	337	'	'
Tax impact related to employee stock-based compensation	-89	'	-89	'	'
Repurchases of common stock	-8,307	'	'	-8,307	'
Repurchases of common stock, Shares	-144.3	-144.3	'	'	'
Ending Balance at Dec. 31, 2011	19,029	'	27,777	-8,919	171
Ending Balance, Shares at Dec. 31, 2011	'	795.6	'	'	'
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'	'	'	'
Net income	4,345	'	'	4,345	'
Other comprehensive income (loss), net of tax	-25	'	'	'	-25
Dividends	-1,187	'	'	-1,187	'
Issuance of common stock in connection with the Company’s equity award programs	1,288	'	1,288	'	'
Issuance of common stock in connection with the Company’s equity award programs, Shares	'	23	'	'	'
Stock-based compensation	359	'	359	'	'
Tax impact related to employee stock-based compensation	-87	'	-87	'	'
Repurchases of common stock	-4,662	'	'	-4,662	'
Repurchases of common stock, Shares	-62.3	-62.3	'	'	'
Ending Balance at Dec. 31, 2012	19,060	'	29,337	-10,423	146
Ending Balance, Shares at Dec. 31, 2012	756.3	756.3	'	'	'
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'	'	'	'
Net income	5,081	'	'	5,081	'
Other comprehensive income (loss), net of tax	-307	'	'	'	-307
Dividends	-1,521	'	'	-1,521	'
Issuance of common stock in connection with the Company’s equity award programs	296	'	296	'	'
Issuance of common stock in connection with the Company’s equity award programs, Shares	'	7.4	'	'	'
Stock-based compensation	400	'	400	'	'
Settlement of conversion value of convertible debt in excess of principal	-99	'	-99	'	'
Settlement of convertible note hedge	99	'	99	'	'
Settlement of warrants	-100	'	-100	'	'
Tax impact related to employee stock-based compensation	-42	'	-42	'	'
Repurchases of common stock	-771	'	'	-771	'
Repurchases of common stock, Shares	-9.1	-9.1	'	'	'
Ending Balance at Dec. 31, 2013	$22,096	'	$29,891	($7,634)	($161)
Ending Balance, Shares at Dec. 31, 2013	754.6	754.6	'	'	'

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Cash flows from operating activities:	'	'	'
Net income	$5,081	$4,345	$3,683
Depreciation and amortization	1,286	1,088	1,060
Stock-based compensation expense	403	362	341
Deferred income taxes	-189	28	-328
Property, plant and equipment impairments	19	178	6
Other items, net	84	-74	63
Changes in operating assets and liabilities, net of acquisitions:	'	'	'
Trade receivables, net	-38	348	-557
Inventories	-7	-150	-383
Other assets	-59	124	-204
Accounts payable	-184	161	-95
Accrued income taxes	-326	87	-20
Legal reserve	0	-780	780
Other liabilities	221	165	773
Net cash provided by operating activities	6,291	5,882	5,119
Cash flows from investing activities:	'	'	'
Purchases of property, plant and equipment	-693	-689	-567
Cash paid for acquisitions, net of cash acquired	-9,434	-2,390	-701
Purchases of marketable securities	-21,965	-26,241	-21,183
Proceeds from sales of marketable securities	19,123	17,372	20,871
Proceeds from maturities of marketable securities	5,090	1,994	749
Change in restricted investments, net	-520	0	0
Other	-70	-36	45
Net cash used in investing activities	-8,469	-9,990	-786
Cash flows from financing activities:	'	'	'
Net proceeds from issuance of debt	8,054	4,933	10,387
Repayment of debt	-3,371	-123	-2,500
Net proceeds from issuance of commercial paper	0	0	762
Repayments of commercial paper	0	0	-762
Repurchases of common stock	-832	-4,607	-8,315
Dividends paid	-1,415	-1,118	-500
Net proceeds from issuance of common stock in connection with the Company's equity award programs	296	1,288	242
Other	-6	46	12
Net cash provided by (used in) financing activities	2,726	419	-674
Increase (decrease) in cash and cash equivalents	548	-3,689	3,659
Cash and cash equivalents at beginning of period	3,257	6,946	3,287
Cash and cash equivalents at end of period	$3,805	$3,257	$6,946

Summary_of_significant_account

Summary of significant accounting policies	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Summary of significant accounting policies	'
	Summary of significant accounting policies
	Business
	Amgen Inc. (including its subsidiaries, referred to as “Amgen,” “the Company,” “we,” “our” or “us”) is a global biotechnology pioneer that discovers, develops, manufactures and delivers innovative human therapeutics. We operate in one business segment: human therapeutics.
	Principles of consolidation
	The consolidated financial statements include the accounts of Amgen as well as its majority-owned subsidiaries. We do not have any significant interests in any variable interest entities. All material intercompany transactions and balances have been eliminated in consolidation.
	Use of estimates
	The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States (GAAP) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results may differ from those estimates.
	Product sales
	Sales of our products are recognized when shipped and title and risk of loss have passed. Product sales are recorded net of accruals for estimated rebates, wholesaler chargebacks, discounts and other deductions (collectively “sales deductions”) and returns. Taxes collected from customers and remitted to government authorities related to the sales of the Company’s products, primarily in Europe, are excluded from revenues.
	With regard to EPOGEN® (epoetin alfa), we have the exclusive right to sell epoetin alfa for dialysis, certain diagnostics and all non-human, non-research uses in the United States. We granted to Ortho Pharmaceutical Corporation (which has assigned its rights under the product license agreement to Janssen Biotech, Inc.), a subsidiary of Johnson & Johnson (J&J), a license relating to epoetin alfa for sales in the United States for all human uses except dialysis and diagnostics. This license agreement, which is perpetual, may be terminated for various reasons, including upon mutual agreement of the parties, or default. The parties are required to compensate each other for epoetin alfa sales that either party makes into the other party’s exclusive market, sometimes referred to as “spillover.” Accordingly, we do not recognize product sales we make into the exclusive market of J&J and do recognize product sales made by J&J into our exclusive market. Sales in our exclusive market are derived from our sales to our customers, as adjusted for spillover. We are employing an arbitrated audit methodology to measure each party’s spillover based on estimates of and subsequent adjustments thereto of third-party data on shipments to and usage by end users.
	We recognize revenue from the sales of product to the U.S. federal government for stockpile in accordance with U.S. Securities and Exchange Commission (SEC) Interpretation, Commission Guidance Regarding Accounting for Sales of Vaccines and Bioterror Countermeasures to the Federal Government for Placement into the Pediatric Vaccine Stockpile or the Strategic National Stockpile (SNS). We recognized $155 million of revenue for NEUPOGEN® during the year ended December 31, 2013, for purchases by the government for the SNS. We are contracted to manage this inventory of product until the government requests shipment.
	Other revenues
	Other revenues consist primarily of royalty income and corporate partner revenues. Royalties from licensees are based on third-party sales of licensed products and are recorded in accordance with contract terms when third-party results are reliably measurable and collectability is reasonably assured. Royalty estimates are made in advance of amounts collected using historical and forecasted trends. Corporate partner revenues are comprised mainly of amounts earned from Kirin-Amgen, Inc. (K-A) and other third parties for certain research and development (R&D) activities, which are recognized as the R&D activities are performed, as well as our share of the U.S. pre-tax Nexavar® commercial profits generated from our collaboration with Bayer HealthCare Pharmaceuticals, Inc. (Bayer). Corporate partner revenues also include license fees and milestone payments earned from K-A and from other third parties. See Multiple-deliverable revenue arrangements, discussed below, Note 6, Collaborative arrangements, and Note 7, Related party transactions.
	Multiple-deliverable revenue arrangements
	From time to time, we enter into arrangements for the R&D, manufacture and/or commercialization of products and product candidates. These arrangements may require us to deliver various rights, services and/or goods across the entire life cycle of a product or product candidate, including (i) intellectual property rights/licenses, (ii) R&D services, (iii) manufacturing services and/or (iv) commercialization services. The underlying terms of these arrangements generally provide for consideration to Amgen in the form of non-refundable upfront license payments, R&D and commercial performance milestone payments, cost sharing and/or royalty payments.
	In arrangements involving the delivery of more than one element, each required deliverable is evaluated to determine whether it qualifies as a separate unit of accounting. For Amgen, this determination is generally based on whether the deliverable has “stand-alone value” to the customer. The arrangement’s consideration that is fixed and determinable is then allocated to each separate unit of accounting based on the relative selling price of each deliverable. The estimated selling price of each deliverable is determined using the following hierarchy of values: (i) vendor-specific objective evidence of fair value, (ii) third-party evidence of selling price and (iii) best estimate of selling price (BESP). The BESP reflects our best estimate of what the selling price would be if the deliverable was regularly sold by us on a stand-alone basis. In general, the consideration allocated to each unit of accounting is recognized as the related goods or services are delivered, limited to the consideration that is not contingent upon future deliverables. Consideration associated with at-risk substantive performance milestones is recognized as revenue upon the achievement of the related milestone, as defined in the respective contracts.
	Research and development costs
	R&D costs are expensed as incurred and include primarily salaries, benefits and other staff-related costs; facilities and overhead costs; clinical trial and related clinical manufacturing costs; contract services and other outside costs; information systems’ costs and amortization of acquired technology used in R&D with alternative future uses. R&D expenses also include costs and cost recoveries associated with third-party R&D arrangements such as with K-A, including upfront fees and milestones paid to third parties in connection with technologies which had not reached technological feasibility and did not have an alternative future use. Net payment or reimbursement of R&D costs is recognized when the obligations are incurred or as we become entitled to the cost recovery. See Note 6, Collaborative arrangements, and Note 7, Related party transactions.
	Selling, general and administrative costs
	Selling, general and administrative (SG&A) expenses are comprised primarily of salaries, benefits and other staff-related costs associated with sales and marketing, finance, legal and other administrative personnel; facilities and overhead costs; outside marketing, advertising and legal expenses; amortization of the U.S. healthcare reform federal excise fee; and other general and administrative costs. Advertising costs are expensed as incurred. SG&A expenses also include costs and cost recoveries associated with marketing and promotion efforts under certain collaboration arrangements. Net payment or reimbursement of SG&A costs is recognized when the obligations are incurred or we become entitled to the cost recovery. See Note 6, Collaborative arrangements.
	Stock-based compensation
	We have stock-based compensation plans under which various types of equity-based awards are granted, including restricted stock units (RSUs), performance units and stock options. The estimated fair values of RSUs and stock option awards which are subject only to service conditions with graded vesting are generally recognized as compensation expense on a straight-line basis over the service period. The estimated fair values of performance unit awards are generally recognized as compensation expense as the awards vest ratably from the grant date to the end of the performance period. See Note 3, Stock-based compensation.
	Income taxes
	We provide for income taxes based on pretax income, applicable tax rates and tax planning opportunities available in the various jurisdictions in which we operate. Deferred income taxes are recorded for the expected tax consequences of temporary differences between the basis of assets and liabilities for financial reporting purposes and amounts recognized for income tax purposes. We record a valuation allowance to reduce our deferred tax assets to the amount of future tax benefit that is more likely than not to be realized.
	We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by the taxing authorities based on the technical merits of the position. The tax benefit recognized in the financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized. The amount of unrecognized tax benefits (UTBs) is adjusted as appropriate for changes in facts and circumstances, such as significant amendments to existing tax law, new regulations or interpretations by the taxing authorities, new information obtained during a tax examination, or resolution of an examination. We recognize both accrued interest and penalties, where appropriate, related to UTBs in income tax expense. See Note 4, Income taxes.
	Business combinations
	Business combinations are accounted for using the acquisition method of accounting. Under the acquisition method, assets acquired, including in-process research and development (IPR&D) projects, and liabilities assumed are recorded at their respective fair values as of the acquisition date in our consolidated financial statements. The excess of the fair value of consideration transferred over the fair value of the net assets acquired is recorded as goodwill. Contingent consideration obligations incurred in connection with a business combination (including the assumption of an acquiree's liability arising from a business combination it consummated prior to our acquisition) are recorded at their fair values on the acquisition date and remeasured at their fair values each subsequent reporting period until the related contingencies are resolved. The resulting changes in fair values are recorded in earnings. See Note 2, Business combinations, and Note 16, Fair value measurement.
	Cash equivalents
	We consider cash equivalents to be only those investments which are highly liquid, readily convertible to cash and which mature within three months from the date of purchase.
	Available-for-sale investments
	We consider our investment portfolio available-for-sale and, accordingly, these investments are recorded at fair value with unrealized gains and losses generally recorded in other comprehensive income. Investments with maturities beyond one year, other than Restricted investments, may be classified as short-term marketable securities in the Consolidated Balance Sheets due to their highly liquid nature and because they represent the Company's investments that are available for current operations. See Note 9, Available-for-sale investments, and Note 16, Fair value measurement.
	Inventories
	Inventories are stated at the lower of cost or market. Cost, which includes amounts related to materials, labor and overhead, is determined in a manner that approximates the first-in, first-out method. See Note 10, Inventories.
	Derivatives
	We recognize all of our derivative instruments as either assets or liabilities at fair value in the Consolidated Balance Sheets. The accounting for changes in the fair value of a derivative instrument depends upon whether it has been formally designated and qualifies as part of a hedging relationship under the applicable accounting standards and, further, on the type of hedging relationship. For derivatives formally designated as hedges, we assess both at inception and quarterly thereafter, whether the hedging derivatives are highly effective in offsetting changes in either the fair value or cash flows of the hedged item. Our derivatives that are not designated and do not qualify as hedges are adjusted to fair value through current earnings. See Note 16, Fair value measurement, and Note 17, Derivative instruments.
	Property, plant and equipment, net
	Property, plant and equipment is recorded at historical cost, net of accumulated depreciation, amortization and, if applicable, impairment charges. We review our property, plant and equipment assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Depreciation is provided over the assets’ useful lives on a straight-line basis. Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or lease terms. See Note 11, Property, plant and equipment.
	Goodwill and other intangible assets
	Finite-lived intangible assets are recorded at cost, net of accumulated amortization and, if applicable, impairment charges. Amortization of finite-lived intangible assets is provided over their estimated useful lives on a straight-line basis. We review our finite-lived intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. See Note 12, Goodwill and other intangible assets.
	The estimated fair values of IPR&D projects acquired in a business combination which are not complete are capitalized and accounted for as indefinite-lived intangible assets until completion or abandonment of the related R&D efforts. Upon successful completion of the project, the capitalized amount is amortized over its estimated useful life. If a project is abandoned, all remaining capitalized amounts are written-off immediately. There are often major risks and uncertainties associated with IPR&D projects as we are required to obtain regulatory approvals in order to be able to market these products. Such approvals require completing clinical trials that demonstrate a product candidate is safe and effective. Consequently, the eventual realized value of the acquired IPR&D project may vary from its estimated fair value at the date of acquisition, and IPR&D impairment charges may occur in future periods.
	Capitalized IPR&D projects are tested for impairment annually and whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. We consider various factors for potential impairment including the current legal and regulatory environment and the competitive landscape. Adverse clinical trial results, significant delays in obtaining market approval and the inability to bring a product to market could result in the related intangible assets to be partially or fully impaired.
	We perform an impairment test of goodwill annually and whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. To date, an impairment of goodwill has not been recorded. See Note 12, Goodwill and other intangible assets.
	Restricted investments
	We have restricted investments on our Consolidated Balance Sheet that are owned by ATL Holdings Limited (ATL Holdings), a wholly-owned subsidiary. ATL Holdings is an entity distinct from the Company and its other subsidiaries, with separate assets and liabilities. Because a third party owns Class A preferred shares of ATL Holdings, this entity is required to hold restricted cash or investments. See Note 14, Financing arrangements.
	Contingencies
	In the ordinary course of business, we are involved in various legal proceedings and other matters such as intellectual property disputes, contractual disputes, governmental investigations and class action suits which are complex in nature and have outcomes that are difficult to predict. Certain of these proceedings are discussed in Note 18, Contingencies and commitments. We record accruals for loss contingencies to the extent that we conclude that it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. We consider all relevant factors when making assessments regarding these contingencies.
	While it is not possible to accurately predict or determine the eventual outcomes of these items, an adverse determination in one or more of these items currently pending could have a material adverse effect on our consolidated results of operations, financial position or cash flows.
	Foreign currency translation
	The net assets of international subsidiaries where the local currencies have been determined to be the functional currencies are translated into U.S. dollars using current exchange rates. The U.S. dollar effects that arise from translating net assets of these subsidiaries at changing rates are recognized in other comprehensive income. The earnings of these subsidiaries are translated into U.S. dollars using average exchange rates.
	Reclassifications
	Prior-period amounts for amortization of certain acquired intangible assets have been reclassified within Operating expenses in our Consolidated Statements of Income to conform to the current-period presentation.
	Recent accounting pronouncements
	In January 2013, we adopted a new accounting standard that requires additional disclosures regarding amounts that are reclassified out of accumulated other comprehensive income (AOCI). In accordance with the requirements of the standard, the effects of significant reclassifications out of AOCI, by component, on the respective lines in the Consolidated Statements of Income are presented in Note 15, Stockholders' equity. The standard was required to be applied prospectively beginning January 1, 2013.

Business_combinations

Business combinations	12 Months Ended
	Dec. 31, 2013
Business Combinations [Abstract]	'
Business combinations	'
	Business combinations
	Onyx Pharmaceuticals
	On October 1, 2013, we acquired all of the outstanding stock of Onyx Pharmaceuticals, Inc. (Onyx), a global biopharmaceutical company engaged in the development and commercialization of innovative therapies for improving the lives of people with cancer. Onyx has a multiple myeloma franchise, with Kyprolis® for Injection already approved in the United States, and with oprozomib being evaluated in clinical trials for patients with hematologic malignancies. In addition, Onyx has three partnered oncology assets: Nexavar® tablets (an Onyx and Bayer compound), Stivarga® tablets (a Bayer compound), and palbociclib (a Pfizer, Inc. (Pfizer) compound). This transaction, which was accounted for as a business combination, provides us with an opportunity to expand our oncology franchise. Onyx’s operations have been included in our consolidated financial statements commencing on the acquisition date.
	The aggregate consideration to acquire Onyx was paid in cash and consisted of (in millions):
	Total consideration transferred	$	9,515
	Compensation expense	197
	Total cash paid	$	9,712
	The $9,515 million cash payment consisted of a $9,184 million cash payment to the outstanding common stockholders and $331 million cash payment to the Onyx equity award holders for services rendered prior to October 1, 2013 under the Onyx equity award plans. The remaining $197 million of cash, which related to the accelerated vesting of the remaining Onyx equity awards, was recognized as compensation expense during the three months ended December 31, 2013. This amount was included primarily in Selling, general and administrative expense in the Consolidated Statement of Income.
	The consideration to acquire Onyx was preliminarily allocated to the acquisition date fair values of assets acquired and liabilities assumed as follows (in millions):
	Cash and cash equivalents	$	319
	Marketable securities	337
	Inventories	250
	Indefinite-lived intangible assets - IPR&D	1,160
	Finite-lived intangible assets - Developed product technology rights	5,910
	Finite-lived intangible assets - Licensing rights	2,792
	Goodwill	2,526
	Convertible debt	(742		)
	Assumed contingent consideration	(261		)
	Deferred income taxes, net	(2,918		)
	Other assets (liabilities), net	142
	Total consideration	$	9,515
	The developed product technology rights acquired relate to Kyprolis® which is approved in the U.S. This product technology is being amortized on a straight-line basis over the estimated useful life of 12 years.
	Licensing rights acquired represent the aggregate estimated fair values of receiving future milestone, royalty and/or profit sharing payments associated with various contract agreements that were entered into by Onyx prior to the acquisition. The weighted-average useful life of these finite-lived intangible assets is ten years and they are primarily being amortized on a straight-line basis.
	The fair value of the developed product technology rights and licensing rights acquired were determined by estimating the probability-weighted net cash flows attributable to these rights discounted to present value using a discount rate that represents the estimated rate that market participants would use to value this intangible asset.
	The estimated fair value of acquired IPR&D is related to: (i) the development of Kyprolis® in the territories outside the U.S. (excluding Japan), where regulatory approval to market the product has not been received, and (ii) oprozomib. The estimated fair values were determined using a probability-weighted income approach, which discounts expected future cash flows to present value using a discount rate that represents the estimated rate that market participants would use to value the assets. The projected cash flows from these projects were based on certain assumptions, including estimates of future revenues and expenses, the time and resources needed to complete development and the probabilities of obtaining marketing approval from regulatory agencies.
	We assumed contingent consideration obligations upon the acquisition of Onyx arising from Onyx's 2009 acquisition of Proteolix, Inc. There are two separate milestone payments of $150 million each which would be triggered if Kyprolis® receives specified marketing approvals for relapsed multiple myeloma on or before March 31, 2016, by each of the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The assumed contingent consideration value was determined by discounting probability-adjusted cash outflows to present value using a discount rate that represents the estimated rate that market participants would use.
	The excess of the acquisition date consideration over the fair values assigned to the assets acquired and the liabilities assumed of $2.5 billion was recorded as goodwill, which is not deductible for tax purposes and represents the future economic benefits arising from other assets acquired that could not be individually identified and separately recognized and the expected synergies and other benefits that we believe will result from combining the operations of Onyx with our operations.
	Our accounting for this acquisition is preliminary. The fair value estimates for the assets acquired and liabilities assumed were based upon preliminary calculations and valuations and our estimates and assumptions are subject to change as we obtain additional information for our estimates during the measurement period (up to one year from the acquisition date). The primary areas of those preliminary estimates that are not yet finalized relate to certain tangible assets and liabilities acquired, identifiable intangible assets and tax related items.
	We incurred $36 million of transaction-related expense which was recorded in Selling, general, and administrative expenses in the Consolidated Statement of Income for the year ended December 31, 2013.
	The following table presents supplemental pro forma information for the year ended December 31, 2013 and 2012, as if the acquisition of Onyx had occurred on January 1, 2012 (in millions, unaudited):
		2013				2012
	Pro forma net revenues	$	19,141			$	17,616
	Pro forma net income	4,848				3,700
	The unaudited pro forma consolidated results include pro forma adjustments that assume the acquisition occurred on January 1, 2012. The primary adjustments include: (i) the $197 million cash payment that was paid and recognized as compensation expense during the fourth quarter of 2013 related to the accelerated vesting of the remaining Onyx equity awards was included in the net income attributable to Amgen for the year ended December 31, 2012, and (ii) additional intangible amortization expense of $488 million and $412 million was included in the year ended December 31, 2013 and 2012, respectively. The adjustments also include the impact of additional interest expense on debt issued in connection with the acquisition of Onyx assuming the debt was incurred on January 1, 2012. The unaudited pro forma consolidated results are not necessarily indicative of what our consolidated results of operations actually would have been had we completed the acquisition on January 1, 2012. In addition, the unaudited pro forma consolidated results do not purport to project the future results of operations of the combined company nor do they reflect the expected realization of any cost savings associated with the acquisition.
	deCODE Genetics
	On December 10, 2012, we acquired for cash all of the outstanding stock of deCODE Genetics (deCODE), a privately held company that is a global leader in human genetics. The transaction provides us with an opportunity to enhance our efforts to identify and validate human disease targets. Consideration was allocated primarily to a finite-lived intangible asset of discovery capacity in the genetics of human diseases with an estimated useful life of 10 years.
	KAI Pharmaceuticals
	On July 5, 2012, we acquired for cash all of the outstanding stock of KAI Pharmaceuticals (KAI), a privately held biotechnology company that is developing velcalcetide (formerly AMG 416), its lead product candidate, which is in phase 3 clinical development for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease (CKD) who are on dialysis. The transaction provides us with an opportunity to further expand our nephrology pipeline. The acquired IPR&D is related to velcalcetide.
	Goodwill is attributable primarily to expected synergies and other benefits from combining KAI with our nephrology development and commercialization activities.
	Mustafa Nevzat Pharmaceuticals
	On June 12, 2012, we acquired for cash substantially all of the outstanding stock of Mustafa Nevzat Pharmaceuticals (MN), a privately held company that is a leading supplier of pharmaceuticals to the hospital sector and a major supplier of injectable medicines in Turkey. The transaction provides us with the opportunity to expand our presence in Turkey and the surrounding region.
	The finite-lived intangible assets acquired are related primarily to the fair values of MN's regulatory approvals and customer relationships with regard to the marketing of pharmaceutical products and are being amortized on a straight-line basis over their estimated useful lives. The weighted-average useful life of these intangible assets is eight years.
	Goodwill is attributable primarily to MN's expected continued commercial presence in Turkey and other benefits.
	Micromet, Inc.
	On March 7, 2012, we acquired for cash consideration Micromet, Inc. (Micromet), a publicly held biotechnology company focused on the discovery, development and commercialization of innovative antibody-based therapies for the treatment of cancer. This transaction provides us with an opportunity to further expand our oncology pipeline.
	The estimated fair value of acquired IPR&D is related to blinatumomab, which is in phase 3 clinical development for the treatment of acute lymphoblastic leukemia (ALL) and outlicense agreements entered into by Micromet prior to our acquisition of the company where we continue to play an active role in the development of the respective programs.
	During 2012, a non-key program under one of these outlicensing arrangements was terminated and resulted in an impairment charge of $19 million which was included in Other operating expenses.
	The R&D technology rights acquired relate to Micromet's BiTE® technology platform which has produced various product candidates that are currently being developed as cancer treatments by Micromet and others and may lead to the development of additional product candidates. The fair value of this technology is being amortized on a straight-line basis over its estimated useful life of 10 years.
	Goodwill is attributable primarily to expected synergies and other benefits from combining Micromet with our oncology development and commercialization activities.
	BioVex Group, Inc.
	On March 4, 2011, we acquired all of the outstanding stock of BioVex Group, Inc. (BioVex), a privately held biotechnology company developing treatments for cancer and for the prevention of infectious disease, including talimogene laherparepvec, a novel oncolytic vaccine in phase 3 clinical development for the treatment of melanoma. The transaction provides us with an opportunity to expand our efforts to bring novel therapeutics to market.
	The acquisition date consideration consisted of $407 million of cash and contingent consideration obligations with an aggregate acquisition date fair value of $190 million. The contingent consideration obligations are additional payments to be made to the former shareholders of BioVex of up to $575 million contingent upon the achievement of various regulatory and sales milestones with regard to talimogene laherparepvec, including the filing of a Biologics License Application (BLA) with the FDA; the first commercial sale in each of the United States and the European Union (EU) following receipt of marketing approval, which includes use of the product in specified patient populations; and upon achieving specified levels of sales. No payments have been made as of December 31, 2013.
	The contingent consideration obligations to make regulatory milestone payments were valued based on assumptions regarding the probability of achieving the milestones and making the related payments, with such amounts discounted to present value based on our credit risk. The contingent consideration obligations to make sales milestone payments were valued based on assumptions regarding the probability of achieving specified product sales thresholds to determine the required payments, with such amounts discounted to present value based on our credit risk. See Note 16, Fair value measurement for information regarding the estimated fair values of these obligations as of December 31, 2013.
	The estimated fair value of acquired IPR&D is related to talimogene laherparepvec. Goodwill is attributable primarily to future economic benefit arising from other assets acquired that could not be individually identified.
	The consideration to acquire deCODE, KAI, MN, Micromet, and BioVex was allocated to the acquisition date fair values of the assets acquired and liabilities assumed as follows (in millions):
			deCODE				KAI			MN			Micromet			BioVex
	IPR&D		$	—			$	240		$	—		$	570		$	675
	Developed product technology rights		—				—			81			—			—
	R&D technology rights		465				—			—			350			—
	Marketing-related rights		—				—			82			—			—
	Deferred income taxes, net		(37		)		(59		)	(45		)	(191		)	(246		)
	Other assets (liabilities), net		(29		)		26			179			170			(2		)
	Goodwill		—				125			380			247			170
Total consideration		$	399			$	332		$	677		$	1,146		$	597
deCODE’s preliminary goodwill estimate at December 31, 2012 has been revised primarily for adjustments of the preliminary amount allocated to the fair value of acquired R&D technology rights of $64 million based on finalizing our financial assumptions and net deferred tax adjustments of $43 million. Revisions to goodwill at December 31, 2012 for Micromet relate to net deferred tax adjustments of $83 million.
The estimated fair values of intangible assets were primarily determined using a probability-weighted income approach, which discounts expected future cash flows to present value by using a discount rate that represents the estimated rate that market participants would use to value this intangible asset. The projected cash flows were based on certain assumptions, including estimates of future revenues and expenses, the time and resources needed to complete development and the probabilities of obtaining marketing approval from the FDA and other regulatory agencies.
For all IPR&D projects in the acquisitions discussed above, including Onyx, there are major risks and uncertainties associated with the timely and successful completion of development and commercialization of these product candidates, including our ability to confirm their safety and efficacy based on data from clinical trials, our ability to obtain necessary regulatory approvals and our ability to successfully complete these tasks within budgeted costs. We are not able to market a human therapeutic without obtaining regulatory approvals, and such approvals require completing clinical trials that demonstrate a product candidate is safe and effective. Consequently, the eventual realized value, if any, of these acquired IPR&D projects may vary from their estimated fair values at the dates of acquisition.
Other acquisitions
We also acquired the businesses described below during 2011:
On April 7, 2011, we acquired all of the outstanding stock of Laboratório Químico Farmacêutico Bérgamo Ltda (Bergamo), a privately held Brazilian pharmaceutical company.
On May 16, 2011, we acquired a manufacturing facility in Dun Laoghaire, Ireland, from Pfizer. Under the terms of the agreement, most staff at the facility became Amgen employees, and we agreed to manufacture certain products for Pfizer at the facility for a certain period.
On June 15, 2011, we reacquired rights to distribute certain of our products in the Brazilian pharmaceutical market from our local distributor in Brazil and its parent company, Hypermarcas, and in connection therewith acquired all business operations related to these products in Brazil.
The aggregate acquisition date consideration for these businesses was approximately $453 million, composed primarily of cash paid to the former owners of the businesses. The aggregate acquisition date consideration was allocated to (i) goodwill of $265 million, of which $130 million related to Bergamo was tax deductible: (ii) property, plant and equipment of $99 million; (iii) amortizable intangible assets composed primarily of licenses to distribute products and customer contracts of $58 million; and (iv) other assets, net of $31 million. Goodwill resulting from these acquisitions is attributable primarily to the benefits of immediate, direct access to the Brazilian market for expediting our international expansion efforts and geographic diversification to assist in risk mitigation efforts related to our manufacturing operations.
The operations of each of the acquired businesses discussed above, excluding Onyx, were not material individually or in the aggregate to our consolidated financial statements. Pro forma supplemental consolidated results of operations that assumes the acquisitions of the businesses discussed above all occurred on January 1 of the year prior to the year of acquisition are not provided because the impact would not be material to our consolidated results of operations either individually or in the aggregate.
Results of operations from acquired companies have been included in our consolidated financial statements as of the acquisition date. The goodwill valued in these acquisitions, excluding Bergamo, is non-deductible for tax purposes.
Filgrastim and pegfilgrastim rights acquisition
In October 2013, we entered into an agreement to acquire the licenses to filgrastim and pegfilgrastim effective January 1, 2014, that were held by F. Hoffmann-La Roche Ltd. (“Roche”) in approximately 100 markets in Eastern Europe, Latin America, Asia, the Middle East and Africa, for total cash consideration of $479 million. This transaction will be accounted for as a business combination as the acquired rights and processes are capable of producing an immediate return to us. We are currently in the process of valuing the assets acquired and liabilities assumed in the business combination.

Stockbased_compensation

Stock-based compensation	12 Months Ended
	Dec. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Stock-based compensation	'
	Stock-based compensation
	On May 22, 2013, our stockholders approved our Amended and Restated 2009 Equity Incentive Plan (the Amended 2009 Plan), which amended and restated our 2009 Equity Incentive Plan (the 2009 Plan) and increased the number of shares of our common stock authorized for issuance pursuant to equity-based awards under the 2009 Plan to approximately 104 million shares (plus any additional shares that are added back into the authorized pool as described below). Like the 2009 Plan, the Amended 2009 Plan provides for grants of equity-based awards, including RSUs, stock options and performance units to employees and consultants of Amgen, its subsidiaries and non-employee members of our Board of Directors. The 2009 Plan replaced our prior equity plans (the Prior Plans), and no further awards may be made under these Prior Plans. Consistent with the 2009 Plan, the pool of shares available under the Amended 2009 Plan is reduced by one share for each stock option granted and by 1.9 shares for other types of awards granted, including RSUs and performance units (full-value awards). Generally, if any shares subject to an award granted under the Amended 2009 Plan expire, or are forfeited, terminated or cancelled without the issuance of shares, the shares subject to such awards are added back into the authorized pool on the same basis that they were removed. In addition, under the Amended 2009 Plan, shares withheld to pay for minimum statutory tax obligations with respect to full value awards will be added back into the authorized pool on the basis of 1.9 shares. As of December 31, 2013, the Amended 2009 Plan provides for future grants and/or issuances of up to approximately 58 million shares of our common stock. Stock-based awards under our employee compensation plans are made with newly issued shares reserved for this purpose.
	The following table reflects the components of stock-based compensation expense recognized in our Consolidated Statements of Income for the years ended December 31, 2013, 2012 and 2011 (in millions):
		2013				2012				2011
	RSUs	$	206			$	186			$	188
	Performance units	163				117				68
	Stock options	34				59				85
	Total stock-based compensation expense, pretax	403				362				341
	Tax benefit from stock-based compensation expense	(149		)		(134		)		(124		)
	Total stock-based compensation expense, net of tax	$	254			$	228			$	217
	Restricted stock units and stock options
	Eligible employees generally receive a grant of RSUs annually with the size and type of award generally determined by the employee’s salary grade and performance level. In addition, certain management and professional level employees typically receive RSU grants upon commencement of employment. Prior to 2012, eligible employees also received a grant of stock options annually. Prior to February 2013, non-employee members of our Board of Directors (outside directors) received a grant of RSUs and stock options annually and received a grant of stock options in connection with their appointment to the Board of Directors. Beginning in April 2013, outside directors receive only annual grants of RSUs.
	Our RSU and stock option grants provide for accelerated or continued vesting in certain circumstances as defined in the plans and related grant agreements, including upon death, disability, a change in control, termination in connection with a change in control and the retirement of employees who meet certain service and/or age requirements. RSUs and stock options granted prior to April 25, 2011, generally vest in equal amounts on each of the first four anniversaries of the grant date. Stock options and RSUs granted on and after April 25, 2011, generally vest in approximately equal amounts on the second, third and fourth anniversaries of the grant date. RSUs granted on and after April 27, 2012, accrue dividend equivalents which are typically payable in shares only when and to the extent the underlying RSUs vest and are issued to the recipient.
	Restricted stock units
	The grant date fair value of an RSU equaled the closing price of our common stock on the grant date for RSUs granted prior to April 25, 2011, and on and after April 27, 2012. Prior to April 2011, we did not have a policy of paying dividends, and beginning April 27, 2012, RSUs granted accrue dividend equivalents during the vesting period. The fair values of RSUs granted on April 25, 2011 through April 26, 2012, are based on the closing price of our common stock on the grant date reduced by the weighted-average expected dividend yield of 2.0% over the weighted-average vesting period, discounted at a weighted-average risk-free interest rate of 1.0%. The weighted-average grant date fair values of RSUs granted in 2013, 2012 and 2011 were $107.01, $72.99 and $51.83, respectively. The following summarizes select information regarding our RSUs during the year ended December 31, 2013:
		Units			Weighted-average
		(in millions)			grant date
					fair value
	Balance nonvested at December 31, 2012	9.4			$	61.14
	Granted	2.8			$	107.01
	Vested	(2.7	)		$	54.74
	Forfeited	(0.7	)		$	69.84
	Balance nonvested at December 31, 2013	8.8			$	76.75
	The total fair values of shares associated with RSUs that vested during the years ended December 31, 2013, 2012 and 2011, were $145 million, $139 million and $176 million, respectively.
	As of December 31, 2013, there was approximately $394 million of unrecognized compensation costs related to nonvested stock option and RSU awards, which is expected to be recognized over a weighted-average period of 1.8 years.
	Stock options
	The exercise price for stock options is set at the closing price of our common stock on the date of grant and the related number of shares granted is fixed at that point in time. Awards granted to employees on and after April 26, 2010, expire 10 years from the date of grant; options granted to employees prior to that date expire seven years from the date of grant.
	We use an option valuation model to estimate the grant date fair value of stock options. The weighted-average assumptions used in the option valuation model and the resulting weighted-average estimated grant date fair values of stock options were as follows for the years ended December 31, 2013, 2012 and 2011:
		2013				2012				2011
	Closing price of our common stock on grant date	$	85.59			$	74.56			$	54.66
	Expected volatility	23.1		%		22.2		%		23.5		%
	Expected life (in years)	8.1				8.1				5.9
	Risk-free interest rate	1.7		%		1.6		%		2.5		%
	Expected dividend yield	2.2		%		2.1		%		2		%
	Fair value of stock options granted	$	17.43			$	14.65			$	11.39
	The expected volatility reflects consideration of the implied volatility in publicly traded instruments associated with Amgen’s common stock during the period the options were granted. We believe implied volatility in these instruments is more indicative of expected future volatility than the historical volatility in the price of our common stock. We use historical data to estimate the expected life of the options. The risk-free interest rates for periods within the expected life of the option are based on the U.S. Treasury yield curve in effect during the period the options were granted. The expected dividend yield for options granted on and after April 25, 2011, was based on expectations regarding our policy of paying dividends announced in April 2011.
	The following summarizes select information regarding our stock options during the year ended December 31, 2013:
		Options			Weighted-				Weighted-		Aggregate
		(in millions)			average				average		intrinsic
					exercise price				remaining		value
									contractual		(in millions)
									life (years)
	Balance unexercised at December 31, 2012	12.3			$	56.09
	Granted	0.1			$	85.59
	Exercised	(4.7	)		$	58.05
	Expired/forfeited	(0.3	)		$	56.93
	Balance unexercised at December 31, 2013	7.4			$	54.91			4.8		$	436
	Vested or expected to vest at December 31, 2013	7.3			$	54.91			4.8		$	434
	Exercisable at December 31, 2013	4.8			$	53.95			3.7		$	291
	The total intrinsic values of options exercised during the years ended December 31, 2013, 2012 and 2011, were $210 million, $320 million and $47 million, respectively. The actual tax benefits realized from tax deductions from option exercises during the three years ended December 31, 2013, 2012 and 2011, were $77 million, $117 million and $14 million, respectively.
	Performance units
	Certain management-level employees also receive annual grants of performance units, which give the recipient the right to receive common stock that is contingent upon achievement of specified pre-established goals over the performance period, which is generally three years. The performance goals for the units granted in 2013, 2012 and 2011, which are accounted for as equity awards, are based upon Amgen’s stockholder return compared with a comparator group of companies, which are considered market conditions and are reflected in the grant date fair values of the units. The expense recognized for the awards is based on the grant date fair value of a unit multiplied by the number of units granted, net of estimated forfeitures. Depending on the outcome of these performance goals, a recipient may ultimately earn a number of units greater or less than the number of units granted. Shares of our common stock are issued on a one-for-one basis for each performance unit earned. In general, participants vest in their performance unit awards at the end of the performance period. The performance award program provides for accelerated or continued vesting in certain circumstances as defined in the plan, including upon death, disability, a change in control and retirement of employees who meet certain service and/or age requirements. Performance units granted in 2012 and later accrue dividend equivalents which are typically payable in shares only when and to the extent the underlying performance units vest and are issued to the recipient, including with respect to market conditions that affect the number of performance units earned.
	We used payout simulation models to estimate the grant date fair value of performance units granted in 2013, 2012 and 2011. The weighted-average assumptions used in these models and the resulting weighted-average grant date fair values of our performance units were as follows for the years ended December 31, 2013, 2012 and 2011:
		2013				2012				2011
	Closing price of our common stock on grant date	$	92.03			$	68.75			$	51.67
	Volatility	21		%		22.9		%		32.8		%
	Risk-free interest rate	0.4		%		0.5		%		1.2		%
	Fair value of unit	$	102.73			$	78.21			$	49.5
	The payout simulation models also assumed correlations of returns of the stock prices of our common stock and the common stocks of the comparator groups of companies and stock price volatilities of the comparator groups of companies.
	As of December 31, 2013 and 2012, a total of 6.6 million and 5.8 million performance units were outstanding with weighted-average grant date fair values of $76.95 and $65.15 per unit, respectively. During the year ended December 31, 2013, 2.1 million performance units with a weighted-average grant date fair value of $102.73 were granted, 2.4 million performance units with a weighted-average grant date fair value of $49.33 vested, and 0.5 million performance units with a weighted-average grant date fair value of $73.13 were forfeited.
	The total fair values of performance units that vested during 2013, 2012 and 2011 were $270 million, $100 million and $25 million, respectively, based upon the number of performance units earned multiplied by the closing stock price of our common stock on the last day of the performance period.
	As of December 31, 2013, there was approximately $173 million of unrecognized compensation cost related to the 2013 and 2012 performance unit grants that is expected to be recognized over a weighted-average period of approximately 0.9 years.

Income_taxes

Income taxes	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Income taxes	'
	Income taxes
	The provision for income taxes includes the following for the years ended December 31, 2013, 2012 and 2011 (in millions):
		2013				2012				2011
	Current provision:
	Federal	$	54			$	438			$	551
	State	26				47				54
	Foreign	191				158				148
	Total current provision	271				643				753
	Deferred provision (benefit):
	Federal	(86		)		83				(273		)
	State	19				(43		)		(12		)
	Foreign	(20		)		(19		)		(1		)
	Total deferred provision (benefit)	(87		)		21				(286		)
	Total provision	$	184			$	664			$	467
	Deferred income taxes reflect the tax effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes, tax credit carryforwards and the tax effects of net operating loss (NOL) carryforwards.
	Significant components of our deferred tax assets and liabilities are as follows as of December 31, 2013 and 2012 (in millions):
		2013				2012
	Deferred income tax assets:
	NOL and credit carryforwards	$	1,017			$	427
	Expense accruals	697				805
	Expenses capitalized for tax	196				195
	Stock-based compensation	211				115
	Deferred revenue	40				40
	Other	104				83
	Total deferred income tax assets	2,265				1,665
	Valuation allowance	(314		)		(273		)
	Net deferred income tax assets	1,951				1,392
	Deferred income tax liabilities:
	Acquired intangibles	(4,430		)		(1,249		)
	Fixed assets	(8		)		(117		)
	Unremitted foreign earnings	(55		)		(106		)
	Other	(200		)		(145		)
	Total deferred income tax liabilities	(4,693		)		(1,617		)
	Total deferred income taxes, net	$	(2,742	)		$	(225	)
	At December 31, 2013 and 2012, we had net noncurrent deferred tax liabilities of $3.5 billion and $0.9 billion, respectively, related primarily to the difference between the book basis and tax basis of intangible assets acquired in business combinations.  These amounts are included in Other noncurrent liabilities on the Consolidated Balance Sheets.
	Valuation allowances are provided to reduce the amounts of our deferred tax assets to an amount that is more likely than not to be realized based on an assessment of positive and negative evidence, including estimates of future taxable income necessary to realize future deductible amounts.
	The valuation allowance for deferred tax assets increased by $41 million and $147 million in 2013 and 2012, respectively, due primarily to valuation allowances established as part of acquisitions and the Company’s expectation that some state R&D credits will not be utilized.
	At December 31, 2013, we had $341 million of federal tax credit carryforwards available to reduce future federal income taxes and have provided a valuation allowance for $4 million of those federal tax credits. The federal tax credit carryforwards for which no valuation allowance has been provided expire between 2018 and 2033. We had $313 million of tax credit carryforwards available to reduce future state income taxes and have provided a valuation allowance for $202 million of those state tax credit carryforwards. The majority of the state tax credit carryforwards have no expiry; the remainder expires between 2018 and 2020.
	At December 31, 2013, we had $425 million of NOL carryforwards available to reduce future federal income taxes and have provided a valuation allowance for $80 million of those federal NOL carryforwards. The federal NOL carryforwards for which no valuation allowance has been provided expire between 2023 and 2033. We had $883 million of NOL carryforwards available to reduce future state income taxes and have provided a valuation allowance for $266 million of those state NOL carryforwards. The state NOLs for which no valuation allowance has been provided expire between 2014 and 2033. We had $1.3 billion of NOL carryforwards available to reduce future foreign income taxes and have provided a valuation allowance for $770 million of those foreign NOL carryforwards. The majority of the foreign NOLs have no expiry; the remainder of the foreign NOLs expire between 2014 and 2022.
	The reconciliation of the total gross amounts of UTBs (excluding interest, penalties, foreign tax credits and the federal tax benefit of state taxes related to UTBs) for the years ended December 31, 2013, 2012 and 2011 is as follows (in millions):
		2013				2012				2011
	Balance at beginning of year	$	1,200			$	975			$	920
	Additions based on tax positions related to the current year	335				300				283
	Additions based on tax positions related to prior years	96				5				1
	Reductions for tax positions of prior years	(192		)		(50		)		(8		)
	Settlements	(24		)		(30		)		(221		)
	Balance at end of year	$	1,415			$	1,200			$	975
	Substantially all of the UTBs as of December 31, 2013, if recognized, would affect our effective tax rate. During the year ended December 31, 2013, we settled our examination with the Internal Revenue Service (IRS) for the years ended December 31, 2007, 2008, and 2009. During the year ended December 31, 2012, we settled examinations with various state and foreign tax authorities for prior tax years. During the year ended December 31, 2011, we settled our examination with the IRS related to certain transfer pricing tax positions for the years ended December 31, 2007, 2008 and 2009. As a result of these developments, we remeasured our UTBs accordingly. As of December 31, 2013, we believe it is reasonably possible that our gross liabilities for UTBs may decrease by approximately $70 million within the succeeding twelve months due to the resolution of state audits.
	Interest and penalties related to UTBs are included in our provision for income taxes. During 2013, 2012 and 2011, we accrued approximately $32 million, $30 million and $23 million, respectively, of interest and penalties through the income tax provision in the Consolidated Statements of Income. At December 31, 2013 and 2012, accrued interest and penalties associated with UTBs totaled approximately $99 million and $102 million, respectively.
	The reconciliation between the federal statutory tax rate applied to income before income taxes and our effective tax rate for the years ended December 31, 2013, 2012 and 2011, is as follows:
		2013			2012			2011
	Federal statutory tax rate	35	%		35	%		35	%
	Foreign earnings, including earnings invested indefinitely	(21.3	)%		(17.8	)%		(19.4	)%
	Credits, Puerto Rico Excise Tax	(4.7	)%		(5.2	)%		(6.5	)%
	Credits, primarily federal R&D	(3.0	)%		—	%		(1.5	)%
	State taxes	0.8	%		0.6	%		0.7	%
	Audit settlements (federal, state, foreign)	(3.7	)%		0.3	%		—	%
	Legal settlements	—	%		(0.2	)%		2.2	%
	Other, net	0.4	%		0.6	%		0.8	%
	Effective tax rate	3.5	%		13.3	%		11.3	%
	The effective tax rates for the years ended December 31, 2013, 2012 and 2011, are different from the federal statutory rates primarily as a result of indefinitely invested earnings of our foreign operations. We do not provide for U.S. income taxes on undistributed earnings of our foreign operations that are intended to be invested indefinitely outside the United States. Substantially all of the benefit from foreign earnings on our effective tax rate results from foreign income associated with the Company’s operation conducted in Puerto Rico that is subject to a tax incentive grant that expires in 2020. At December 31, 2013, the cumulative amount of these earnings was approximately $25.5 billion. If these earnings were repatriated to the United States, we would be required to accrue and pay approximately $9.1 billion of additional income taxes based on the current tax rates in effect.
	Our total foreign income before income taxes was approximately $3.7 billion, $3.3 billion and $3.0 billion for the years ended December 31, 2013, 2012 and 2011, respectively.
	Puerto Rico imposes an excise tax on the gross intercompany purchase price of goods and services from our manufacturer in Puerto Rico. The rate was 4.0% in 2011, 3.75% in 2012, 2.75% in the first half of 2013 and 4.0% effective July 1, 2013 through December 31, 2017. We account for the excise tax as a manufacturing cost that is capitalized in inventory and expensed in cost of sales when the related products are sold. For U.S. income tax purposes, the excise tax results in foreign tax credits that are generally recognized in our provision for income taxes when the excise tax is incurred.
Because the American Taxpayer Relief Act of 2012 was not enacted until 2013, certain provisions of the Act benefiting the Company's 2012 federal taxes, including the retroactive extension of the R&D tax credit for 2012, were not recognized in the Company's 2012 financial results and instead are reflected in the Company's 2013 financial results. The tax benefit of the retroactive extension of the 2012 R&D tax credit that was recognized in 2013 was $70 million.
Income taxes paid during the years ended December 31, 2013, 2012 and 2011, totaled $321 million, $502 million and $595 million, respectively.
One or more of our legal entities file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions and certain foreign jurisdictions. Our income tax returns are routinely audited by the tax authorities in those jurisdictions. Significant disputes may arise with these tax authorities involving issues of the timing and amount of deductions, the use of tax credits and allocations of income among various tax jurisdictions because of differing interpretations of tax laws and regulations. We are no longer subject to U.S. federal income tax examinations for tax years ending on or before December 31, 2009, or to California state income tax examinations for tax years ending on or before December 31, 2005.

Earnings_per_share

Earnings per share	12 Months Ended
	Dec. 31, 2013
Earnings Per Share [Abstract]	'
Earnings per share	'
	Earnings per share
	The computation of basic earnings per share (EPS) is based on the weighted-average number of our common shares outstanding. The computation of diluted EPS is based on the weighted-average number of our common shares outstanding and dilutive potential common shares, which include principally shares that may be issued under: our stock option, restricted stock and performance unit awards, determined using the treasury stock method; and our convertible notes and warrants while outstanding (collectively “dilutive securities”). For further information regarding our convertible notes and warrants, see Note 14, Financing arrangements.
	The computation for basic and diluted EPS was as follows (in millions, except per share data):
		2013		2012		2011
	Income (Numerator):
	Net income for basic and diluted EPS	$	5,081	$	4,345	$	3,683
	Shares (Denominator):
	Weighted-average shares for basic EPS	753		775		905
	Effect of dilutive securities	12		12		7
	Weighted-average shares for diluted EPS	765		787		912
	Basic EPS	$	6.75	$	5.61	$	4.07
	Diluted EPS	$	6.64	$	5.52	$	4.04
	For the year ended December 31, 2013, the number of anti-dilutive employee stock-based awards excluded from the computation of diluted EPS was not significant. For the years ended December 31, 2012 and 2011, there were employee stock-based awards, calculated on a weighted-average basis, to acquire 6 million and 33 million shares of our common stock, respectively, that are not included in the computation of diluted EPS because their impact would have been anti-dilutive.

Collaborative_arrangements

Collaborative arrangements	12 Months Ended
	Dec. 31, 2013
Collaborative arrangements [Abstract]	'
Collaborative arrangements	'
	Collaborative arrangements
	A collaborative arrangement is a contractual arrangement that involves a joint operating activity which involves two or more parties who are both: (i) active participants in the activity; and (ii) exposed to significant risks and rewards dependent on the commercial success of the activity.
	From time to time, we enter into collaborative arrangements for the R&D, manufacture and/or commercialization of products and product candidates. These collaborations generally provide for non-refundable upfront license fees, development and commercial performance milestone payments, cost sharing, royalty payments and/or profit sharing. Our collaboration agreements are performed with no guarantee of either technological or commercial success and each is unique in nature. Our significant arrangements are discussed below.
	Pfizer Inc.
	The co-promotion term of our Enbrel® collaboration agreement with Pfizer in the United States and Canada expired on October 31, 2013. Under the collaboration agreement, Amgen and Pfizer shared in the agreed-upon selling and marketing expenses approved by a joint committee. We paid Pfizer a percentage of annual gross profits on our ENBREL sales in the United States and Canada on a scale that increased with gross profits; however, we maintained a majority share of ENBREL profits. Upon expiration of the co-promotion term, we are required to pay Pfizer residual royalties based on a declining percentage of annual net ENBREL sales in the United States and Canada for three years, ranging from 12% to 10%. The amounts of such payments are anticipated to be significantly less than what would be owed based on the terms of the previous ENBREL profit share. Effective November 1, 2016, there will be no further royalty payments.
	We determined that we were and continue to be the principal participant in the collaboration with Pfizer to market ENBREL in the United States and Canada. Accordingly, we recorded our product sales of ENBREL to third parties net of estimated returns, rebates and other deductions. For the years ended December 31, 2013, 2012 and 2011, ENBREL sales aggregated $4.6 billion, $4.2 billion and $3.7 billion, respectively.
	During the years ended December 31, 2013, 2012 and 2011, the aggregate net amounts due to Pfizer under this arrangement for the ENBREL profit share expense and royalties on ENBREL sales during the three months ended December 31, 2013, after the expiration of the co-promotion term, net of their share of selling and marketing expense was $1.3 billion, $1.3 billion and $1.1 billion, respectively. The amounts we pay to Pfizer are included in Selling, general and administrative expense in the Consolidated Statements of Income.
	Glaxo Group Limited
	We are in a collaboration with Glaxo Group Limited (Glaxo), a wholly owned subsidiary of GlaxoSmithKline plc, for the commercialization of denosumab for osteoporosis indications in Europe, Australia, New Zealand and Mexico (the Primary Territories). We have retained the rights to commercialize denosumab for all indications in the United States and Canada and for oncology indications in the Primary Territories. Under a related agreement, Glaxo will commercialize denosumab for all indications in countries, excluding Japan, where we did not have a commercial presence at the commencement of the agreement, including China, Brazil, India, Taiwan and South Korea (the Expansion Territories). In the Expansion Territories, Glaxo is responsible for all development and commercialization costs and will purchase denosumab from us to meet demand. We have the option of expanding our role in the commercialization of denosumab in the Primary Territories and certain of the Expansion Territories. In the Primary Territories, we share equally in the commercialization profits and losses related to the collaboration after accounting for expenses, including an amount payable to us in recognition of our discovery and development of denosumab. Glaxo is also responsible for bearing a portion of the cost of certain specified development activities in the Primary Territories.
	The collaboration agreement with Glaxo for the Primary Territories will expire in 2022 and the related agreement for the Expansion Territories will expire in 2024, unless either agreement is terminated earlier in accordance with its terms.
	As the principal participant in the Primary Territories, Amgen records related product sales to third parties net of estimated returns, rebates and other deductions. During the years ended December 31, 2013, 2012 and 2011, product sales in the Primary Territories for osteoporosis indications were $219 million, $139 million and $62 million, respectively. In the Expansion Territories, we record product sales to Glaxo. During the years ended December 31, 2013, 2012 and 2011, product sales of denosumab to Glaxo for the Expansion Territories were not material.
	During the year ended December 31, 2013, the net cost recoveries due to Glaxo were $16 million. During the years ended December 31, 2012 and 2011 the cost recoveries due from Glaxo were $10 million and $30 million, respectively. Cost recoveries are included in Selling, general and administrative expense in the Consolidated Statements of Income.
	AstraZeneca Plc.
	We are in a collaboration with AstraZeneca Plc. (AstraZeneca) to jointly develop and commercialize certain monoclonal antibodies from Amgen's clinical inflammation portfolio, including brodalumab, AMG 139, AMG 157, AMG 181 and AMG 557. The agreement covers the worldwide development and commercialization of these antibodies, except for certain Asian countries for brodalumab and Japan for AMG 557, which are licensed to other third parties.
	Under the terms of the agreement, approximately 65% of related development costs for the 2012-2014 periods will be funded by AstraZeneca, thereafter, the companies will share costs equally. If approved for sale, Amgen would receive a low-single-digit royalty rate for brodalumab and a mid-single-digit royalty rate for the rest of the portfolio, after which the worldwide commercialization profits and losses related to the collaboration products would be shared equally. In 2012, we received a payment of $50 million, in connection with the transfer of technology rights, which was recognized in Other revenues in the Consolidated Statement of Income. During the years ended December 31, 2013 and 2012, cost recoveries recognized for development costs were $194 million and $28 million, respectively, which are included in Research and development expense in the Consolidated Statements of Income.
	The collaboration agreement will continue in effect unless terminated in accordance with its terms.
	Takeda Pharmaceutical Company Limited
	In 2008, we entered into an arrangement with Takeda Pharmaceutical Company Limited (Takeda), that provided Takeda both: (i) the exclusive rights to develop and commercialize for the Japanese market up to 12 molecules, including Vectibix®, from our portfolio across a range of therapeutic areas, including oncology and inflammation (collectively the “Japanese market products”) and (ii) the right to collaborate with us on the worldwide (outside Japan) development and commercialization of our product candidate, motesanib. In 2011, we announced that the motesanib pivotal phase 3 trial (MONET1) had not met its primary objective of demonstrating an improvement in overall survival in patients with advanced non-squamous non small cell lung cancer.
	In June 2012, the parties materially modified this arrangement such that Amgen licensed all of its rights to motesanib to Takeda which now has control over the worldwide development and commercialization of motesanib. In exchange for licensing motesanib to Takeda, we received an additional upfront payment of $3 million and approximately $21 million in additional cost reimbursements. We may also receive substantive success-based regulatory approval milestones and royalties on global sales of motesanib, if approved for sale, that are substantially lower than those under the 2008 arrangement. As of the date of modification, $230 million of the up-front payments we received in 2008 remained in deferred revenue on the Consolidated Balance Sheet. This amount was recognized as Other revenues in 2012 upon modification of the arrangement and subsequent completion of the transfer of rights to motesanib.
	During the years ended December 31, 2013, 2012 and 2011, cost recoveries from Takeda were $34 million, $74 million and $83 million, respectively, and are included in Research and development expense in the Consolidated Statements of Income. In addition, for the years December 31, 2013, 2012 and 2011, we recognized royalties on sales of Vectibix® in Japan of $18 million, $21 million and $20 million respectively, in Other revenues in the Consolidated Statements of Income.
	UCB
	We are in a collaboration with UCB for the development and commercialization of romosozumab. We have the rights to commercialize romosozumab for all indications in the United States, Canada, Mexico and Japan. UCB has the rights for all EU members at the time of first regulatory approval, Australia and New Zealand. Prior to commercialization, countries that have not been initially designated will be designated to Amgen or UCB in accordance with the terms of the agreement.
	Generally, development costs are shared equally and we will share equally in the worldwide commercialization profits and losses related to the collaboration after accounting for expenses.
	The collaboration agreement will continue in effect unless terminated earlier in accordance with its terms.
	During the years ended December 31, 2013, 2012 and 2011, the net costs recovered from UCB were $66 million, $71 million, and $35 million, respectively, which are included in Research and development expense in the Consolidated Statements of Income.
	Bayer HealthCare Pharmaceuticals Inc.
	As a result of our acquisition of Onyx, we are now party to a collaboration with Bayer to jointly develop and commercialize Nexavar® worldwide, except in Japan. The rights to develop and market Nexavar® in Japan are reserved to Bayer. Bayer has no obligation to pay royalties to Amgen for sales of Nexavar® in Japan.
	Nexavar® is currently marketed and sold in more than 100 countries around the world for the treatment of unresectable liver cancer and advanced kidney cancer. In the United States, Nexavar® is also approved for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment. Under the related agreements, we are currently funding 50% of mutually agreed R&D costs worldwide, excluding Japan. In the United States, we co-promote Nexavar® with Bayer and share equally in the profits or losses. We contribute half of the overall number of sales force personnel required to market and promote Nexavar® and half of the medical science liaisons to support Nexavar® in the United States. In the United States, each party bears its own sales force and medical science liaison expenses which are not included in the calculation of the profits or losses of the collaboration. Outside of the United States, excluding Japan, Bayer manages all commercialization activities and incurs all of the sales and marketing expenditures, and we reimburse Bayer for half of those expenditures. In all countries outside of the United States, except Japan, we receive 50% of net profits on sales of Nexavar® after deducting certain Bayer-related costs.
	The collaboration with Bayer will terminate when patents expire that were issued in connection with product candidates discovered under the agreements, or at the time when neither we nor Bayer are entitled to profit sharing under the agreement, whichever happens last.
	Amgen is acting as an agent under the collaboration and as such, revenue is derived by calculating net sales of Nexavar® to third-party customers and deducting the cost of goods sold, distribution costs, marketing costs, phase 4 clinical trial costs, allocable overhead costs and certain other costs. During the fourth quarter of 2013, Amgen recorded a net Nexavar® collaboration profit of $78 million, which was recognized as Other revenues in the Consolidated Statements of Income. In addition, during the fourth quarter of 2013, net R&D expenses related to the collaboration of $13 million were recognized in the Consolidated Statements of Income.
	Other
	In addition to the collaborations discussed above, we have various others that are not individually significant to our business at this time. Pursuant to the terms of those agreements, we may be required to pay or we may receive additional amounts upon the achievement of various development and commercial milestones which in the aggregate could be significant. We may also incur or have reimbursed to us significant R&D costs if the related product candidate were to advance to late stage clinical trials. In addition, if any products related to these collaborations are approved for sale, we may be required to pay or we may receive significant royalties on future sales. The payment of these amounts, however, is contingent upon the occurrence of various future events, which have a high degree of uncertainty of occurring.

Related_party_transactions

Related party transactions	12 Months Ended
	Dec. 31, 2013
Related Party Transactions [Abstract]	'
Related party transactions	'
	Related party transactions
	We own a 50% interest in K-A, a corporation formed in 1984 with Kirin Holdings Company, Limited (Kirin) for the development and commercialization of certain products based on advanced biotechnology. All of our rights to manufacture and market certain products including pegfilgrastim, granulocyte colony-stimulating factor, darbepoetin alfa, recombinant human erythropoietin and romiplostim are pursuant to exclusive licenses from K-A, which we currently market under the brand names Neulasta®, NEUPOGEN®, Aranesp®, EPOGEN®, and Nplate®, respectively.
	We account for our interest in K-A using the equity method and include our share of K-A’s profits or losses in Selling, general and administrative expense in the Consolidated Statements of Income. Our share of K-A’s profits and losses was losses of $6 million and $24 million, and profit of $47 million, for the years ended December 31, 2013, 2012 and 2011, respectively. The carrying value of our equity method investment in K-A, net of dividends received, was approximately $0.3 billion and $0.4 billion, as of December 31, 2013 and 2012, respectively, and is included in noncurrent Other assets in the Consolidated Balance Sheets.
	K-A’s revenues consist of royalty income related to its licensed technology rights. K-A receives royalty income from us, as well as from Kirin and J&J under separate product license contracts for certain geographic areas outside the United States. During the years ended December 31, 2013, 2012 and 2011, K-A earned royalties from us of $272 million, $274 million and $298 million, respectively. These amounts are included in Cost of sales in the Consolidated Statements of Income.
	K-A’s expenses consist primarily of costs related to R&D activities conducted on its behalf by Amgen and Kirin. K-A pays Amgen and Kirin for such services at negotiated rates. During the years ended December 31, 2013, 2012 and 2011, we earned revenues from K-A of $117 million, $115 million and $130 million, respectively, for certain R&D activities performed on K-A’s behalf. These amounts are recognized as Other revenues in the Consolidated Statements of Income. We may also receive several individually immaterial milestones aggregating $85 million upon the achievement of various substantive success-based development and regulatory approval milestones contingent upon the occurrence of various future events, most of which have a high degree of uncertainty of occurring. During the years ended December 31, 2013, 2012 and 2011, we recorded cost recoveries from K-A of $218 million, $142 million and $85 million, respectively, related to certain third-party costs. These amounts are included in Research and development expense in the Consolidated Statements of Income.
	As of December 31, 2013 and 2012, K-A owed us $22 million and we owed K-A $31 million, respectively, which are included in Other current assets and Accrued liabilities in the Consolidated Balance Sheets, respectively.

Other_charges

Other charges	12 Months Ended
	Dec. 31, 2013
Restructuring and Related Activities [Abstract]	'
Other charges	'
	Other charges
	Manufacturing operations optimization
	In order to optimize our network of manufacturing facilities and improve cost effectiveness, we determined that certain manufacturing facilities located in Boulder, Colorado, were no longer needed and accordingly, they were abandoned during the fourth quarter of 2012. This resulted in the write-off of the carrying value of the facility, which aggregated $118 million, during the year ended December 31, 2012. The amount is included in Cost of sales in the Consolidated Statements of Income.
	On January 18, 2011, we entered into an agreement whereby Boehringer Ingelheim (BI) agreed to acquire our rights in and substantially all assets at our manufacturing facility located in Fremont, California. The transaction closed in March 2011. In connection with the closing of the transaction, BI assumed our obligations under certain of the facility’s operating lease contracts and entered into an agreement to manufacture certain quantities of our marketed product Vectibix® for us at this facility through December 31, 2012 (the supply period).
	These assets continued to be carried on our Consolidated Balance Sheets until the accounting requirements to recognize the sale were met, and estimated useful lives of the remaining fixed assets were reduced to coincide with the supply period. During each of the years ended December 31, 2012 and 2011, we recorded incremental depreciation of approximately $42 million in excess of what otherwise would have been recorded. In addition, due to the assignment to BI of the obligations under certain of the facility’s operating leases, we recorded charges of approximately $23 million during the year ended December 31, 2011, with respect to the lease period beyond the end of the supply period. These amounts were recorded in Cost of sales in the Consolidated Statements of Income.
	Other cost savings initiatives
	As part of our efforts to improve cost efficiencies in our operations, we recorded certain charges aggregating approximately $71 million, $175 million and $109 million during the years ended December 31, 2013, 2012 and 2011, respectively, which are included in Other operating expenses in the Consolidated Statements of Income. The expenses are primarily severance-related. The 2012 charges also included expenses associated with abandoning leased facilities.
	Legal settlement
	During the year ended December 31, 2011, we recorded a loss accrual of $780 million in connection with an agreement in principle to settle allegations relating to our sales and marketing practices arising out of previously disclosed federal civil and criminal investigations in the U.S. Attorney’s Offices for the Eastern District of New York and the Western District of Washington. This amount was recorded in Other operating expense in the Consolidated Statement of Income.

Availableforsale_investments

Available-for-sale investments	12 Months Ended
	Dec. 31, 2013
Investments, Debt and Equity Securities [Abstract]	'
Available-for-sale investments	'
	Available-for-sale investments
	The amortized cost, gross unrealized gains, gross unrealized losses and estimated fair values of available-for-sale investments by type of security were as follows (in millions):
	Type of security as of December 31, 2013	Amortized		Gross		Gross			Estimated
		cost		unrealized		unrealized			fair value
				gains		losses
	U.S. Treasury securities	$	4,737	$	2	$	(9	)	$	4,730
	Other government-related debt securities:
	U.S.	1,087		—		(8		)	1,079
	Foreign and other	1,574		13		(41		)	1,546
	Corporate debt securities:
	Financial	3,667		28		(19		)	3,676
	Industrial	3,745		36		(21		)	3,760
	Other	388		4		(2		)	390
	Residential mortgage-backed securities	1,478		3		(21		)	1,460
	Other mortgage- and asset-backed securities	1,555		1		(45		)	1,511
	Money market mutual funds	3,366		—		—			3,366
	Other short-term interest-bearing securities	750		—		—			750
	Total interest-bearing securities	22,347		87		(166		)	22,268
	Equity securities	85		10		—			95
	Total available-for-sale investments	$	22,432	$	97	$	(166	)	$	22,363
	Type of security as of December 31, 2012	Amortized		Gross		Gross			Estimated
		cost		unrealized		unrealized			fair value
				gains		losses
	U.S. Treasury securities	$	4,443	$	15	$	—		$	4,458
	Other government-related debt securities:
	U.S.	1,018		12		—			1,030
	Foreign and other	1,549		60		(1		)	1,608
	Corporate debt securities:
	Financial	3,266		96		(1		)	3,361
	Industrial	4,283		100		(3		)	4,380
	Other	441		11		—			452
	Residential mortgage-backed securities	1,828		9		(8		)	1,829
	Other mortgage- and asset-backed securities	1,769		7		(9		)	1,767
	Money market mutual funds	2,620		—		—			2,620
	Other short-term interest-bearing securities	2,186		—		—			2,186
	Total interest-bearing securities	23,403		310		(22		)	23,691
	Equity securities	52		2		—			54
	Total available-for-sale investments	$	23,455	$	312	$	(22	)	$	23,745
	The fair values of available-for-sale investments by classification in the Consolidated Balance Sheets were as follows (in millions):
	Classification in the Consolidated Balance Sheets	2013		2012
	Cash and cash equivalents	$	3,266	$	2,887
	Marketable securities	15,596		20,804
	Other assets — noncurrent	95		54
	Restricted investments	3,406		—
	Total available-for-sale investments	$	22,363	$	23,745
	Cash and cash equivalents in the table above excludes cash of $539 million and $370 million as of December 31, 2013 and 2012, respectively. On September 30, 2013, $2,881 million of marketable securities, $526 million of cash and cash equivalents and $4 million of related interest receivable were reclassified to Restricted investments on our Consolidated Balance Sheet, and these funds continue to be held in interest-bearing securities and cash. Restricted investments in the table above excludes interest receivable of $6 million as of December 31, 2013.
	The fair values of available-for-sale interest-bearing security investments by contractual maturity, except for mortgage- and asset-backed securities that do not have a single maturity date, were as follows (in millions):
	Contractual maturity	2013		2012
	Maturing in one year or less	$	6,799	$	7,175
	Maturing after one year through three years	4,785		5,014
	Maturing after three years through five years	6,057		6,286
	Maturing after five years through ten years	1,656		1,620
	Mortgage- and asset-backed securities	2,971		3,596
	Total interest-bearing securities	$	22,268	$	23,691
	For the years ended December 31, 2013, 2012 and 2011, realized gains totaled $158 million, $186 million and $191 million, respectively, and realized losses totaled $83 million, $54 million and $37 million, respectively. The cost of securities sold is based on the specific identification method. Most of our available-for-sale investments that were in an unrealized loss position, which totaled $166 million as of December 31, 2013, have been in a continuous unrealized loss position for less than 12 months. These investments had an aggregate fair value of $10.0 billion as of December 31, 2013.
	The primary objective of our investment portfolio is to enhance overall returns in an efficient manner while maintaining safety of principal, prudent levels of liquidity and acceptable levels of risk. Our investment policy limits interest-bearing security investments to certain types of debt and money market instruments issued by institutions with primarily investment grade credit ratings and places restrictions on maturities and concentration by asset class and issuer.
	We review our available-for-sale investments for other-than-temporary declines in fair value below our cost basis each quarter and whenever events or changes in circumstances indicate that the cost basis of an asset may not be recoverable. This evaluation is based on a number of factors including, the length of time and the extent to which the fair value has been below our cost basis and adverse conditions related specifically to the security, including any changes to the credit rating of the security. As of December 31, 2013 and 2012, we believe the cost bases for our available-for-sale investments were recoverable in all material respects.

Inventories

Inventories	12 Months Ended
	Dec. 31, 2013
Inventory Disclosure [Abstract]	'
Inventories	'
	Inventories
	Inventories consisted of the following (in millions):
		2013		2012
	Raw materials	$	217	$	192
	Work in process	2,064		1,723
	Finished goods	738		829
	Total inventories	$	3,019	$	2,744

Property_plant_and_equipment

Property, plant and equipment	12 Months Ended
	Dec. 31, 2013
Property, Plant and Equipment [Abstract]	'
Property, plant and equipment	'
	Property, plant and equipment
	Property, plant and equipment consisted of the following as of December 31, 2013 and 2012 (dollar amounts in millions):
		Useful life (in years)	2013			2012
	Land	—	$	408		$	412
	Buildings and improvements	Oct-40	3,467			3,510
	Manufacturing equipment	12-Aug	2,024			2,007
	Laboratory equipment	12-Aug	1,165			1,056
	Other	15-Mar	4,107			3,891
	Construction in progress	—	1,120			1,071
	Property, plant and equipment, gross		12,291			11,947
	Less accumulated depreciation and amortization		(6,942		)	(6,621		)
	Property, plant and equipment, net		$	5,349		$	5,326
	During the years ended December 31, 2013, 2012 and 2011, we recognized depreciation and amortization charges associated with our property, plant and equipment of $644 million, $689 million and $679 million, respectively.

Goodwill_and_intangible_assets

Goodwill and intangible assets	12 Months Ended
	Dec. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Goodwill and other intangible assets	'
	Goodwill and other intangible assets
	Goodwill
	The changes in the carrying amounts of goodwill for the years ended December 31, 2013 and 2012, were as follows (in millions):
		2013			2012
	Beginning balance	$	12,662		$	11,750
	Goodwill resulting from acquisitions of businesses	2,526			928
	Currency translation and other adjustments	(220		)	(16		)
	Ending balance	$	14,968		$	12,662
	Identifiable intangible assets
	Identifiable intangible assets consisted of the following as of December 31, 2013 and 2012 (in millions):
		2013								2012
		Gross			Accumulated			Intangible		Gross		Accumulated			Intangible
		carrying			amortization			assets, net		carrying		amortization			assets, net
		amount								amount
	Finite-lived intangible assets:
	Developed product technology rights	$	10,130		$	(3,347	)	$	6,783	$	4,220	$	(2,942	)	$	1,278
	Licensing rights	3,241			(366		)	2,875		445		(268		)	177
	R&D technology rights	1,207			(496		)	711		1,130		(411		)	719
	Marketing-related rights	619			(366		)	253		648		(313		)	335
	Total finite-lived intangible assets	15,197			(4,575		)	10,622		6,443		(3,934		)	2,509
	Indefinite-lived intangible assets:
	IPR&D	2,640			—			2,640		1,459		—			1,459
	Total identifiable intangible assets	$	17,837		$	(4,575	)	$	13,262	$	7,902	$	(3,934	)	$	3,968
	Developed product technology rights consist of rights related to marketed products acquired in business combinations. Licensing rights are composed primarily of intangible assets acquired as part of the acquisition of Onyx and capitalized payments to third parties for milestones related to regulatory approvals to commercialize products and up-front payments associated with royalty obligations for marketed products. R&D technology rights consist of technology used in R&D with alternative future uses. Marketing-related intangible assets are composed primarily of rights related to the sale and distribution of marketed products. For information related to the acquisition of certain of these intangible assets, see Note 2, Business combinations.
	IPR&D consists of R&D projects acquired in a business combination which are not complete due to remaining technological risks and/or the lack of receipt of the required regulatory approvals. These projects include Kyprolis®, a treatment for multiple myeloma being developed for use outside the U.S. (excluding Japan) acquired in the Onyx transaction; velcalcetide, a treatment for secondary hyperparathyroidism in patients with CKD who are on dialysis acquired in the KAI transaction; blinatumomab, a treatment for ALL acquired in the Micromet transaction, and talimogene laherparepvec, a treatment for melanoma acquired in the BioVex transaction (see Note 2, Business combinations).
	During the years ended December 31, 2013, 2012 and 2011, we recognized amortization charges associated with our finite-lived intangible assets of $642 million, $397 million and $380 million, respectively. The total estimated amortization for each of the next five years for our intangible assets is $1.2 billion, $1.2 billion, $1.2 billion, $1.1 billion and $902 million in 2014, 2015, 2016, 2017 and 2018, respectively.

Accrued_liabilities

Accrued liabilities	12 Months Ended
	Dec. 31, 2013
Payables and Accruals [Abstract]	'
Accrued liabilities	'
	Accrued liabilities
	Accrued liabilities consisted of the following as of December 31, 2013 and 2012 (in millions):
		2013		2012
	Sales deductions	$	1,248	$	1,129
	Employee compensation and benefits	1,003		1,010
	Clinical development costs	522		361
	Dividends payable	460		355
	Sales returns reserve	295		346
	Other	1,127		1,590
	Total accrued liabilities	$	4,655	$	4,791

Financing_arrangements

Financing arrangements	12 Months Ended
	Dec. 31, 2013
Debt Disclosure [Abstract]	'
Financing arrangements	'
	Financing arrangements
	The carrying values and the fixed contractual coupon rates of our long-term borrowings were as follows (in millions):
		2013				2012
	0.375% convertible notes due 2013 (0.375% 2013 Convertible Notes)	$	—			$	2,488
	1.875% notes due 2014 (1.875% 2014 Notes)	1,000				1,000
	4.85% notes due 2014 (4.85% 2014 Notes)	1,000				1,000
	2.30% notes due 2016 (2.30% 2016 Notes)	749				749
	2.50% notes due 2016 (2.50% 2016 Notes)	999				999
	2.125% notes due 2017 (2.125% 2017 Notes)	1,248				1,248
	5.85% notes due 2017 (5.85% 2017 Notes)	1,099				1,099
	6.15% notes due 2018 (6.15% 2018 Notes)	500				499
	Master Repurchase Agreement obligation due 2018	3,100				—
	Term Loan due 2018	4,875				—
	4.375% euro denominated notes due 2018 (4.375% 2018 euro Notes)	751				723
	5.70% notes due 2019 (5.70% 2019 Notes)	999				999
	2.125% euro denominated notes due 2019 (2.125% 2019 euro Notes)	925				887
	4.50% notes due 2020 (4.50% 2020 Notes)	300				300
	3.45% notes due 2020 (3.45% 2020 Notes)	898				897
	4.10% notes due 2021 (4.10% 2021 Notes)	998				998
	3.875% notes due 2021 (3.875% 2021 Notes)	1,746				1,745
	3.625% notes due 2022 (3.625% 2022 Notes)	747				747
	5.50% pound sterling denominated notes due 2026 (5.50% 2026 pound sterling Notes)	781				763
	4.00% pound sterling denominated notes due 2029 (4.00% 2029 pound sterling Notes)	1,144				1,117
	6.375% notes due 2037 (6.375% 2037 Notes)	899				899
	6.90% notes due 2038 (6.90% 2038 Notes)	499				499
	6.40% notes due 2039 (6.40% 2039 Notes)	996				996
	5.75% notes due 2040 (5.75% 2040 Notes)	697				697
	4.95% notes due 2041 (4.95% 2041 Notes)	596				595
	5.15% notes due 2041 (5.15% 2041 Notes)	2,233				2,232
	5.65% notes due 2042 (5.65% 2042 Notes)	1,244				1,244
	5.375% notes due 2043 (5.375% 2043 Notes)	1,000				1,000
	Other notes	105				109
	Total debt	32,128				26,529
	Less current portion	(2,505		)		(2,495		)
	Total noncurrent debt	$	29,623			$	24,034
	Debt repayments
	During the year ended December 31, 2013, our 0.375% 2013 Convertible Notes matured/converted, and the $2.5 billion principal amount was settled in cash. We also repaid $742 million of convertible debt assumed in the acquisition of Onyx, $125 million of principal on our Term Loan Credit Facility and $4 million of Other notes. During the year ended December 31, 2012, we repaid $123 million of Other notes. In February 2011, our 0.125% 2011 Convertible Notes became due, and we repaid the $2.5 billion aggregate principal amount.
	Debt issuances
	We issued debt and debt securities in various offerings during the three years ended December 31, 2013, including:
	•	In 2013, we issued $8.1 billion of debt in connection with the acquisition of Onyx, comprised of obligations under a Master Repurchase Agreement and a Term Loan.
	•	In 2012, we issued $5.0 billion aggregate principal amount of notes, comprised of the 2.125% 2017 Notes, the 2.125% 2019 euro Notes (€675 million aggregate principal amount), the 3.625% 2022 Notes, the 4.00% 2029 pound sterling Notes (£700 million aggregate principal amount) and the 5.375% 2043 Notes.
	•	In 2011, we issued $10.5 billion aggregate principal amount of notes, comprised of the 1.875% 2014 Notes, the 2.30% 2016 Notes, the 2.50% 2016 Notes, the 4.375% 2018 euro Notes (€550 million aggregate principal amount), the 4.10% 2021 Notes, the 3.875% 2021 Notes, the 5.50% 2026 pound sterling Notes (£475 million aggregate principal amount), the 5.15% 2041 Notes and the 5.65% 2042 Notes.
	Debt issuance costs incurred in connection with these debt issuances in 2013, 2012 and 2011 totaled $46 million, $25 million and $55 million, respectively. These debt issuance costs are being amortized over the respective lives of the debt, and the related charge is included in Interest expense, net, in the Consolidated Statements of Income.
	All of our notes other than our Other notes may be redeemed at any time at our option, in whole or in part, at the principal amount of the notes being redeemed plus accrued interest and a make-whole amount, as defined. In addition, except with respect to our 4.85% 2014 Notes and Other notes, in the event of a change-in-control triggering event, as defined, we may be required to purchase for cash all or a portion of these notes at a price equal to 101% of the principal amount of the notes plus accrued interest.
	Master Repurchase Agreement
	We entered into a Master Repurchase Agreement (Repurchase Agreement) pursuant to which Amgen sold 34,097 Class A preferred shares of one of its wholly-owned subsidiaries, ATL Holdings, on September 30, 2013. The Class A preferred shares have a liquidation preference of $100,000 per share. Pursuant to the Repurchase Agreement, we are obligated to repurchase the Class A preferred shares from the counterparties for the aggregate sale price of $3.1 billion, plus any accrued and unpaid payment obligations described below, on September 28, 2018. The $3.1 billion obligation to repurchase the preferred shares is accounted for as long-term debt on our Consolidated Balance Sheet.
	Under the Repurchase Agreement, we are obligated to make payments to the counterparties based on the sale price of the outstanding preferred shares at a floating interest rate based on the London Interbank Offered Rate (LIBOR) plus 1.1%. The Repurchase Agreement contains customary events of default, and we have the right to repurchase all or a portion of the Class A preferred shares at any time prior to the required repurchase date.
	Term Loan
	On October 1, 2013, we borrowed $5.0 billion under a Term Loan Credit Facility which bears interest at a floating rate based on LIBOR plus additional interest, initially 1%, which can vary based on the credit ratings assigned to our long-term debt by Standard & Poor’s Financial Services LLC (S&P) and Moody’s Investor Service, Inc. (Moody’s). A portion of the principal amount of this debt is to be repaid at the end of each quarter equal to $125 million, with the balance due on October 1, 2018. The outstanding balance of this loan may be prepaid in whole or in part at any time without penalty. This credit facility includes the same financial covenant as our revolving credit facility with respect to our level of borrowings in relation to our equity, as defined.
	Convertible Notes
	In 2006, we issued $2.5 billion principal amount of 0.375% 2013 Convertible Notes at par. The conversion value was payable in: (i) cash equal to the lesser of the principal amount of the note or the conversion value, as defined, and (ii) cash, shares of our common stock, or a combination of cash and shares of our common stock, at our option, to the extent the conversion value exceeded the principal amount of the note (the excess conversion value). In February 2013, our 0.375% 2013 Convertible Notes matured/converted, and accordingly, the $2.5 billion principal amount was settled in cash. We also elected to pay the note holders who converted their notes $99 million of cash for the excess conversion value, as allowed by the original terms of the notes.
	Concurrent with the issuance of the 0.375% 2013 Convertible Notes in February 2006, we purchased a convertible note hedge. The convertible note hedge allowed us to receive shares of our common stock and/or cash from the counterparty to the transaction equal to the amounts of common stock and/or cash related to the excess conversion value that we would issue and/or pay to the holders of the 0.375% 2013 Convertible Notes upon conversion. As a result of the conversion of the 0.375% 2013 Convertible Notes, we received $99 million of cash from the counterparty to offset the corresponding amount paid to the note holders.
	On May 1, 2013, warrants to acquire 32 million shares of our common stock at an exercise price of $104.80 originally sold in connection with the issuance of the 0.375% 2013 Convertible Notes were exercised resulting in a net cash payment of $100 million.
	Because the convertible note hedges and warrants could have been settled at our option in cash or shares of our common stock, and these contracts met all of the applicable criteria for equity classification under the applicable accounting standards, the cost of the convertible note hedges, the net proceeds from the sale of the warrants and the settlement of these contracts were classified in Stockholders’ equity in the Consolidated Balance Sheets. In addition, because both of these contracts are classified in Stockholders’ equity and were indexed to our common stock, they were not accounted for as derivatives.
	Because these convertible notes were cash settleable, their debt and equity components were bifurcated and accounted for separately. The discounted carrying value of the debt component resulting from the bifurcation was accreted back to the principal amount over the period the notes were outstanding, resulting in the recognition of non-cash interest expense. The total aggregate amount repaid, including the amount related to the debt discount, is included in Cash flows from financing activities in the Consolidated Statement of Cash Flows. After giving effect to this bifurcation, the effective interest rate on the 0.375% 2013 Convertible Notes was 6.35%. For the years ended December 31, 2013, 2012 and 2011, total interest expenses for the 0.375% 2013 Convertibles Notes were $13 million, $151 million and $143 million, respectively, including non-cash interest expenses of $12 million, $142 million and $133 million, respectively. The carrying amount of the equity component of this debt was $829 million as of December 31, 2013 and 2012.
	Other notes
	Other notes include our notes due in 2097 with carrying value of $100 million and debt assumed in the acquisition of MN with a carrying value of $5 million and $9 million at December 31, 2013 and 2012, respectively.
	Interest rate swaps
	To achieve a desired mix of fixed and floating interest rate debt, we entered into interest rate swap contracts that effectively converted a fixed-rate interest coupon for certain of our debt issuances to a floating LIBOR-based coupon over the life of the respective note. These interest rate swap contracts qualified and were designated as fair value hedges. During the year ended December 31, 2013, we entered into interest rate swap contracts with respect to certain of our outstanding notes. The effective interest rates on these notes after giving effect to the related interest rate swap contracts and the notional amounts of the contracts were as follows as of December 31, 2013 (dollar amounts in millions):
		Effective interest rate		Notional amount
	3.45% 2020 Notes	LIBOR + 1.1%		$	900
	4.10% 2021 Notes	LIBOR + 1.7%		1,000
	3.875% 2021 Notes	LIBOR + 2.0%		1,750
3.625% 2022 Notes	LIBOR + 1.6%		750
			$	4,400
We previously had interest rate swap contracts with an aggregate notional amount of $3.6 billion outstanding with rates that ranged from LIBOR plus 0.3% to LIBOR plus 2.6%. Due to historically low interest rates, we terminated all of these swap contracts in May 2012. See Note 17, Derivative instruments.
Cross-currency swaps
In order to hedge our exposure to foreign currency exchange rate risk associated with certain of our long-term notes denominated in foreign currencies, we entered into cross-currency swap contracts. The terms of these contracts effectively convert the interest payments and principal repayment on our 2.125% 2019 euro Notes, 5.50% 2026 pound sterling Notes and 4.00% 2029 pound sterling Notes from euros/pounds sterling to U.S. dollars. These cross-currency swap contracts have been designated as cash flow hedges. For information regarding the terms of these contracts, see Note 17, Derivative instruments.
Shelf registration statements and other facilities
As of December 31, 2013, we have a commercial paper program that allows us to issue up to $2.5 billion of unsecured commercial paper to fund our working capital needs. At December 31, 2013 and 2012, we had no amounts outstanding under our commercial paper program.
In December 2011, we entered into a $2.5 billion syndicated, unsecured, revolving credit agreement which is available for general corporate purposes or as a liquidity backstop to our commercial paper program. The commitments under the revolving credit agreement may be increased by up to $500 million with the agreement of the banks. Each bank which is a party to the agreement has an initial commitment term of five years. This term may be extended for up to two additional one-year periods with the agreement of the banks. Annual commitment fees for this agreement are 0.1% based on our current credit rating. Generally, we would be charged interest at LIBOR plus 0.9% for any amounts borrowed under this facility. As of December 31, 2013 and 2012, no amounts were outstanding under this facility.
In March 2011, we filed a shelf registration statement with the SEC to replace an existing shelf registration statement that was scheduled to expire in April 2011. This shelf registration statement allows us to issue unspecified amounts of debt securities; common stock; preferred stock; warrants to purchase debt securities, common stock, preferred stock or depository shares; rights to purchase common stock or preferred stock; securities purchase contracts; securities purchase units; and depository shares. Under this shelf registration statement, all of the securities available for issuance may be offered from time to time with terms to be determined at the time of issuance. This shelf registration statement expires in March 2014 and is expected to be renewed before its expiration date.
In 1997, we established a $400 million medium-term note program under which medium-term debt securities may be offered from time to time with terms to be determined at the time of issuance. As of December 31, 2013 and 2012, no securities were outstanding under this medium-term note program.
Certain of our financing arrangements contain non-financial covenants. In addition, our revolving credit agreement and Term Loan Credit Agreement each include a financial covenant with respect to the level of our borrowings in relation to our equity, as defined. We were in compliance with all applicable covenants under these arrangements as of December 31, 2013.
Contractual maturities of long-term debt obligations
The aggregate contractual maturities of all long-term debt obligations due subsequent to December 31, 2013, are as follows (in millions):
Maturity date	Amount
2014	$	2,505
2015	500
2016	2,250
2017	2,850
2018	7,228
Thereafter	16,873
Total	$	32,206
Interest costs
Interest costs are expensed as incurred, except to the extent such interest is related to construction in progress, in which case interest is capitalized. Interest expense, net, for the years ended December 31, 2013, 2012 and 2011, was $1.0 billion, $1.1 billion and $610 million, respectively. Interest costs capitalized for the years ended December 31, 2013, 2012 and 2011, were $18 million, $26 million and $22 million, respectively. Interest paid, net of interest rate swaps, during the years ended December 31, 2013, 2012 and 2011, totaled $930 million, $406 million and $446 million, respectively. Interest paid in 2012 is net of the $397 million received upon settlement of the interest rate swaps. See Note 17, Derivative instruments.

Stockholders_equity

Stockholders' equity	12 Months Ended
	Dec. 31, 2013
Equity [Abstract]	'
Stockholders' equity	'
	Stockholders’ equity
	Stock repurchase program
	Activity under our stock repurchase program was as follows (in millions):
		2013							2012							2011
		Shares			Dollars				Shares			Dollars				Shares		Dollars
	First quarter	9.1			$	771			21			$	1,429			—		$	—
	Second quarter	—			—				17.4			1,203				12.9		732
	Third quarter	—			—				9.7			797				45.4		2,421
	Fourth quarter	—			—				14.2			1,233				86		5,154		(1)
	Total stock repurchases	9.1			$	771			62.3			$	4,662			144.3		$	8,307
	___________
	-1	Includes the repurchase of 83.3 million shares of our common stock at an average price paid per share of $60.08, including related expenses, for an aggregate cost of $5.0 billion, under a modified Dutch auction tender offer.
	As of December 31, 2013, $1.6 billion remained available under our Board of Directors-approved stock repurchase program.
	Dividends
	On July 28 and October 13, 2011, the Board of Directors declared quarterly cash dividends of $0.28 per share of common stock, which were paid on September 8 and December 8, 2011, respectively. On December 15, 2011, and March 15, July 19 and October 10, 2012, the Board of Directors declared quarterly cash dividends of $0.36 per share of common stock, which were paid on March 7, June 7, September 7 and December 7, 2012, respectively. On December 13, 2012, March 6, July 26, and October 16, 2013, the Board of Directors declared quarterly cash dividends of $0.47 per share of common stock, which were paid on March 7, June 7, September 6, and December 6, 2013, respectively. Additionally, on December 13, 2013, the Board of Directors declared a quarterly cash dividend of $0.61 per share of common stock, which will be paid on March 7, 2014 to all stockholders of record as of the close of business on February 13, 2014.
	Accumulated other comprehensive income
	The components of AOCI were as follows (in millions):
		Foreign				Cash flow				Available-for-sale				Other			AOCI
		currency				hedges				securities
		translation
	Balance as of December 31, 2010	$	22			$	3			$	135			$	(7	)	$	153
	Foreign currency translation adjustments	(6		)		—				—				—			(6		)
	Unrealized gains (losses)	—				(51		)		125				2			76
	Reclassification adjustments to income	—				112				(154		)		—			(42		)
	Other	—				—				—				(8		)	(8		)
	Income taxes	5				(21		)		14				—			(2		)
	Balance as of December 31, 2011	21				43				120				(13		)	171
	Foreign currency translation adjustments	(13		)		—				—				—			(13		)
	Unrealized gains (losses)	—				15				233				(1		)	247
	Reclassification adjustments to income	—				(134		)		(132		)		—			(266		)
	Income taxes	4				41				(38		)		—			7
	Balance as of December 31, 2012	12				(35		)		183				(14		)	146
	Foreign currency translation adjustments	(71		)		—				—				—			(71		)
	Unrealized gains (losses)	—				88				(284		)		(1		)	(197		)
	Reclassification adjustments to income	—				(85		)		(75		)		—			(160		)
	Other	—				—				—				(2		)	(2		)
	Income taxes	(9		)		(1		)		133				—			123
	Balance as of December 31, 2013	$	(68	)		$	(33	)		$	(43	)		$	(17	)	$	(161	)
	Income tax expenses/benefits for unrealized gains and losses and the related reclassification adjustments to income for cash flow hedges were a $34 million expense and $33 million benefit in 2013, an $8 million expense and $49 million benefit in 2012 and a $20 million benefit and $41 million expense in 2011, respectively. Income tax expenses/benefits for unrealized gains and losses and the related reclassification adjustments to income for available-for-sale securities were a $105 million benefit and $28 million benefit for 2013, an $87 million expense and $49 million benefit in 2012 and a $45 million expense and $59 million benefit in 2011, respectively.
	The reclassifications out of AOCI to Net income were as follows (in millions):
			Amounts reclassified out of AOCI
	Components of AOCI		Year Ended December 31, 2013				Line item affected in the Statements of Income
	Cash flow hedges:
	Foreign currency contract gains		$	4			Product sales
	Cross-currency swap contract gains		82				Interest and other income, net
	Forward interest rate contract losses		(1		)		Interest expense, net
			85				Total before income tax
			(33		)		Tax (expense)
			52				Net of taxes
	Available-for-sale securities:
	Net realized gains (losses)		$	75			Interest and other income, net
			(28		)		Tax (expense)
			47				Net of taxes
	Other
	In addition to common stock, our authorized capital includes 5 million shares of preferred stock, $0.0001 par value. As of December 31, 2013 and 2012, no shares of preferred stock were issued or outstanding.

Fair_value_measurement

Fair value measurement	12 Months Ended
	Dec. 31, 2013
Fair Value Disclosures [Abstract]	'
Fair value measurement	'
	Fair value measurement
	To estimate the fair value of our financial assets and liabilities we use valuation approaches within a hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy is divided into three levels based on the source of inputs as follows:
	Level 1	—	Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access
	Level 2	—	Valuations for which all significant inputs are observable, either directly or indirectly, other than level 1 inputs
	Level 3	—	Valuations based on inputs that are unobservable and significant to the overall fair value measurement
	The availability of observable inputs can vary among the various types of financial assets and liabilities. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used for measuring fair value may fall into different levels of the fair value hierarchy. In such cases, for financial statement disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is categorized is based on the lowest level of input used that is significant to the overall fair value measurement.
	The fair value of each major class of the Company’s financial assets and liabilities measured at fair value on a recurring basis was as follows (in millions):
	Fair value measurement as of December 31, 2013, using:		Quoted prices in			Significant other		Significant		Total
			active markets for			observable		unobservable
			identical assets			inputs		inputs
			(Level 1)			(Level 2)		(Level 3)
	Assets:
	Available-for-sale investments:
	U.S. Treasury securities		$	4,730		$	—	$	—	$	4,730
	Other government-related debt securities:
	U.S.		—			1,079		—		1,079
	Foreign and other		—			1,546		—		1,546
	Corporate debt securities:
	Financial		—			3,676		—		3,676
	Industrial		—			3,760		—		3,760
	Other		—			390		—		390
	Residential mortgage-backed securities		—			1,460		—		1,460
	Other mortgage- and asset-backed securities		—			1,511		—		1,511
	Money market mutual funds		3,366			—		—		3,366
	Other short-term interest bearing securities		—			750		—		750
	Equity securities		95			—		—		95
	Derivatives:
	Foreign currency contracts		—			53		—		53
	Cross-currency swap contracts		—			193		—		193
	Total assets		$	8,191		$	14,418	$	—	$	22,609
	Liabilities:
	Derivatives:
	Foreign currency contracts		$	—		$	107	$	—	$	107
	Cross-currency swap contracts		—			4		—		4
	Interest rate swap contracts		—			161		—		161
	Contingent consideration obligations in connection with business combinations		—			—		595		595
	Total liabilities		$	—		$	272	$	595	$	867
	Fair value measurement as of December 31, 2012, using:		Quoted prices in			Significant  other		Significant		Total
			active markets for			observable		unobservable
			identical assets			inputs		inputs
			(Level 1)			(Level 2)		(Level 3)
	Assets:
	Available-for-sale investments:
	U.S. Treasury securities		$	4,458		$	—	$	—	$	4,458
	Other government-related debt securities:
	U.S.		—			1,030		—		1,030
	Foreign and other		—			1,608		—		1,608
	Corporate debt securities:
	Financial		—			3,361		—		3,361
	Industrial		—			4,380		—		4,380
	Other		—			452		—		452
	Residential mortgage-backed securities		—			1,829		—		1,829
	Other mortgage- and asset-backed securities		—			1,767		—		1,767
	Money market mutual funds		2,620			—		—		2,620
	Other short-term interest-bearing securities		—			2,186		—		2,186
	Equity securities		54			—		—		54
	Derivatives:
	Foreign currency contracts		—			46		—		46
	Cross-currency swap contracts		—			65		—		65
	Total assets		$	7,132		$	16,724	$	—	$	23,856
	Liabilities:
	Derivatives:
	Foreign currency contracts		$	—		$	59	$	—	$	59
Cross-currency swap contracts		—			6		—		6
Contingent consideration obligations in connection with a business combination		—			—		221		221
Total liabilities		$	—		$	65	$	221	$	286
The fair values of our U.S. Treasury securities, money market mutual funds and equity securities are based on quoted market prices in active markets with no valuation adjustment.
Most of our other government-related and corporate debt securities are investment grade with maturity dates of five years or less from the balance sheet date. Our other government-related debt securities portfolio is composed of securities with weighted-average credit ratings of A+ by S&P, Moody's or Fitch, Inc. (Fitch); and our corporate debt securities portfolio has a weighted-average credit rating of A- or equivalent by S&P or Fitch and BBB+ by Moody's. We estimate the fair values of these securities by taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income- and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities; issuer credit spreads; benchmark securities; and other observable inputs.
Our residential mortgage-, other mortgage- and asset-backed securities portfolio is composed entirely of senior tranches, with credit ratings of AAA by S&P, Moody's or Fitch. We estimate the fair values of these securities by taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income- and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities; issuer credit spreads; benchmark securities; prepayment/default projections based on historical data; and other observable inputs.
We value our other short-term interest-bearing securities at amortized cost, which approximates fair value given their near term maturity dates.
All of our foreign currency forward and option derivatives contracts have maturities of three years or less and all are with counterparties that have minimum credit ratings of A- or equivalent by S&P, Moody’s or Fitch. We estimated the fair values of these contracts by taking into consideration valuations obtained from a third-party valuation service that utilizes an income-based industry standard valuation model for which all significant inputs are observable, either directly or indirectly. These inputs include foreign currency rates, LIBOR cash and swap rates and obligor credit default swap rates. In addition, inputs for our foreign currency option contracts also include implied volatility measures. These inputs, where applicable, are at commonly quoted intervals. See Note 17, Derivative instruments.
Our cross-currency swap contracts are with counterparties that have minimum credit ratings of A- or equivalent by S&P, Moody’s or Fitch. We estimated the fair values of these contracts by taking into consideration valuations obtained from a third-party valuation service that utilizes an income-based industry standard valuation model for which all significant inputs are observable either directly or indirectly. These inputs include foreign currency exchange rates, LIBOR, swap rates, obligor credit default swap rates and cross-currency basis swap spreads. See Note 17, Derivative instruments.
Our interest rate swap contracts are with counterparties that have minimum credit ratings of A- or equivalent by S&P, Moody’s or Fitch. We estimated the fair values of these contracts by using an income-based industry standard valuation model for which all significant inputs were observable either directly or indirectly. These inputs included LIBOR, swap rates and obligor credit default swap rates.
Contingent consideration obligations
We have incurred contingent consideration obligations as the result of our acquisition of a business and upon the assumption of contingent consideration obligations incurred by an acquired company discussed below. These contingent consideration obligations are recorded at their estimated fair values, and we revalue these obligations each reporting period until the related contingencies are resolved. Changes in fair values of contingent consideration obligations are recognized in Other operating expenses in the Consolidated Statements of Income.
The changes in carrying amounts of contingent consideration obligations for the years ended December 31, 2013 and 2012, were as follows (in millions):
	2013			2012
Beginning balance	$	221		$	190
Additions from Onyx acquisition	261			—
Net changes in valuation	113			31
Ending balance	$	595		$	221
As a result of our acquisition of BioVex in March 2011, we are obligated to pay its former shareholders up to $575 million of additional consideration contingent upon achieving up to eight separate regulatory and sales-related milestones with regard to talimogene laherparepvec, which was acquired in the acquisition and is currently in phase 3 clinical development for the treatment of melanoma. The three largest of these potential payments are $125 million each, including the amount due if a BLA is filed with the FDA. Potential payments are also due upon the first commercial sale in each of the United States and the EU following receipt of marketing approval which includes use of the product in specified patient populations and upon achievement of specified levels of sales within specified periods of time. The fair value measurements of these obligations are based on significant unobservable inputs, including the estimated probabilities and timing of achieving the related regulatory and commercial events in connection with these milestones and, as applicable, estimated annual sales. Significant changes which increase or decrease the probabilities of achieving the related regulatory and commercial events, shorten or lengthen the time required to achieve such events, or increase of decrease estimated annual sales would result in corresponding increases or decreases in the fair values of these obligations, as applicable.
We estimate the fair values of the obligations to the former shareholders of BioVex by using a combination of probability-adjusted discounted cash flows, option pricing techniques and a simulation model of expected annual sales. Quarterly, management in our R&D and commercial sales organizations review key assumptions used in the fair value measurements of these obligations. In the absence of any significant changes in key assumptions, the changes in fair values of these contingent consideration obligations reflect the passage of time and changes in our credit risk adjusted rate used to discount obligations to present value. During the year ended December 31, 2013, there were increases in management's estimates of the probabilities of completing the BLA filing and receiving approval to market talimogene laherparepvec in specified patient populations in the United States and EU. Due primarily to these changes in key assumptions, the estimated aggregate fair value of the contingent consideration obligations increased by $113 million and $31 million in the years ended December 31, 2013 and 2012, respectively.
We assumed contingent consideration obligations of $261 million upon the acquisition of Onyx arising from Onyx's 2009 acquisition of Proteolix, Inc. See Note 2, Business combinations. As of December 31, 2013, there are two separate milestone payments of $150 million each which would be triggered if Kyprolis® receives specified marketing approvals for relapsed multiple myeloma on or before March 31, 2016, by each of the FDA and the EMA. The fair value measurements of these obligations are based on significant unobservable inputs, including the estimated probabilities and timing of achieving the related regulatory approvals. Significant changes which increase or decrease the probabilities of receiving regulatory approvals or shorten or lengthen the time required to achieve such approvals would result in corresponding increases or decreases in the fair values of these obligations. We estimate the fair values of contingent obligations to the former shareholders of Proteolix, Inc. by using probability-adjusted discounted cash flows. There was no significant change in the fair value of these contingent consideration obligations from the date of our acquisition of Onyx to December 31, 2013.
There have been no transfers of assets or liabilities between the fair value measurement levels, and there were no material remeasurements to fair value during the years ended December 31, 2013 and 2012, of assets and liabilities that are not measured at fair value on a recurring basis, except as discussed in Note 2, Business combinations, regarding the impairment of an intangible asset and Note 8, Other charges, regarding an impairment of fixed assets which were recognized during the year ended December 31, 2012.
Summary of the fair value of other financial instruments
Cash equivalents
The estimated fair values of cash equivalents approximate their carrying values due to the short-term nature of these financial instruments.
Borrowings
We estimated the fair value of our long-term debt (Level 2) by taking into consideration indicative prices obtained from a third-party financial institution that utilizes industry standard valuation models, including both income- and market-based approaches, for which all significant inputs are observable either directly or indirectly. These inputs include reported trades of and broker/dealer quotes on the same or similar securities; credit spreads; benchmark yields; foreign currency exchange rates, as applicable; and other observable inputs. As of December 31, 2013 and 2012, the aggregate fair values of our long-term debt were $33.5 billion and $29.9 billion, respectively, and the carrying values were $32.1 billion and $26.5 billion, respectively.

Derivative_instruments

Derivative instruments	12 Months Ended
	Dec. 31, 2013
Derivative Instruments and Hedging Activities Disclosure [Abstract]	'
Derivative instruments	'
	Derivative instruments
	The Company is exposed to foreign currency exchange rate and interest rate risks related to its business operations. To reduce our risks related to these exposures, we utilize or have utilized certain derivative instruments, including foreign currency forward, foreign currency option, cross-currency swap, forward interest rate and interest rate swap contracts. We do not use derivatives for speculative trading purposes.
	Cash flow hedges
	We are exposed to possible changes in the values of certain anticipated foreign currency cash flows resulting from changes in foreign currency exchange rates, associated primarily with our euro-denominated international product sales. Increases and decreases in the cash flows associated with our international product sales due to movements in foreign currency exchange rates are offset partially by the corresponding increases and decreases in our international operating expenses resulting from these foreign currency exchange rate movements. To further reduce our exposure to foreign currency exchange rate fluctuations on our international product sales, we enter into foreign currency forward and option contracts to hedge a portion of our projected international product sales primarily over a three-year time horizon, with, at any given point in time, a higher percentage of nearer-term projected product sales being hedged than in successive periods. As of December 31, 2013, 2012 and 2011, we had open foreign currency forward contracts with notional amounts of $4.0 billion, $3.7 billion and $3.5 billion, respectively, and open foreign currency option contracts with notional amounts of $516 million, $200 million and $292 million, respectively. These foreign currency forward and option contracts, primarily euro based, have been designated as cash flow hedges, and accordingly, the effective portions of the unrealized gains and losses on these contracts are reported in AOCI and reclassified to earnings in the same periods during which the hedged transactions affect earnings.
	To hedge our exposure to foreign currency exchange rate risk associated with certain of our long-term notes denominated in foreign currencies, we entered into cross-currency swap contracts. Under the terms of these contracts, we paid euros/pounds sterling and received U.S. dollars for the notional amounts at the inception of the contracts, and we exchange interest payments based on these notional amounts at fixed rates over the lives of the contracts in which we pay U.S. dollars and receive euros/pounds sterling. In addition, we will pay U.S. dollars to and receive euros/pounds sterling from the counterparties at the maturities of the contracts for these same notional amounts. The terms of these contracts correspond to the related hedged notes, effectively converting the interest payments and principal repayment on these notes from euros/pounds sterling to U.S. dollars. These cross-currency swap contracts have been designated as cash flow hedges, and accordingly, the effective portions of the unrealized gains and losses on these contracts are reported in AOCI and reclassified to earnings in the same periods during which the hedged debt affects earnings. The notional amounts and interest rates of our cross-currency swaps are as follows (notional amounts in millions):
			Foreign currency							U.S. dollars
	Hedged notes		Notional Amount				Interest rate			Notional Amount				Interest rate
	2.125% 2019 euro Notes		€	675			2.125	%		$	864			2.6	%
	5.50% 2026 pound sterling Notes		£	475			5.5	%		$	748			5.8	%
	4.00% 2029 pound sterling Notes		£	700			4	%		$	1,122			4.3	%
	In connection with the anticipated issuance of long-term fixed-rate debt, we occasionally enter into forward interest rate contracts in order to hedge the variability in cash flows due to changes in the applicable Treasury rate between the time we enter into these contracts and the time the related debt is issued. Gains and losses on such contracts, which are designated as cash flow hedges, are reported in AOCI and amortized into earnings over the lives of the associated debt issuances.
	The effective portion of the unrealized gain/(loss) recognized in other comprehensive income for our derivative instruments designated as cash flow hedges was as follows (in millions):
		Years ended December 31,
	Derivatives in cash flow hedging relationships	2013				2012				2011
	Foreign currency contracts	$	(44	)		$	(63	)		$	(25	)
	Cross-currency swap contracts	132				85				(26		)
	Forward interest rate contracts	—				(7		)		—
	Total	$	88			$	15			$	(51	)
	The location in the Consolidated Statements of Income and the effective portion of the gain/(loss) reclassified out of AOCI into earnings for our derivative instruments designated as cash flow hedges were as follows (in millions):
					Years ended December 31,
	Derivatives in cash flow hedging relationships		Statements of Income location		2013				2012				2011
	Foreign currency contracts		Product sales		$	4			$	74			$	(108	)
	Cross-currency swap contracts		Interest and other income, net		82				61				(3		)
	Forward interest rate contracts		Interest expense, net		(1		)		(1		)		(1		)
	Total				$	85			$	134			$	(112	)
	No portions of our cash flow hedge contracts are excluded from the assessment of hedge effectiveness, and the gains and losses of the ineffective portions of these hedging instruments were not material for the years ended December 31, 2013, 2012 and 2011. As of December 31, 2013, the amounts expected to be reclassified out of AOCI into earnings over the next 12 months are approximately $51 million of net losses on our foreign currency and cross-currency swap contracts and approximately $1 million of losses on forward interest rate contracts.
	Fair value hedges
	To achieve a desired mix of fixed and floating interest rates on our long-term debt, we enter into interest rate swap contracts, which qualified and are designated as fair value hedges. The terms of these interest rate swap contracts correspond to the related hedged debt instruments and effectively converted a fixed interest rate coupon to a floating LIBOR-based coupon over the lives of the respective notes. During the year ended December 31, 2013, we entered into interest rate swap contracts with an aggregate notional amount of $4.4 billion with respect to our 3.45% 2020 Notes, 4.10% 2021 Notes, 3.875% 2021 Notes and 3.625% 2022 Notes. The contracts have rates that range from three-month LIBOR plus 1.1% to three-month LIBOR plus 2.0%. In addition, we previously had interest rate swap contracts outstanding with an aggregate notional amount of $3.6 billion with respect to our 4.85% 2014 Notes, 5.85% 2017 Notes, 6.15% 2018 Notes and 5.70% 2019 Notes with rates that ranged from LIBOR 0.3% to LIBOR plus 2.6%. Due to historically low interest rates, in May 2012 we terminated all of these contracts resulting in the receipt of $397 million from the counterparties, which was included in Net cash provided by operating activities in the Consolidated Statements of Cash Flows. This amount is being recognized in Interest expense, net in the Consolidated Statements of Income over the remaining lives of the related debt issuances.
	For derivative instruments that are designated and qualify as fair value hedges, the unrealized gain or loss on the derivative resulting from the change in fair value during the period as well as the offsetting unrealized loss or gain of the hedged item resulting from the change in fair value during the period attributable to the hedged risk is recognized in current earnings. During the year ended December 31, 2013, we included the unrealized gains on the hedged debt of $161 million in the same line item, Interest expense, net, in the Consolidated Statement of Income, as the offsetting unrealized losses of $161 million on the related interest rate swap agreements. During the years ended December 31, 2012 and 2011, we included the unrealized losses on the hedged debt of $20 million and $182 million, respectively, in the same line item, Interest expense, net, in the Consolidated Statements of Income, as the offsetting unrealized gains of $20 million and $182 million, respectively, on the related interest rate swap agreements.
	Derivatives not designated as hedges
	We enter into foreign currency forward contracts that are not designated as hedging transactions to reduce our exposure to foreign currency fluctuations of certain assets and liabilities denominated in foreign currencies. These exposures are hedged on a month-to-month basis. As of December 31, 2013, 2012 and 2011, the total notional amounts of these foreign currency forward contracts were $999 million, $629 million and $389 million, respectively.
	The location in the Consolidated Statements of Income and the amount of gain/(loss) recognized in earnings for our derivative instruments not designated as hedging instruments were as follows (in millions):
					Years ended December 31,
	Derivatives not designated as hedging instruments		Statements of Income location		2013				2012				2011
	Foreign currency contracts		Interest and other income, net		$	15			$	19			$	(1	)
	The fair values of derivatives included in the Consolidated Balance Sheets were as follows (in millions):
		Derivative assets						Derivative liabilities
	31-Dec-13	Balance Sheet location		Fair value				Balance Sheet location		Fair value
	Derivatives designated as hedging instruments:
	Cross-currency swap contracts	Other current assets/ Other noncurrent assets		$	193			Accrued liabilities/ Other noncurrent liabilities		$	4
	Foreign currency contracts	Other current assets/ Other noncurrent assets		53				Accrued liabilities/ Other noncurrent liabilities		104
	Interest rate swap contracts	Other current assets/ Other noncurrent assets		—				Accrued liabilities/ Other noncurrent liabilities		161
	Total derivatives designated as hedging instruments			246						269
	Derivatives not designated as hedging instruments:
	Foreign currency contracts	Other current assets		—				Accrued liabilities		3
	Total derivatives not designated as hedging instruments			—						3
	Total derivatives			$	246					$	272
		Derivative assets						Derivative liabilities
	31-Dec-12	Balance Sheet location		Fair value				Balance Sheet location		Fair value
	Derivatives designated as hedging instruments:
	Cross-currency swap contracts	Other current assets/ Other noncurrent assets		65				Accrued liabilities/ Other noncurrent liabilities		6
	Foreign currency contracts	Other current assets/ Other noncurrent assets		45				Accrued liabilities/ Other noncurrent liabilities		58
	Total derivatives designated as hedging instruments			110						64
	Derivatives not designated as hedging instruments:
	Foreign currency contracts	Other current assets		1				Accrued liabilities		1
	Total derivatives not designated as hedging instruments			1						1
	Total derivatives			$	111					$	65
	Our derivative contracts that were in liability positions as of December 31, 2013, contain certain credit-risk-related contingent provisions that would be triggered if: (i) we were to undergo a change in control and (ii) our or the surviving entity’s creditworthiness deteriorates, which is generally defined as having either a credit rating that is below investment grade or a materially weaker creditworthiness after the change in control. If these events were to occur, the counterparties would have the right, but not the obligation, to close the contracts under early-termination provisions. In such circumstances, the counterparties could request immediate settlement of these contracts for amounts that approximate the then current fair values of the contracts. In addition, our derivative contracts are not subject to any type of master netting arrangement, and amounts due to or from a counterparty under these contracts may only be offset against other amounts due to or from the same counterparty if an event of default or termination, as defined, were to occur.
	The cash flow effects of our derivatives contracts for the three years ended December 31, 2013, are included within Net cash provided by operating activities in the Consolidated Statements of Cash Flows.

Contingencies_and_commitments

Contingencies and commitments	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Contingencies and commitments	'
	Contingencies and commitments
	Contingencies
	In the ordinary course of business, we are involved in various legal proceedings and other matters, including those discussed in this Note, that are complex in nature and have outcomes that are difficult to predict.
	We record accruals for loss contingencies to the extent that we conclude that it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. We evaluate, on a quarterly basis, developments in legal proceedings and other matters that could cause an increase or decrease in the amount of the liability that has been accrued previously.
	Our legal proceedings range from cases brought by a single plaintiff or defendant to class actions with thousands of putative class members. These legal proceedings, as well as other matters, involve various aspects of our business and a variety of claims (including but not limited to patent infringement, marketing, pricing and trade practices and securities law), some of which present novel factual allegations and/or unique legal theories. In each of the matters described in this filing, plaintiffs seek an award of a not-yet-quantified amount of damages or an amount that is not material. In addition, a number of the matters pending against us are at very early stages of the legal process (which in complex proceedings of the sort faced by us often extend for several years). As a result, none of the matters described in this filing have progressed sufficiently through discovery and/or development of important factual information and legal issues to enable us to estimate a range of possible loss, if any, or such amounts are not material. While it is not possible to accurately predict or determine the eventual outcomes of these items, an adverse determination in one or more of these items currently pending could have a material adverse effect on our consolidated results of operations, financial position or cash flows.
	Certain of our legal proceedings and other matters are discussed below:
	Sandoz Patent Litigation
	On June 24, 2013, Sandoz, Inc. filed suit in the U.S. District Court for the Northern District of California against Amgen and Roche. Sandoz's complaint alleges that Sandoz has initiated a Phase III clinical study of an etanercept product in patients with moderate to severe chronic plaque-type psoriasis and it intends to seek FDA regulatory approval to market and sell etanercept in the United States upon completion of the clinical trial. Sandoz seeks a declaratory judgment of non-infringement, invalidity and unenforceability of U.S. Patent Nos. 8,063,182 and 8,163,522. These patents are owned by Roche, and Amgen holds an exclusive license to these patents. The '182 and '522 patents expire in November 2028 and April 2029, respectively. On defendants’ motion, the court entered judgment dismissing the case for lack of subject matter jurisdiction on November 19, 2013. On December 12, 2013, Sandoz appealed the dismissal to the U.S. Court of Appeals for the Federal Circuit.
	Onyx Litigation
	Between August 28, 2013 and September 16, 2013, nine plaintiffs filed purported class action lawsuits against Onyx, its directors, Amgen and Arena Acquisition Company (Arena), and unnamed “John Doe” defendants in connection with Amgen’s acquisition of Onyx. Seven of those purported class actions were brought in the Superior Court of the State of California for the County of San Mateo, captioned Lawrence I. Silverstein and Phil Rosen v. Onyx Pharmaceuticals, Inc., et al. (August 28, 2013) (“Silverstein”), Laura Robinson v. Onyx Pharmaceuticals, Inc., et al. (originally filed in the Superior Court for the County of San Francisco on August 28, 2013, and re-filed in the Superior Court for the County of San Mateo on August 29, 2013) (“Robinson”), John Solak v. Onyx Pharmaceuticals, Inc., et al. (August 30, 2013), Louisiana Municipal Police Employees’ Retirement System and Hubert Chow v. Onyx Pharmaceuticals, Inc., et al. (September 3, 2013) (“Louisiana Municipal”), Laurine Jonopulos v. Onyx Pharmaceuticals, Inc., et al. (September 4, 2013) (“Jonopulos”), Clifford G. Martin v. Onyx Pharmaceuticals, Inc., et al. (September 9, 2013) (“Martin”) and Merrill L. Magowan v. Onyx Pharmaceuticals, Inc. et al. (September 9, 2013) (“Magowan”). The eighth and ninth purported class actions were brought in the Court of Chancery of the State of Delaware, captioned Mark D. Smilow, IRA v. Onyx Pharmaceuticals Inc., et al. (August 29, 2013) and William L. Fitzpatric v. Onyx Pharmaceuticals, Inc., et al. (September 16, 2013) (“Fitzpatric”). On September 5, 2013, the plaintiff in the John Solak case filed a request for dismissal of the case without prejudice. On September 10, 2013, the plaintiff in the Mark D. Smilow, IRA case filed a notice and proposed order of voluntary dismissal of the case without prejudice. On September 10, 2013, plaintiffs in the Silverstein and Louisiana Municipal cases filed an amended complaint alleging substantially the same claims and seeking substantially the same relief as in their individual purported class action lawsuits. Each of the lawsuits alleges that the Onyx director defendants breached their fiduciary duties to Onyx shareholders, and that the other defendants aided and abetted such breaches, by seeking to sell Onyx through an allegedly unfair process and for an unfair price and on unfair terms. The Magowan and Fitzpatric complaints and the amended complaint filed in the Silverstein and Louisiana Municipal cases also alleged that the individual defendants breached their fiduciary duties with respect to the contents of the tender offer solicitation material. Each of the lawsuits sought, among other things, rescission of the merger agreement and attorneys’ fees and costs, and certain of the lawsuits sought other relief. The Silverstein, Robinson, Louisiana Municipal and Jonopulos cases were designated as “complex” and assigned to the Honorable Marie S. Weiner, who subsequently entered an order consolidating the Silverstein, Robinson, Louisiana Municipal, Jonopulos, Martin and Magowan cases (the Consolidated Cases). On October 31, 2013, the plaintiffs in the Consolidated Cases filed a consolidated class action complaint seeking certification of a class and alleging breach of fiduciary duties of loyalty and good faith against the Onyx directors and aiding and abetting breach of fiduciary duties against Onyx. The complaint sought certification of a class of all Onyx shareholders, damages (including pre- and post-judgment interest), attorneys’ fees and expenses plus other relief. The plaintiffs in the Consolidated Cases simultaneously filed a notice of dismissal without prejudice of Amgen and Arena. Onyx and the Onyx directors filed demurrers to the consolidated class action complaint on November 22, 2013. Following a January 3, 2014 hearing, on January 9, 2014, the court entered an order overruling the demurrer on the breach of fiduciary duty of loyalty and good faith against the Onyx directors and sustained the demurrer without leave to amend against Onyx.
	Federal Securities Litigation - In re Amgen Inc. Securities Litigation
	The six federal class action stockholder complaints filed against Amgen Inc., Kevin W. Sharer, Richard D. Nanula, Dennis M. Fenton, Roger M. Perlmutter, Brian M. McNamee, George J. Morrow, Edward V. Fritzky, Gilbert S. Omenn and Franklin P. Johnson, Jr., (the Federal Defendants) in the U.S. District Court for the Central District of California (the California Central District Court) on April 17, 2007 (Kairalla v. Amgen Inc., et al.), May 1, 2007 (Mendall v. Amgen Inc., et al., & Jaffe v. Amgen Inc., et al.), May 11, 2007 (Eldon v. Amgen Inc., et al.), May 21, 2007 (Rosenfield v. Amgen Inc., et al.) and June 18, 2007 (Public Employees' Retirement Association of Colorado v. Amgen Inc., et al.) were consolidated by the California Central District Court into one action captioned In re Amgen Inc. Securities Litigation. The consolidated complaint was filed with the California Central District Court on October 2, 2007. The consolidated complaint alleges that Amgen and these officers and directors made false statements that resulted in: (i) deceiving the investing public regarding Amgen's prospects and business; (ii) artificially inflating the prices of Amgen's publicly traded securities and (iii) causing plaintiff and other members of the class to purchase Amgen publicly traded securities at inflated prices. The complaint also makes off-label marketing allegations that, throughout the class period, the Federal Defendants improperly marketed Aranesp® and EPOGEN® for off-label uses while aware that there were alleged safety signals with these products. The plaintiffs seek class certification, compensatory damages, legal fees and other relief deemed proper. The Federal Defendants filed a motion to dismiss on November 8, 2007. On February 4, 2008, the California Central District Court granted in part, and denied in part, the Federal Defendants' motion to dismiss the consolidated amended complaint. Specifically, the California Central District Court granted the Federal Defendants' motion to dismiss as to individual defendants Fritzky, Omenn, Johnson, Fenton and McNamee, but denied the Federal Defendants' motion to dismiss as to individual defendants Sharer, Nanula, Perlmutter and Morrow.
	A class certification hearing before the California Central District Court, was held on July 17, 2009, and on August 12, 2009, the California Central District Court granted plaintiffs' motion for class certification. On August 28, 2009, Amgen filed a petition for permission to appeal with the U.S. Court of Appeals for the Ninth Circuit (the Ninth Circuit Court) under Rule 23(f), regarding the Order on Class Certification and the Ninth Circuit Court granted Amgen's permission to appeal on December 11, 2009. On February 2, 2010, the California Central District Court granted Amgen's motion to stay the underlying action pending the outcome of the Ninth Circuit Court 23(f) appeal. On October 14, 2011, the appeal under Rule 23(f) was argued before the Ninth Circuit Court and on December 28, 2011, the Ninth Circuit Court denied the appeal. Amgen filed a petition for certiorari with the U.S. Supreme Court on March 3, 2012, and on June 11, 2012, the Court granted Amgen's petition. Oral argument occurred on November 5, 2012. On February 27, 2013, the U.S. Supreme Court affirmed the decision of the Ninth Circuit Court and remanded the case back to the California Central District Court for further proceedings. A revised July 28, 2015, trial date has been set by the California Central District Court.
	State Derivative Litigation
	Larson v. Sharer, et al.
	The three state stockholder derivative complaints filed against Amgen Inc., Kevin W. Sharer, George J. Morrow, Dennis M. Fenton, Brian M. McNamee, Roger M. Perlmutter, David Baltimore, Gilbert S. Omenn, Judith C. Pelham, Frederick W. Gluck, Jerry D. Choate, J. Paul Reason, Frank J. Biondi, Jr., Leonard D. Schaeffer, Frank C. Herringer, Richard D. Nanula, Willard H. Dere, Edward V. Fritzky, Franklin P. Johnson, Jr. and Donald B. Rice as defendants (the State Defendants) on May 1, 2007 (Larson v. Sharer, et al., & Anderson v. Sharer, et al.), and August 13, 2007 (Weil v. Sharer, et al.) in the Superior Court of the State of California, Ventura County (the Superior Court) were consolidated by the Superior Court under one action captioned Larson v. Sharer, et al. The consolidated complaint was filed on July 5, 2007. The complaint alleges that the State Defendants breached their fiduciary duties, wasted corporate assets, were unjustly enriched and violated the California Corporations Code. Plaintiffs allege that the State Defendants failed to disclose and/or misrepresented results of Aranesp® clinical studies, marketed both Aranesp® and EPOGEN® for off-label uses and that these actions or inactions caused stockholders to suffer damages. The complaints also allege insider trading by the State Defendants. The plaintiffs seek treble damages based on various causes of action, reformed corporate governance, equitable and/or injunctive relief, restitution, disgorgement of profits, benefits and other compensation, and legal costs.
	An amended consolidated complaint was filed on March 13, 2008, adding Anthony Gringeri as a State Defendant and removing the causes of action for insider selling and misappropriation of information, violation of California Corporations Code Section 25402 and violation of California Corporations Code Section 25403. On July 14, 2008, the Superior Court dismissed without prejudice the consolidated state derivative class action. The judge also ordered a stay of any re-filing of an amended complaint until the federal court has determined in the In re Amgen Inc. Securities Litigation action whether any securities fraud occurred. On July 3, 2013, the parties filed a stipulation to permit the plaintiffs to file an amended complaint asserting additional grounds for the defendants' alleged breaches of fiduciary duty.
	Federal Derivative Litigation
	On May 7, 2007, the stockholder derivative lawsuit of Durgin v. Sharer, et al., was filed in the California Central District Court and named Amgen Inc., Kevin W. Sharer, George J. Morrow, Dennis M. Fenton, Brian M. McNamee, Roger M. Perlmutter, David Baltimore, Gilbert S. Omenn, Judith C. Pelham, Frederick W. Gluck, Jerry D. Choate, J. Paul Reason, Frank J. Biondi, Jr., Leonard D. Schaeffer, Frank C. Herringer, Richard D. Nanula, Edward V. Fritzky and Franklin P. Johnson, Jr. as defendants. The complaint alleges the same claims and requests the same relief as in the three state stockholder derivative complaints now consolidated as Larson v. Sharer, et al. The case has been stayed for all purposes until thirty days after a final ruling on the motion to dismiss by the California Central District Court in the In re Amgen Inc. Securities Litigation action.
	On September 21, 2007, the stockholder derivative lawsuit of Rosenblum v. Sharer, et al., was filed in the California Central District Court. This lawsuit was brought by a stockholder who previously made a demand on the Amgen Board on May 14, 2007. The complaint alleges that the defendants breached their fiduciary duties, wasted corporate assets and were unjustly enriched. Plaintiffs allege that the defendants failed to disclose and/or misrepresented results of Aranesp® clinical studies, marketed both Aranesp® and EPOGEN® for off-label uses and that these actions or inactions as well as the Amgen market strategy caused damage to the Company resulting in several inquiries, investigations and lawsuits that are costly to defend. The complaint also alleges insider trading by the defendants. The plaintiffs seek treble damages based on various causes of action, reformed corporate governance, equitable and/or injunctive relief, restitution, disgorgement of profits, benefits and other compensation, and legal costs. The case was stayed for all purposes until thirty days after a final ruling on the motion to dismiss by the California Central District Court in the In re Amgen Inc. Securities Litigation action.
	Thereafter, on May 1, 2008, plaintiff in Rosenblum v. Sharer, et al., filed an amended complaint which removed Dennis Fenton as a defendant and also eliminated the claims for insider selling by defendants. On July 30, 2008, the California Central District Court granted Amgen and the defendants' motion to dismiss without prejudice and also granted a stay of the case pending resolution of the In re Amgen Inc. Securities Litigation action.
	ERISA Litigation
	On August 20, 2007, the ERISA class action lawsuit of Harris v. Amgen Inc., et al., was filed in the California Central District Court and named Amgen Inc., Kevin W. Sharer, Frank J. Biondi, Jr., Jerry Choate, Frank C. Herringer, Gilbert S. Omenn, David Baltimore, Judith C. Pelham, Frederick W. Gluck, Leonard D. Schaeffer, Jacqueline Allred, Raul Cermeno, Jackie Crouse, Lori Johnston, Michael Kelly and Charles Bell as defendants. Plaintiffs claim that Amgen and the individual defendants breached their fiduciary duties by failing to inform current and former employees who participated in the Amgen Retirement and Savings Plan and the Retirement and Savings Plan for Amgen Manufacturing Limited of the alleged off-label promotion of both Aranesp® and EPOGEN® while a number of studies allegedly demonstrated safety concerns in patients using ESAs. On February 4, 2008, the California Central District Court dismissed the complaint with prejudice as to plaintiff Harris, who had filed claims against Amgen Inc. The claims alleged by the second plaintiff, Ramos, were also dismissed but the court granted the plaintiff leave to amend his complaint. On February 1, 2008, the plaintiffs appealed the decision by the California Central District Court to dismiss the claims of both plaintiffs Harris and Ramos to the Ninth Circuit Court. On May 19, 2008, plaintiff Ramos in the Harris v. Amgen Inc., et al., action filed another lawsuit captioned Ramos v. Amgen Inc., et al., in the California Central District Court. The lawsuit is another ERISA class action. The Ramos v. Amgen Inc., et al., matter names the same defendants in the Harris v. Amgen Inc., et al., matter plus four new defendants: Amgen Manufacturing Limited, Richard Nanula, Dennis Fenton and the Fiduciary Committee. On July 14, 2009, the Ninth Circuit Court reversed the California Central District Court's decision in the Harris matter and remanded the case back to the California Central District Court. In the meantime, a third ERISA class action was filed by Don Hanks on June 2, 2009 in the California Central District Court alleging the same ERISA violations as in the Harris and Ramos lawsuits.
	On August 10, 2009, the Harris, Ramos and Hanks matters were consolidated by the California Central District Court into one action captioned Harris, et. al. v. Amgen Inc. On October 13, 2009, the California Central District Court granted plaintiffs Harris' and Ramos' motion to be appointed interim co-lead counsel. Plaintiffs filed an amended complaint on November 11, 2009 and added two additional plaintiffs, Jorge Torres and Albert Cappa. Amgen filed a motion to dismiss the amended/consolidated complaint, and on March 2, 2010, the California Central District Court dismissed the entire lawsuit without prejudice. Plaintiffs filed an amended complaint on March 23, 2010. Amgen then filed another motion to dismiss on April 20, 2010. On June 16, 2010, the California Central District Court entered an order dismissing the entire lawsuit with prejudice. On June 24, 2010, the plaintiffs filed a notice of appeal with the Ninth Circuit Court. On June 4, 2013, the Ninth Circuit Court reversed the decision of the California Central District Court and remanded the case back to the California Central District Court for further proceedings. On June 18, 2013, Amgen petitioned the Ninth Circuit Court for rehearing and/or rehearing en banc. The Ninth Circuit Court issued an amended opinion and denied Amgen’s petition for rehearing and rehearing en banc on October 23, 2013. Amgen moved for a stay of the mandate which the Ninth Circuit Court granted on November 5, 2013. A petition for certiorari was filed with the U.S. Supreme Court on January 21, 2014.
	Commitments
	We lease certain facilities and equipment related primarily to administrative, R&D, sales and marketing activities under non-cancelable operating leases that expire through 2032. The following table summarizes the minimum future rental commitments under non-cancelable operating leases as of December 31, 2013 (in millions):
	2014	$	140
	2015	125
	2016	114
	2017	95
	2018	86
	Thereafter	345
	Total minimum operating lease commitments	$	905
	Included in the table above are future rental commitments for abandoned leases in the amount of $293 million. Rental expense on operating leases for the years ended December 31, 2013, 2012 and 2011, was $125 million, $117 million and $131 million, respectively.

Segment_information

Segment information	12 Months Ended
	Dec. 31, 2013
Segment Reporting [Abstract]	'
Segment information	'
	Segment information
	We operate in one business segment — human therapeutics. Therefore, results of our operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting. Enterprise-wide disclosures about product sales; revenues and long-lived assets by geographic area; and revenues from major customers are presented below.
	Revenues
	Revenues were as follows for the years ended December 31, 2013, 2012 and 2011 (in millions):
		2013			2012			2011
	Product sales:
	Neulasta®	$	4,392		$	4,092		$	3,952
	NEUPOGEN®	1,398			1,260			1,260
	ENBREL	4,551			4,236			3,701
	Aranesp®	1,911			2,040			2,303
	EPOGEN®	1,953			1,941			2,040
	Sensipar®/Mimpara®	1,089			950			808
	Vectibix®	389			359			322
	Nplate®	427			368			297
	XGEVA®	1,019			748			351
	Prolia®	744			472			203
	Kyprolis®	73			—			—
	Other	246			173			58
	Total product sales	18,192			16,639			15,295
	Other revenues	484			626			287
	Total revenues	$	18,676		$	17,265		$	15,582
	Geographic information
	Outside the United States, we sell products principally in Europe and Canada. The geographic classification of product sales was based on the location of the customer. The geographic classification of all other revenues was based on the domicile of the entity from which the revenues were earned.
	Certain geographic information with respect to revenues and long-lived assets (consisting of property, plant and equipment) was as follows (in millions):
		Years ended December 31,
		2013			2012			2011
	Revenues:
	United States	$	14,480		$	13,415		$	11,985
	Rest of the world (ROW)	4,196			3,850			3,597
	Total revenues	$	18,676		$	17,265		$	15,582
		December 31,
		2013			2012
	Long-lived assets:
	United States	$	2,772		$	2,906
	Puerto Rico	1,822			1,908
	ROW	755			512
	Total long-lived assets	$	5,349		$	5,326
	Major customers
	In the United States, we sell primarily to pharmaceutical wholesale distributors. We utilize those wholesale distributors as the principal means of distributing our products to healthcare providers. In Europe, we sell principally to healthcare providers and/or pharmaceutical wholesale distributors depending on the distribution practice in each country. We monitor the financial condition of our larger customers, and we limit our credit exposure by setting credit limits and, for certain customers, may require letters of credit.
	We had product sales to three customers each accounting for more than 10% of total revenues for the years ended December 31, 2013, 2012 and 2011. For 2013, on a combined basis, these customers accounted for 75% and 93% of worldwide gross revenues and U.S. gross product sales, respectively, as noted in the following table. Certain information with respect to these customers for the years ended December 31, 2013, 2012 and 2011, was as follows (dollar amounts in millions):
		2013			2012			2011
	AmerisourceBergen Corporation:
	Gross product sales	$	8,527		$	7,556		$	7,574
	% of total gross revenues	35		%	34		%	36		%
	% of U.S. gross product sales	44		%	43		%	45		%
	McKesson Corporation:
	Gross product sales	$	6,440		$	5,898		$	4,591
	% of total gross revenues	27		%	27		%	22		%
	% of U.S. gross product sales	32		%	32		%	27		%
	Cardinal Health, Inc.:
	Gross product sales	$	3,209		$	3,245		$	3,021
	% of total gross revenues	13		%	15		%	14		%
	% of U.S. gross product sales	17		%	19		%	18		%
	At December 31, 2013 and 2012, amounts due from these three customers each exceeded 10% of gross trade receivables and accounted for 63% and 61%, respectively, of net trade receivables on a combined basis. At December 31, 2013 and 2012, 35% and 36%, respectively, of trade receivables, net were due from customers located outside the United States, primarily in Europe. Our total allowance for doubtful accounts as of December 31, 2013 and 2012, was not material.

Quarterly_financial_data

Quarterly financial data	12 Months Ended
	Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract]	'
Quarterly financial data (unaudited)	'
	Quarterly financial data (unaudited)
		2013 Quarters ended
	(In millions, except per share data)	December 31		September  30		June 30		March 31
	Product sales	$	4,799	$	4,647	$	4,595	$	4,151
	Gross profit from product sales	3,770		3,859		3,810		3,407
	Net income	1,021		1,368		1,258		1,434
	Earnings per share:
	Basic	$	1.35	$	1.81	$	1.67	$	1.91
	Diluted	$	1.33	$	1.79	$	1.65	$	1.88
		2012 Quarters ended
	(In millions, except per share data)	December  31		September  30		June 30		March 31
	Product sales	$	4,337	$	4,201	$	4,200	$	3,901
	Gross profit from product sales(1)	3,415		3,426		3,448		3,151
	Net income	788		1,107		1,266		1,184
	Earnings per share:
	Basic	$	1.03	$	1.44	$	1.63	$	1.5
	Diluted	$	1.01	$	1.41	$	1.61	$	1.48
	(1)	Includes the impact of prior-period amounts for amortization of certain acquired intangible assets that have been reclassified within Operating expenses in our Consolidated Statements of Income to conform to the current-period presentation.

SCHEDULE_II_VALUATION_AND_QUAL

SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS	12 Months Ended
	Dec. 31, 2013
Valuation and Qualifying Accounts [Abstract]	'
Schedule of Valuation and Qualifying Accounts Disclosure	'
	SCHEDULE II
	AMGEN INC.
	VALUATION AND QUALIFYING ACCOUNTS
	Years ended December 31, 2013, 2012 and 2011
	(In millions)
	Allowance for doubtful accounts	Balance at		Additions		Other		Deductions		Balance
		beginning		charged to		additions				at end
		of period		costs and						of
				expenses						period
	Year ended December 31, 2013	$	61	$	5	$	—	$	7	$	59
	Year ended December 31, 2012	$	54	$	7	$	—	$	—	$	61
	Year ended December 31, 2011	$	42	$	17	$	—	$	5	$	54

Summary_of_significant_account1

Summary of significant accounting policies (Policies)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Business	'
	Business
	Amgen Inc. (including its subsidiaries, referred to as “Amgen,” “the Company,” “we,” “our” or “us”) is a global biotechnology pioneer that discovers, develops, manufactures and delivers innovative human therapeutics. We operate in one business segment: human therapeutics.
Principles of consolidation	'
	Principles of consolidation
	The consolidated financial statements include the accounts of Amgen as well as its majority-owned subsidiaries. We do not have any significant interests in any variable interest entities. All material intercompany transactions and balances have been eliminated in consolidation.
Use of estimates	'
	Use of estimates
	The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States (GAAP) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results may differ from those estimates.
Product sales	'
	Product sales
	Sales of our products are recognized when shipped and title and risk of loss have passed. Product sales are recorded net of accruals for estimated rebates, wholesaler chargebacks, discounts and other deductions (collectively “sales deductions”) and returns. Taxes collected from customers and remitted to government authorities related to the sales of the Company’s products, primarily in Europe, are excluded from revenues.
	With regard to EPOGEN® (epoetin alfa), we have the exclusive right to sell epoetin alfa for dialysis, certain diagnostics and all non-human, non-research uses in the United States. We granted to Ortho Pharmaceutical Corporation (which has assigned its rights under the product license agreement to Janssen Biotech, Inc.), a subsidiary of Johnson & Johnson (J&J), a license relating to epoetin alfa for sales in the United States for all human uses except dialysis and diagnostics. This license agreement, which is perpetual, may be terminated for various reasons, including upon mutual agreement of the parties, or default. The parties are required to compensate each other for epoetin alfa sales that either party makes into the other party’s exclusive market, sometimes referred to as “spillover.” Accordingly, we do not recognize product sales we make into the exclusive market of J&J and do recognize product sales made by J&J into our exclusive market. Sales in our exclusive market are derived from our sales to our customers, as adjusted for spillover. We are employing an arbitrated audit methodology to measure each party’s spillover based on estimates of and subsequent adjustments thereto of third-party data on shipments to and usage by end users.
	We recognize revenue from the sales of product to the U.S. federal government for stockpile in accordance with U.S. Securities and Exchange Commission (SEC) Interpretation, Commission Guidance Regarding Accounting for Sales of Vaccines and Bioterror Countermeasures to the Federal Government for Placement into the Pediatric Vaccine Stockpile or the Strategic National Stockpile (SNS). We recognized $155 million of revenue for NEUPOGEN® during the year ended December 31, 2013, for purchases by the government for the SNS. We are contracted to manage this inventory of product until the government requests shipment.
Other revenues	'
	Other revenues
	Other revenues consist primarily of royalty income and corporate partner revenues. Royalties from licensees are based on third-party sales of licensed products and are recorded in accordance with contract terms when third-party results are reliably measurable and collectability is reasonably assured. Royalty estimates are made in advance of amounts collected using historical and forecasted trends. Corporate partner revenues are comprised mainly of amounts earned from Kirin-Amgen, Inc. (K-A) and other third parties for certain research and development (R&D) activities, which are recognized as the R&D activities are performed, as well as our share of the U.S. pre-tax Nexavar® commercial profits generated from our collaboration with Bayer HealthCare Pharmaceuticals, Inc. (Bayer). Corporate partner revenues also include license fees and milestone payments earned from K-A and from other third parties. See Multiple-deliverable revenue arrangements, discussed below, Note 6, Collaborative arrangements, and Note 7, Related party transactions.
Multiple-deliverable revenue arrangements	'
	Multiple-deliverable revenue arrangements
	From time to time, we enter into arrangements for the R&D, manufacture and/or commercialization of products and product candidates. These arrangements may require us to deliver various rights, services and/or goods across the entire life cycle of a product or product candidate, including (i) intellectual property rights/licenses, (ii) R&D services, (iii) manufacturing services and/or (iv) commercialization services. The underlying terms of these arrangements generally provide for consideration to Amgen in the form of non-refundable upfront license payments, R&D and commercial performance milestone payments, cost sharing and/or royalty payments.
	In arrangements involving the delivery of more than one element, each required deliverable is evaluated to determine whether it qualifies as a separate unit of accounting. For Amgen, this determination is generally based on whether the deliverable has “stand-alone value” to the customer. The arrangement’s consideration that is fixed and determinable is then allocated to each separate unit of accounting based on the relative selling price of each deliverable. The estimated selling price of each deliverable is determined using the following hierarchy of values: (i) vendor-specific objective evidence of fair value, (ii) third-party evidence of selling price and (iii) best estimate of selling price (BESP). The BESP reflects our best estimate of what the selling price would be if the deliverable was regularly sold by us on a stand-alone basis. In general, the consideration allocated to each unit of accounting is recognized as the related goods or services are delivered, limited to the consideration that is not contingent upon future deliverables. Consideration associated with at-risk substantive performance milestones is recognized as revenue upon the achievement of the related milestone, as defined in the respective contracts.
Research and development costs	'
	Research and development costs
	R&D costs are expensed as incurred and include primarily salaries, benefits and other staff-related costs; facilities and overhead costs; clinical trial and related clinical manufacturing costs; contract services and other outside costs; information systems’ costs and amortization of acquired technology used in R&D with alternative future uses. R&D expenses also include costs and cost recoveries associated with third-party R&D arrangements such as with K-A, including upfront fees and milestones paid to third parties in connection with technologies which had not reached technological feasibility and did not have an alternative future use. Net payment or reimbursement of R&D costs is recognized when the obligations are incurred or as we become entitled to the cost recovery. See Note 6, Collaborative arrangements, and Note 7, Related party transactions.
Selling, general and administrative costs	'
	Selling, general and administrative costs
	Selling, general and administrative (SG&A) expenses are comprised primarily of salaries, benefits and other staff-related costs associated with sales and marketing, finance, legal and other administrative personnel; facilities and overhead costs; outside marketing, advertising and legal expenses; amortization of the U.S. healthcare reform federal excise fee; and other general and administrative costs. Advertising costs are expensed as incurred. SG&A expenses also include costs and cost recoveries associated with marketing and promotion efforts under certain collaboration arrangements. Net payment or reimbursement of SG&A costs is recognized when the obligations are incurred or we become entitled to the cost recovery. See Note 6, Collaborative arrangements.
Stock-based compensation	'
	Stock-based compensation
	We have stock-based compensation plans under which various types of equity-based awards are granted, including restricted stock units (RSUs), performance units and stock options. The estimated fair values of RSUs and stock option awards which are subject only to service conditions with graded vesting are generally recognized as compensation expense on a straight-line basis over the service period. The estimated fair values of performance unit awards are generally recognized as compensation expense as the awards vest ratably from the grant date to the end of the performance period. See Note 3, Stock-based compensation.
Income taxes	'
	Income taxes
	We provide for income taxes based on pretax income, applicable tax rates and tax planning opportunities available in the various jurisdictions in which we operate. Deferred income taxes are recorded for the expected tax consequences of temporary differences between the basis of assets and liabilities for financial reporting purposes and amounts recognized for income tax purposes. We record a valuation allowance to reduce our deferred tax assets to the amount of future tax benefit that is more likely than not to be realized.
	We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by the taxing authorities based on the technical merits of the position. The tax benefit recognized in the financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized. The amount of unrecognized tax benefits (UTBs) is adjusted as appropriate for changes in facts and circumstances, such as significant amendments to existing tax law, new regulations or interpretations by the taxing authorities, new information obtained during a tax examination, or resolution of an examination. We recognize both accrued interest and penalties, where appropriate, related to UTBs in income tax expense. See Note 4, Income taxes.
Business combinations	'
	Business combinations
	Business combinations are accounted for using the acquisition method of accounting. Under the acquisition method, assets acquired, including in-process research and development (IPR&D) projects, and liabilities assumed are recorded at their respective fair values as of the acquisition date in our consolidated financial statements. The excess of the fair value of consideration transferred over the fair value of the net assets acquired is recorded as goodwill. Contingent consideration obligations incurred in connection with a business combination (including the assumption of an acquiree's liability arising from a business combination it consummated prior to our acquisition) are recorded at their fair values on the acquisition date and remeasured at their fair values each subsequent reporting period until the related contingencies are resolved. The resulting changes in fair values are recorded in earnings. See Note 2, Business combinations, and Note 16, Fair value measurement.
Cash equivalents	'
	Cash equivalents
	We consider cash equivalents to be only those investments which are highly liquid, readily convertible to cash and which mature within three months from the date of purchase.
Available-for-sale investments	'
	Available-for-sale investments
	We consider our investment portfolio available-for-sale and, accordingly, these investments are recorded at fair value with unrealized gains and losses generally recorded in other comprehensive income. Investments with maturities beyond one year, other than Restricted investments, may be classified as short-term marketable securities in the Consolidated Balance Sheets due to their highly liquid nature and because they represent the Company's investments that are available for current operations. See Note 9, Available-for-sale investments, and Note 16, Fair value measurement.
Inventories	'
	Inventories
	Inventories are stated at the lower of cost or market. Cost, which includes amounts related to materials, labor and overhead, is determined in a manner that approximates the first-in, first-out method. See Note 10, Inventories.
Derivatives	'
	Derivatives
	We recognize all of our derivative instruments as either assets or liabilities at fair value in the Consolidated Balance Sheets. The accounting for changes in the fair value of a derivative instrument depends upon whether it has been formally designated and qualifies as part of a hedging relationship under the applicable accounting standards and, further, on the type of hedging relationship. For derivatives formally designated as hedges, we assess both at inception and quarterly thereafter, whether the hedging derivatives are highly effective in offsetting changes in either the fair value or cash flows of the hedged item. Our derivatives that are not designated and do not qualify as hedges are adjusted to fair value through current earnings. See Note 16, Fair value measurement, and Note 17, Derivative instruments.
Property, plant and equipment, net	'
	Property, plant and equipment, net
	Property, plant and equipment is recorded at historical cost, net of accumulated depreciation, amortization and, if applicable, impairment charges. We review our property, plant and equipment assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Depreciation is provided over the assets’ useful lives on a straight-line basis. Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or lease terms. See Note 11, Property, plant and equipment.
Goodwill and other intangible assets	'
	Goodwill and other intangible assets
	Finite-lived intangible assets are recorded at cost, net of accumulated amortization and, if applicable, impairment charges. Amortization of finite-lived intangible assets is provided over their estimated useful lives on a straight-line basis. We review our finite-lived intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. See Note 12, Goodwill and other intangible assets.
	The estimated fair values of IPR&D projects acquired in a business combination which are not complete are capitalized and accounted for as indefinite-lived intangible assets until completion or abandonment of the related R&D efforts. Upon successful completion of the project, the capitalized amount is amortized over its estimated useful life. If a project is abandoned, all remaining capitalized amounts are written-off immediately. There are often major risks and uncertainties associated with IPR&D projects as we are required to obtain regulatory approvals in order to be able to market these products. Such approvals require completing clinical trials that demonstrate a product candidate is safe and effective. Consequently, the eventual realized value of the acquired IPR&D project may vary from its estimated fair value at the date of acquisition, and IPR&D impairment charges may occur in future periods.
	Capitalized IPR&D projects are tested for impairment annually and whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. We consider various factors for potential impairment including the current legal and regulatory environment and the competitive landscape. Adverse clinical trial results, significant delays in obtaining market approval and the inability to bring a product to market could result in the related intangible assets to be partially or fully impaired.
	We perform an impairment test of goodwill annually and whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. To date, an impairment of goodwill has not been recorded. See Note 12, Goodwill and other intangible assets.
Restricted investments	'
	Restricted investments
	We have restricted investments on our Consolidated Balance Sheet that are owned by ATL Holdings Limited (ATL Holdings), a wholly-owned subsidiary. ATL Holdings is an entity distinct from the Company and its other subsidiaries, with separate assets and liabilities. Because a third party owns Class A preferred shares of ATL Holdings, this entity is required to hold restricted cash or investments. See Note 14, Financing arrangements.
Contingencies	'
	Contingencies
	In the ordinary course of business, we are involved in various legal proceedings and other matters such as intellectual property disputes, contractual disputes, governmental investigations and class action suits which are complex in nature and have outcomes that are difficult to predict. Certain of these proceedings are discussed in Note 18, Contingencies and commitments. We record accruals for loss contingencies to the extent that we conclude that it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. We consider all relevant factors when making assessments regarding these contingencies.
	While it is not possible to accurately predict or determine the eventual outcomes of these items, an adverse determination in one or more of these items currently pending could have a material adverse effect on our consolidated results of operations, financial position or cash flows.
Foreign currency translation	'
	Foreign currency translation
	The net assets of international subsidiaries where the local currencies have been determined to be the functional currencies are translated into U.S. dollars using current exchange rates. The U.S. dollar effects that arise from translating net assets of these subsidiaries at changing rates are recognized in other comprehensive income. The earnings of these subsidiaries are translated into U.S. dollars using average exchange rates.
Reclassifications	'
	Reclassifications
	Prior-period amounts for amortization of certain acquired intangible assets have been reclassified within Operating expenses in our Consolidated Statements of Income to conform to the current-period presentation.
Recent accounting pronouncements	'
	Recent accounting pronouncements
	In January 2013, we adopted a new accounting standard that requires additional disclosures regarding amounts that are reclassified out of accumulated other comprehensive income (AOCI). In accordance with the requirements of the standard, the effects of significant reclassifications out of AOCI, by component, on the respective lines in the Consolidated Statements of Income are presented in Note 15, Stockholders' equity. The standard was required to be applied prospectively beginning January 1, 2013.

Business_combinations_Tables

Business combinations (Tables)	12 Months Ended
	Dec. 31, 2013
Business Acquisition [Line Items]	'
Schedule of recognized identified assets acquired and liabilities assumed	'
	The consideration to acquire deCODE, KAI, MN, Micromet, and BioVex was allocated to the acquisition date fair values of the assets acquired and liabilities assumed as follows (in millions):
			deCODE				KAI			MN			Micromet			BioVex
	IPR&D		$	—			$	240		$	—		$	570		$	675
	Developed product technology rights		—				—			81			—			—
	R&D technology rights		465				—			—			350			—
	Marketing-related rights		—				—			82			—			—
	Deferred income taxes, net		(37		)		(59		)	(45		)	(191		)	(246		)
	Other assets (liabilities), net		(29		)		26			179			170			(2		)
	Goodwill		—				125			380			247			170
	Total consideration		$	399			$	332		$	677		$	1,146		$	597
Onyx Pharmaceuticals, Inc. [Member]	'
Business Acquisition [Line Items]	'
Aggregate acquisition date consideration to acquire an entity	'
	The aggregate consideration to acquire Onyx was paid in cash and consisted of (in millions):
	Total consideration transferred	$	9,515
	Compensation expense	197
	Total cash paid	$	9,712
Schedule of recognized identified assets acquired and liabilities assumed	'
	The consideration to acquire Onyx was preliminarily allocated to the acquisition date fair values of assets acquired and liabilities assumed as follows (in millions):
	Cash and cash equivalents	$	319
	Marketable securities	337
	Inventories	250
	Indefinite-lived intangible assets - IPR&D	1,160
	Finite-lived intangible assets - Developed product technology rights	5,910
	Finite-lived intangible assets - Licensing rights	2,792
	Goodwill	2,526
	Convertible debt	(742		)
	Assumed contingent consideration	(261		)
	Deferred income taxes, net	(2,918		)
	Other assets (liabilities), net	142
	Total consideration	$	9,515
Business acquisition, pro forma information	'
	The following table presents supplemental pro forma information for the year ended December 31, 2013 and 2012, as if the acquisition of Onyx had occurred on January 1, 2012 (in millions, unaudited):
		2013				2012
	Pro forma net revenues	$	19,141			$	17,616
	Pro forma net income	4,848				3,700

Stockbased_compensation_Stockb

Stock-based compensation Stock-based compensation (Tables)	12 Months Ended
	Dec. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Components of stock-based compensation expense recognized in the Consolidated Statements of Income	'
	The following table reflects the components of stock-based compensation expense recognized in our Consolidated Statements of Income for the years ended December 31, 2013, 2012 and 2011 (in millions):
		2013				2012				2011
	RSUs	$	206			$	186			$	188
	Performance units	163				117				68
	Stock options	34				59				85
	Total stock-based compensation expense, pretax	403				362				341
	Tax benefit from stock-based compensation expense	(149		)		(134		)		(124		)
	Total stock-based compensation expense, net of tax	$	254			$	228			$	217
Restricted stock units Information	'
	The following summarizes select information regarding our RSUs during the year ended December 31, 2013:
		Units			Weighted-average
		(in millions)			grant date
					fair value
	Balance nonvested at December 31, 2012	9.4			$	61.14
	Granted	2.8			$	107.01
	Vested	(2.7	)		$	54.74
	Forfeited	(0.7	)		$	69.84
	Balance nonvested at December 31, 2013	8.8			$	76.75
Weighted average assumptions used and the resulting weighted average grant date fair value of employee stock options	'
	The weighted-average assumptions used in the option valuation model and the resulting weighted-average estimated grant date fair values of stock options were as follows for the years ended December 31, 2013, 2012 and 2011:
		2013				2012				2011
	Closing price of our common stock on grant date	$	85.59			$	74.56			$	54.66
	Expected volatility	23.1		%		22.2		%		23.5		%
	Expected life (in years)	8.1				8.1				5.9
	Risk-free interest rate	1.7		%		1.6		%		2.5		%
	Expected dividend yield	2.2		%		2.1		%		2		%
	Fair value of stock options granted	$	17.43			$	14.65			$	11.39
Stock options information	'
	The following summarizes select information regarding our stock options during the year ended December 31, 2013:
		Options			Weighted-				Weighted-		Aggregate
		(in millions)			average				average		intrinsic
					exercise price				remaining		value
									contractual		(in millions)
									life (years)
	Balance unexercised at December 31, 2012	12.3			$	56.09
	Granted	0.1			$	85.59
	Exercised	(4.7	)		$	58.05
	Expired/forfeited	(0.3	)		$	56.93
	Balance unexercised at December 31, 2013	7.4			$	54.91			4.8		$	436
	Vested or expected to vest at December 31, 2013	7.3			$	54.91			4.8		$	434
	Exercisable at December 31, 2013	4.8			$	53.95			3.7		$	291
Weighted average assumptions used and the resulting weighted average grant date fair value of performance units	'
	The weighted-average assumptions used in these models and the resulting weighted-average grant date fair values of our performance units were as follows for the years ended December 31, 2013, 2012 and 2011:
		2013				2012				2011
	Closing price of our common stock on grant date	$	92.03			$	68.75			$	51.67
	Volatility	21		%		22.9		%		32.8		%
	Risk-free interest rate	0.4		%		0.5		%		1.2		%
	Fair value of unit	$	102.73			$	78.21			$	49.5

Income_taxes_Income_taxes_Tabl

Income taxes Income taxes (Tables)	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Provision for income taxes	'
	The provision for income taxes includes the following for the years ended December 31, 2013, 2012 and 2011 (in millions):
		2013				2012				2011
	Current provision:
	Federal	$	54			$	438			$	551
	State	26				47				54
	Foreign	191				158				148
	Total current provision	271				643				753
	Deferred provision (benefit):
	Federal	(86		)		83				(273		)
	State	19				(43		)		(12		)
	Foreign	(20		)		(19		)		(1		)
	Total deferred provision (benefit)	(87		)		21				(286		)
	Total provision	$	184			$	664			$	467
Significant components of deferred tax assets and liabilities	'
	Significant components of our deferred tax assets and liabilities are as follows as of December 31, 2013 and 2012 (in millions):
		2013				2012
	Deferred income tax assets:
	NOL and credit carryforwards	$	1,017			$	427
	Expense accruals	697				805
	Expenses capitalized for tax	196				195
	Stock-based compensation	211				115
	Deferred revenue	40				40
	Other	104				83
	Total deferred income tax assets	2,265				1,665
	Valuation allowance	(314		)		(273		)
	Net deferred income tax assets	1,951				1,392
	Deferred income tax liabilities:
	Acquired intangibles	(4,430		)		(1,249		)
	Fixed assets	(8		)		(117		)
	Unremitted foreign earnings	(55		)		(106		)
	Other	(200		)		(145		)
	Total deferred income tax liabilities	(4,693		)		(1,617		)
	Total deferred income taxes, net	$	(2,742	)		$	(225	)
Reconciliation of total gross amounts of unrecognized tax benefits (excluding interest, penalties, foreign tax credits and the federal tax benefit of state taxes related to unrecognized tax benefits)	'
	The reconciliation of the total gross amounts of UTBs (excluding interest, penalties, foreign tax credits and the federal tax benefit of state taxes related to UTBs) for the years ended December 31, 2013, 2012 and 2011 is as follows (in millions):
		2013				2012				2011
	Balance at beginning of year	$	1,200			$	975			$	920
	Additions based on tax positions related to the current year	335				300				283
	Additions based on tax positions related to prior years	96				5				1
	Reductions for tax positions of prior years	(192		)		(50		)		(8		)
	Settlements	(24		)		(30		)		(221		)
	Balance at end of year	$	1,415			$	1,200			$	975
Reconciliation between the federal statutory tax rate and effective tax rate	'
	The reconciliation between the federal statutory tax rate applied to income before income taxes and our effective tax rate for the years ended December 31, 2013, 2012 and 2011, is as follows:
		2013			2012			2011
	Federal statutory tax rate	35	%		35	%		35	%
	Foreign earnings, including earnings invested indefinitely	(21.3	)%		(17.8	)%		(19.4	)%
	Credits, Puerto Rico Excise Tax	(4.7	)%		(5.2	)%		(6.5	)%
	Credits, primarily federal R&D	(3.0	)%		—	%		(1.5	)%
	State taxes	0.8	%		0.6	%		0.7	%
	Audit settlements (federal, state, foreign)	(3.7	)%		0.3	%		—	%
	Legal settlements	—	%		(0.2	)%		2.2	%
	Other, net	0.4	%		0.6	%		0.8	%
	Effective tax rate	3.5	%		13.3	%		11.3	%

Earnings_per_share_Tables

Earnings per share (Tables)	12 Months Ended
	Dec. 31, 2013
Earnings Per Share [Abstract]	'
Computation for basic and diluted earnings per share	'
	The computation for basic and diluted EPS was as follows (in millions, except per share data):
		2013		2012		2011
	Income (Numerator):
	Net income for basic and diluted EPS	$	5,081	$	4,345	$	3,683
	Shares (Denominator):
	Weighted-average shares for basic EPS	753		775		905
	Effect of dilutive securities	12		12		7
	Weighted-average shares for diluted EPS	765		787		912
	Basic EPS	$	6.75	$	5.61	$	4.07
	Diluted EPS	$	6.64	$	5.52	$	4.04

Availableforsale_investments_T

Available-for-sale investments (Tables)	12 Months Ended
	Dec. 31, 2013
Investments, Debt and Equity Securities [Abstract]	'
Amortized cost, gross unrealized gains, gross unrealized losses and estimated fair values of available-for-sale investments by type of security	'
	The amortized cost, gross unrealized gains, gross unrealized losses and estimated fair values of available-for-sale investments by type of security were as follows (in millions):
	Type of security as of December 31, 2013	Amortized		Gross		Gross			Estimated
		cost		unrealized		unrealized			fair value
				gains		losses
	U.S. Treasury securities	$	4,737	$	2	$	(9	)	$	4,730
	Other government-related debt securities:
	U.S.	1,087		—		(8		)	1,079
	Foreign and other	1,574		13		(41		)	1,546
	Corporate debt securities:
	Financial	3,667		28		(19		)	3,676
	Industrial	3,745		36		(21		)	3,760
	Other	388		4		(2		)	390
	Residential mortgage-backed securities	1,478		3		(21		)	1,460
	Other mortgage- and asset-backed securities	1,555		1		(45		)	1,511
	Money market mutual funds	3,366		—		—			3,366
	Other short-term interest-bearing securities	750		—		—			750
	Total interest-bearing securities	22,347		87		(166		)	22,268
	Equity securities	85		10		—			95
	Total available-for-sale investments	$	22,432	$	97	$	(166	)	$	22,363
	Type of security as of December 31, 2012	Amortized		Gross		Gross			Estimated
		cost		unrealized		unrealized			fair value
				gains		losses
	U.S. Treasury securities	$	4,443	$	15	$	—		$	4,458
	Other government-related debt securities:
	U.S.	1,018		12		—			1,030
	Foreign and other	1,549		60		(1		)	1,608
	Corporate debt securities:
	Financial	3,266		96		(1		)	3,361
	Industrial	4,283		100		(3		)	4,380
	Other	441		11		—			452
	Residential mortgage-backed securities	1,828		9		(8		)	1,829
	Other mortgage- and asset-backed securities	1,769		7		(9		)	1,767
	Money market mutual funds	2,620		—		—			2,620
	Other short-term interest-bearing securities	2,186		—		—			2,186
	Total interest-bearing securities	23,403		310		(22		)	23,691
	Equity securities	52		2		—			54
	Total available-for-sale investments	$	23,455	$	312	$	(22	)	$	23,745
Fair values of available-for-sale investments by classification in the Consolidated Balance Sheets	'
	The fair values of available-for-sale investments by classification in the Consolidated Balance Sheets were as follows (in millions):
	Classification in the Consolidated Balance Sheets	2013		2012
	Cash and cash equivalents	$	3,266	$	2,887
	Marketable securities	15,596		20,804
	Other assets — noncurrent	95		54
	Restricted investments	3,406		—
	Total available-for-sale investments	$	22,363	$	23,745
Fair values of available-for-sale interest-bearing security investments by contractual maturity	'
	The fair values of available-for-sale interest-bearing security investments by contractual maturity, except for mortgage- and asset-backed securities that do not have a single maturity date, were as follows (in millions):
	Contractual maturity	2013		2012
	Maturing in one year or less	$	6,799	$	7,175
	Maturing after one year through three years	4,785		5,014
	Maturing after three years through five years	6,057		6,286
	Maturing after five years through ten years	1,656		1,620
	Mortgage- and asset-backed securities	2,971		3,596
	Total interest-bearing securities	$	22,268	$	23,691

Inventories_Tables

Inventories (Tables)	12 Months Ended
	Dec. 31, 2013
Inventory Disclosure [Abstract]	'
Inventories	'
	Inventories consisted of the following (in millions):
		2013		2012
	Raw materials	$	217	$	192
	Work in process	2,064		1,723
	Finished goods	738		829
	Total inventories	$	3,019	$	2,744

Property_plant_and_equipment_T

Property, plant and equipment (Tables)	12 Months Ended
	Dec. 31, 2013
Property, Plant and Equipment [Abstract]	'
Property, plant and equipment	'
	Property, plant and equipment consisted of the following as of December 31, 2013 and 2012 (dollar amounts in millions):
		Useful life (in years)	2013			2012
	Land	—	$	408		$	412
	Buildings and improvements	Oct-40	3,467			3,510
	Manufacturing equipment	12-Aug	2,024			2,007
	Laboratory equipment	12-Aug	1,165			1,056
	Other	15-Mar	4,107			3,891
	Construction in progress	—	1,120			1,071
	Property, plant and equipment, gross		12,291			11,947
	Less accumulated depreciation and amortization		(6,942		)	(6,621		)
	Property, plant and equipment, net		$	5,349		$	5,326

Goodwill_and_intangible_assets1

Goodwill and intangible assets (Tables)	12 Months Ended
	Dec. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Schedule of goodwill	'
	The changes in the carrying amounts of goodwill for the years ended December 31, 2013 and 2012, were as follows (in millions):
		2013			2012
	Beginning balance	$	12,662		$	11,750
	Goodwill resulting from acquisitions of businesses	2,526			928
	Currency translation and other adjustments	(220		)	(16		)
	Ending balance	$	14,968		$	12,662
Schedule of identifiable intangible assets	'
	Identifiable intangible assets consisted of the following as of December 31, 2013 and 2012 (in millions):
		2013								2012
		Gross			Accumulated			Intangible		Gross		Accumulated			Intangible
		carrying			amortization			assets, net		carrying		amortization			assets, net
		amount								amount
	Finite-lived intangible assets:
	Developed product technology rights	$	10,130		$	(3,347	)	$	6,783	$	4,220	$	(2,942	)	$	1,278
	Licensing rights	3,241			(366		)	2,875		445		(268		)	177
	R&D technology rights	1,207			(496		)	711		1,130		(411		)	719
	Marketing-related rights	619			(366		)	253		648		(313		)	335
	Total finite-lived intangible assets	15,197			(4,575		)	10,622		6,443		(3,934		)	2,509
	Indefinite-lived intangible assets:
	IPR&D	2,640			—			2,640		1,459		—			1,459
	Total identifiable intangible assets	$	17,837		$	(4,575	)	$	13,262	$	7,902	$	(3,934	)	$	3,968

Accrued_liabilities_Accrued_li

Accrued liabilities Accrued liabilities (Tables)	12 Months Ended
	Dec. 31, 2013
Payables and Accruals [Abstract]	'
Accrued liabilities	'
	Accrued liabilities consisted of the following as of December 31, 2013 and 2012 (in millions):
		2013		2012
	Sales deductions	$	1,248	$	1,129
	Employee compensation and benefits	1,003		1,010
	Clinical development costs	522		361
	Dividends payable	460		355
	Sales returns reserve	295		346
	Other	1,127		1,590
	Total accrued liabilities	$	4,655	$	4,791

Financing_arrangements_Tables

Financing arrangements (Tables)	12 Months Ended
	Dec. 31, 2013
Debt Disclosure [Abstract]	'
Carrying values and the fixed contractual coupon rates of long-term borrowings	'
	The carrying values and the fixed contractual coupon rates of our long-term borrowings were as follows (in millions):
		2013				2012
	0.375% convertible notes due 2013 (0.375% 2013 Convertible Notes)	$	—			$	2,488
	1.875% notes due 2014 (1.875% 2014 Notes)	1,000				1,000
	4.85% notes due 2014 (4.85% 2014 Notes)	1,000				1,000
	2.30% notes due 2016 (2.30% 2016 Notes)	749				749
	2.50% notes due 2016 (2.50% 2016 Notes)	999				999
	2.125% notes due 2017 (2.125% 2017 Notes)	1,248				1,248
	5.85% notes due 2017 (5.85% 2017 Notes)	1,099				1,099
	6.15% notes due 2018 (6.15% 2018 Notes)	500				499
	Master Repurchase Agreement obligation due 2018	3,100				—
	Term Loan due 2018	4,875				—
	4.375% euro denominated notes due 2018 (4.375% 2018 euro Notes)	751				723
	5.70% notes due 2019 (5.70% 2019 Notes)	999				999
	2.125% euro denominated notes due 2019 (2.125% 2019 euro Notes)	925				887
	4.50% notes due 2020 (4.50% 2020 Notes)	300				300
	3.45% notes due 2020 (3.45% 2020 Notes)	898				897
	4.10% notes due 2021 (4.10% 2021 Notes)	998				998
	3.875% notes due 2021 (3.875% 2021 Notes)	1,746				1,745
	3.625% notes due 2022 (3.625% 2022 Notes)	747				747
	5.50% pound sterling denominated notes due 2026 (5.50% 2026 pound sterling Notes)	781				763
	4.00% pound sterling denominated notes due 2029 (4.00% 2029 pound sterling Notes)	1,144				1,117
	6.375% notes due 2037 (6.375% 2037 Notes)	899				899
	6.90% notes due 2038 (6.90% 2038 Notes)	499				499
	6.40% notes due 2039 (6.40% 2039 Notes)	996				996
	5.75% notes due 2040 (5.75% 2040 Notes)	697				697
	4.95% notes due 2041 (4.95% 2041 Notes)	596				595
	5.15% notes due 2041 (5.15% 2041 Notes)	2,233				2,232
	5.65% notes due 2042 (5.65% 2042 Notes)	1,244				1,244
	5.375% notes due 2043 (5.375% 2043 Notes)	1,000				1,000
	Other notes	105				109
	Total debt	32,128				26,529
	Less current portion	(2,505		)		(2,495		)
	Total noncurrent debt	$	29,623			$	24,034
Schedule of interest rate derivatives	'
	The effective interest rates on these notes after giving effect to the related interest rate swap contracts and the notional amounts of the contracts were as follows as of December 31, 2013 (dollar amounts in millions):
		Effective interest rate		Notional amount
	3.45% 2020 Notes	LIBOR + 1.1%		$	900
	4.10% 2021 Notes	LIBOR + 1.7%		1,000
	3.875% 2021 Notes	LIBOR + 2.0%		1,750
	3.625% 2022 Notes	LIBOR + 1.6%		750
				$	4,400
Aggregate contractual maturities of long-term debt obligations	'
	The aggregate contractual maturities of all long-term debt obligations due subsequent to December 31, 2013, are as follows (in millions):
	Maturity date	Amount
	2014	$	2,505
	2015	500
	2016	2,250
	2017	2,850
	2018	7,228
	Thereafter	16,873
	Total	$	32,206

Stockholders_equity_Tables

Stockholders' equity (Tables)	12 Months Ended
	Dec. 31, 2013
Equity [Abstract]	'
Summary of activity under our stock repurchase program	'
	Activity under our stock repurchase program was as follows (in millions):
		2013							2012							2011
		Shares			Dollars				Shares			Dollars				Shares		Dollars
	First quarter	9.1			$	771			21			$	1,429			—		$	—
	Second quarter	—			—				17.4			1,203				12.9		732
	Third quarter	—			—				9.7			797				45.4		2,421
	Fourth quarter	—			—				14.2			1,233				86		5,154		(1)
	Total stock repurchases	9.1			$	771			62.3			$	4,662			144.3		$	8,307
	___________
	-1	Includes the repurchase of 83.3 million shares of our common stock at an average price paid per share of $60.08, including related expenses, for an aggregate cost of $5.0 billion, under a modified Dutch auction tender offer.
Components of Accumulated Other Comprehensive Income	'
	The components of AOCI were as follows (in millions):
		Foreign				Cash flow				Available-for-sale				Other			AOCI
		currency				hedges				securities
		translation
	Balance as of December 31, 2010	$	22			$	3			$	135			$	(7	)	$	153
	Foreign currency translation adjustments	(6		)		—				—				—			(6		)
	Unrealized gains (losses)	—				(51		)		125				2			76
	Reclassification adjustments to income	—				112				(154		)		—			(42		)
	Other	—				—				—				(8		)	(8		)
	Income taxes	5				(21		)		14				—			(2		)
	Balance as of December 31, 2011	21				43				120				(13		)	171
	Foreign currency translation adjustments	(13		)		—				—				—			(13		)
	Unrealized gains (losses)	—				15				233				(1		)	247
	Reclassification adjustments to income	—				(134		)		(132		)		—			(266		)
	Income taxes	4				41				(38		)		—			7
	Balance as of December 31, 2012	12				(35		)		183				(14		)	146
	Foreign currency translation adjustments	(71		)		—				—				—			(71		)
	Unrealized gains (losses)	—				88				(284		)		(1		)	(197		)
	Reclassification adjustments to income	—				(85		)		(75		)		—			(160		)
	Other	—				—				—				(2		)	(2		)
	Income taxes	(9		)		(1		)		133				—			123
	Balance as of December 31, 2013	$	(68	)		$	(33	)		$	(43	)		$	(17	)	$	(161	)
Reclassification out of Accumulated Other Comprehensive Income	'
	The reclassifications out of AOCI to Net income were as follows (in millions):
			Amounts reclassified out of AOCI
	Components of AOCI		Year Ended December 31, 2013				Line item affected in the Statements of Income
	Cash flow hedges:
	Foreign currency contract gains		$	4			Product sales
	Cross-currency swap contract gains		82				Interest and other income, net
	Forward interest rate contract losses		(1		)		Interest expense, net
			85				Total before income tax
			(33		)		Tax (expense)
			52				Net of taxes
	Available-for-sale securities:
	Net realized gains (losses)		$	75			Interest and other income, net
			(28		)		Tax (expense)
			47				Net of taxes

Fair_value_measurement_Tables

Fair value measurement (Tables)	12 Months Ended
	Dec. 31, 2013
Fair Value Disclosures [Abstract]	'
Fair value of each major class of financial assets and liabilities measured at fair value on a recurring basis	'
	The fair value of each major class of the Company’s financial assets and liabilities measured at fair value on a recurring basis was as follows (in millions):
	Fair value measurement as of December 31, 2013, using:		Quoted prices in			Significant other		Significant		Total
			active markets for			observable		unobservable
			identical assets			inputs		inputs
			(Level 1)			(Level 2)		(Level 3)
	Assets:
	Available-for-sale investments:
	U.S. Treasury securities		$	4,730		$	—	$	—	$	4,730
	Other government-related debt securities:
	U.S.		—			1,079		—		1,079
	Foreign and other		—			1,546		—		1,546
	Corporate debt securities:
	Financial		—			3,676		—		3,676
	Industrial		—			3,760		—		3,760
	Other		—			390		—		390
	Residential mortgage-backed securities		—			1,460		—		1,460
	Other mortgage- and asset-backed securities		—			1,511		—		1,511
	Money market mutual funds		3,366			—		—		3,366
	Other short-term interest bearing securities		—			750		—		750
	Equity securities		95			—		—		95
	Derivatives:
	Foreign currency contracts		—			53		—		53
	Cross-currency swap contracts		—			193		—		193
	Total assets		$	8,191		$	14,418	$	—	$	22,609
	Liabilities:
	Derivatives:
	Foreign currency contracts		$	—		$	107	$	—	$	107
	Cross-currency swap contracts		—			4		—		4
	Interest rate swap contracts		—			161		—		161
	Contingent consideration obligations in connection with business combinations		—			—		595		595
	Total liabilities		$	—		$	272	$	595	$	867
	Fair value measurement as of December 31, 2012, using:		Quoted prices in			Significant  other		Significant		Total
			active markets for			observable		unobservable
			identical assets			inputs		inputs
			(Level 1)			(Level 2)		(Level 3)
	Assets:
	Available-for-sale investments:
	U.S. Treasury securities		$	4,458		$	—	$	—	$	4,458
	Other government-related debt securities:
	U.S.		—			1,030		—		1,030
	Foreign and other		—			1,608		—		1,608
	Corporate debt securities:
	Financial		—			3,361		—		3,361
	Industrial		—			4,380		—		4,380
	Other		—			452		—		452
	Residential mortgage-backed securities		—			1,829		—		1,829
	Other mortgage- and asset-backed securities		—			1,767		—		1,767
	Money market mutual funds		2,620			—		—		2,620
	Other short-term interest-bearing securities		—			2,186		—		2,186
	Equity securities		54			—		—		54
	Derivatives:
	Foreign currency contracts		—			46		—		46
	Cross-currency swap contracts		—			65		—		65
	Total assets		$	7,132		$	16,724	$	—	$	23,856
	Liabilities:
	Derivatives:
	Foreign currency contracts		$	—		$	59	$	—	$	59
	Cross-currency swap contracts		—			6		—		6
	Contingent consideration obligations in connection with a business combination		—			—		221		221
	Total liabilities		$	—		$	65	$	221	$	286
Change in carrying amounts of contingent consideration obligations	'
	The changes in carrying amounts of contingent consideration obligations for the years ended December 31, 2013 and 2012, were as follows (in millions):
		2013			2012
	Beginning balance	$	221		$	190
	Additions from Onyx acquisition	261			—
	Net changes in valuation	113			31
	Ending balance	$	595		$	221

Derivative_instruments_Tables

Derivative instruments (Tables)	12 Months Ended
	Dec. 31, 2013
Derivative Instruments and Hedging Activities Disclosure [Abstract]	'
Schedule of notional amounts and interest rates for cross-currency swaps	'
	The notional amounts and interest rates of our cross-currency swaps are as follows (notional amounts in millions):
			Foreign currency							U.S. dollars
	Hedged notes		Notional Amount				Interest rate			Notional Amount				Interest rate
	2.125% 2019 euro Notes		€	675			2.125	%		$	864			2.6	%
	5.50% 2026 pound sterling Notes		£	475			5.5	%		$	748			5.8	%
	4.00% 2029 pound sterling Notes		£	700			4	%		$	1,122			4.3	%
Effective portion of the unrealized gain (loss) recognized in Other Comprehensive Income for our derivative instruments designated as cash flow hedges	'
	The effective portion of the unrealized gain/(loss) recognized in other comprehensive income for our derivative instruments designated as cash flow hedges was as follows (in millions):
		Years ended December 31,
	Derivatives in cash flow hedging relationships	2013				2012				2011
	Foreign currency contracts	$	(44	)		$	(63	)		$	(25	)
	Cross-currency swap contracts	132				85				(26		)
	Forward interest rate contracts	—				(7		)		—
	Total	$	88			$	15			$	(51	)
Location in the Consolidated Statements of Income and the effective portion of gain (loss) reclassified from Accumulated Other Comprehensive Income into earnings for our derivative instruments designated as cash flow hedges	'
	The location in the Consolidated Statements of Income and the effective portion of the gain/(loss) reclassified out of AOCI into earnings for our derivative instruments designated as cash flow hedges were as follows (in millions):
					Years ended December 31,
	Derivatives in cash flow hedging relationships		Statements of Income location		2013				2012				2011
	Foreign currency contracts		Product sales		$	4			$	74			$	(108	)
	Cross-currency swap contracts		Interest and other income, net		82				61				(3		)
	Forward interest rate contracts		Interest expense, net		(1		)		(1		)		(1		)
	Total				$	85			$	134			$	(112	)
Location in the Consolidated Statements of Income and the amount of gain (loss) recognized in earnings for the derivative instruments not designated as hedging instruments	'
	The location in the Consolidated Statements of Income and the amount of gain/(loss) recognized in earnings for our derivative instruments not designated as hedging instruments were as follows (in millions):
					Years ended December 31,
	Derivatives not designated as hedging instruments		Statements of Income location		2013				2012				2011
	Foreign currency contracts		Interest and other income, net		$	15			$	19			$	(1	)
Fair values of derivatives included in the Consolidated Balance Sheets	'
	The fair values of derivatives included in the Consolidated Balance Sheets were as follows (in millions):
		Derivative assets						Derivative liabilities
	31-Dec-13	Balance Sheet location		Fair value				Balance Sheet location		Fair value
	Derivatives designated as hedging instruments:
	Cross-currency swap contracts	Other current assets/ Other noncurrent assets		$	193			Accrued liabilities/ Other noncurrent liabilities		$	4
	Foreign currency contracts	Other current assets/ Other noncurrent assets		53				Accrued liabilities/ Other noncurrent liabilities		104
	Interest rate swap contracts	Other current assets/ Other noncurrent assets		—				Accrued liabilities/ Other noncurrent liabilities		161
	Total derivatives designated as hedging instruments			246						269
	Derivatives not designated as hedging instruments:
	Foreign currency contracts	Other current assets		—				Accrued liabilities		3
	Total derivatives not designated as hedging instruments			—						3
	Total derivatives			$	246					$	272
		Derivative assets						Derivative liabilities
	31-Dec-12	Balance Sheet location		Fair value				Balance Sheet location		Fair value
	Derivatives designated as hedging instruments:
	Cross-currency swap contracts	Other current assets/ Other noncurrent assets		65				Accrued liabilities/ Other noncurrent liabilities		6
	Foreign currency contracts	Other current assets/ Other noncurrent assets		45				Accrued liabilities/ Other noncurrent liabilities		58
	Total derivatives designated as hedging instruments			110						64
	Derivatives not designated as hedging instruments:
	Foreign currency contracts	Other current assets		1				Accrued liabilities		1
	Total derivatives not designated as hedging instruments			1						1
	Total derivatives			$	111					$	65

Contingencies_and_commitments_

Contingencies and commitments (Tables)	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Minimum future rental commitments under non-cancelable operating leases	'
	The following table summarizes the minimum future rental commitments under non-cancelable operating leases as of December 31, 2013 (in millions):
	2014	$	140
	2015	125
	2016	114
	2017	95
	2018	86
	Thereafter	345
	Total minimum operating lease commitments	$	905

Segment_information_Segment_in

Segment information Segment information (Tables)	12 Months Ended
	Dec. 31, 2013
Segment Reporting [Abstract]	'
Revenues	'
	Revenues were as follows for the years ended December 31, 2013, 2012 and 2011 (in millions):
		2013			2012			2011
	Product sales:
	Neulasta®	$	4,392		$	4,092		$	3,952
	NEUPOGEN®	1,398			1,260			1,260
	ENBREL	4,551			4,236			3,701
	Aranesp®	1,911			2,040			2,303
	EPOGEN®	1,953			1,941			2,040
	Sensipar®/Mimpara®	1,089			950			808
	Vectibix®	389			359			322
	Nplate®	427			368			297
	XGEVA®	1,019			748			351
	Prolia®	744			472			203
	Kyprolis®	73			—			—
	Other	246			173			58
	Total product sales	18,192			16,639			15,295
	Other revenues	484			626			287
	Total revenues	$	18,676		$	17,265		$	15,582
Geographical information with respect to revenues and long-lived assets	'
	Certain geographic information with respect to revenues and long-lived assets (consisting of property, plant and equipment) was as follows (in millions):
		Years ended December 31,
		2013			2012			2011
	Revenues:
	United States	$	14,480		$	13,415		$	11,985
	Rest of the world (ROW)	4,196			3,850			3,597
	Total revenues	$	18,676		$	17,265		$	15,582
		December 31,
		2013			2012
	Long-lived assets:
	United States	$	2,772		$	2,906
	Puerto Rico	1,822			1,908
	ROW	755			512
	Total long-lived assets	$	5,349		$	5,326
Revenues earned from major customers	'
	Certain information with respect to these customers for the years ended December 31, 2013, 2012 and 2011, was as follows (dollar amounts in millions):
		2013			2012			2011
	AmerisourceBergen Corporation:
	Gross product sales	$	8,527		$	7,556		$	7,574
	% of total gross revenues	35		%	34		%	36		%
	% of U.S. gross product sales	44		%	43		%	45		%
	McKesson Corporation:
	Gross product sales	$	6,440		$	5,898		$	4,591
	% of total gross revenues	27		%	27		%	22		%
	% of U.S. gross product sales	32		%	32		%	27		%
	Cardinal Health, Inc.:
	Gross product sales	$	3,209		$	3,245		$	3,021
	% of total gross revenues	13		%	15		%	14		%
	% of U.S. gross product sales	17		%	19		%	18		%

Quarterly_financial_data_Table

Quarterly financial data (Tables)	12 Months Ended
	Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract]	'
Quarterly financial data (unaudited)	'
		2013 Quarters ended
	(In millions, except per share data)	December 31		September  30		June 30		March 31
	Product sales	$	4,799	$	4,647	$	4,595	$	4,151
	Gross profit from product sales	3,770		3,859		3,810		3,407
	Net income	1,021		1,368		1,258		1,434
	Earnings per share:
	Basic	$	1.35	$	1.81	$	1.67	$	1.91
	Diluted	$	1.33	$	1.79	$	1.65	$	1.88
		2012 Quarters ended
	(In millions, except per share data)	December  31		September  30		June 30		March 31
	Product sales	$	4,337	$	4,201	$	4,200	$	3,901
	Gross profit from product sales(1)	3,415		3,426		3,448		3,151
	Net income	788		1,107		1,266		1,184
	Earnings per share:
	Basic	$	1.03	$	1.44	$	1.63	$	1.5
	Diluted	$	1.01	$	1.41	$	1.61	$	1.48
	(1)	Includes the impact of prior-period amounts for amortization of certain acquired intangible assets that have been reclassified within Operating expenses in our Consolidated Statements of Income to conform to the current-period presentation.

Summary_of_significant_account2

Summary of significant accounting policies (Details) (USD $)	3 Months Ended								12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
									segment
Accounting Policies [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Number of business segment	'	'	'	'	'	'	'	'	1	'	'
Revenue from External Customer [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Product sales	$4,799	$4,647	$4,595	$4,151	$4,337	$4,201	$4,200	$3,901	$18,192	$16,639	$15,295
NEUPOGEN [Member]	'	'	'	'	'	'	'	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Product sales	'	'	'	'	'	'	'	'	1,398	1,260	1,260
NEUPOGEN [Member] | U.S. federal government stockpiles [Member]	'	'	'	'	'	'	'	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Product sales	'	'	'	'	'	'	'	'	$155	'	'

Business_combinations_Details

Business combinations (Details) (Onyx Pharmaceuticals, Inc. [Member], USD $)	0 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013
Onyx Pharmaceuticals, Inc. [Member]	'
Business Acquisition [Line Items]	'
Total cash paid	$9,515
Compensation expense	197
Total consideration transferred	$9,712

Business_combinations_Details_

Business combinations (Details 1) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013
In Millions, unless otherwise specified				Onyx Pharmaceuticals, Inc. [Member]	Onyx Pharmaceuticals, Inc. [Member]	Onyx Pharmaceuticals, Inc. [Member]
					Developed Product Technology Rights [Member]	Licensing Rights [Member]
Allocation of the total consideration to the acquisition date fair values of assets acquired and liabilities assumed	'	'	'	'	'	'
Cash and cash equivalents	'	'	'	$319	'	'
Marketable securities	'	'	'	337	'	'
Inventories	'	'	'	250	'	'
Indefinite-lived intangible assets - IPR&D	'	'	'	1,160	'	'
Finite-lived intangible assets	'	'	'	'	5,910	2,792
Goodwill	14,968	12,662	11,750	2,526	'	'
Convertible debt	'	'	'	-742	'	'
Assumed contingent consideration	'	'	'	-261	'	'
Deferred tax assets (liabilities), net	'	'	'	-2,918	'	'
Other assets (liabilities), net	'	'	'	142	'	'
Total consideration	'	'	'	$9,515	'	'

Business_combinations_Details_1

Business combinations (Details 2) (Onyx Pharmaceuticals, Inc. [Member], USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Onyx Pharmaceuticals, Inc. [Member]	'	'
Business Acquisition [Line Items]	'	'
Pro forma net sales	$19,141	$17,616
Pro forma net income	$4,848	$3,700

Business_combinations_Details_2

Business combinations (Details 3) (USD $)

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 10, 2012

Dec. 10, 2012

Jul. 05, 2012

Jul. 05, 2012

Jun. 12, 2012

Jun. 12, 2012

Jun. 12, 2012

Mar. 07, 2012

Mar. 07, 2012

Mar. 07, 2012

Mar. 04, 2011

Mar. 04, 2011

In Millions, unless otherwise specified

deCODE [Member]

deCODE [Member]

Kai [Member]

Kai [Member]

MN [Member]

MN [Member]

MN [Member]

Micromet [Member]

Micromet [Member]

Micromet [Member]

Biovex [Member]

Biovex [Member]

R&D Technology Rights [Member]

IPR&D [Member]

Developed Product Technology Rights [Member]

Marketing-related Rights [Member]

R&D Technology Rights [Member]

IPR&D [Member]

IPR&D [Member]

Business Acquisition [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

IPR&D

'

'

'

'

'

'

$240

'

'

'

'

'

$570

'

$675

Finite-lived intangible assets

'

'

'

'

465

'

'

'

81

82

'

350

'

'

'

Deferred income taxes, net

'

'

'

-37

'

-59

'

-45

'

'

-191

'

'

-246

'

Other assets (liabilities), net

'

'

'

-29

'

26

'

179

'

'

170

'

'

-2

'

Goodwill

14,968

12,662

11,750

'

'

125

'

380

'

'

247

'

'

170

'

Total consideration

'

'

'

$399

'

$332

'

$677

'

'

$1,146

'

'

$597

'

Business_combinations_Details_3

Business combinations (Details Textual) (USD $)

12 Months Ended

0 Months Ended

1 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

In Millions, unless otherwise specified

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Sep. 30, 2013

Dec. 31, 2013

Sep. 30, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 10, 2012

Dec. 31, 2012

Jun. 12, 2012

Jun. 12, 2012

Dec. 31, 2013

Dec. 31, 2012

Mar. 07, 2012

Mar. 07, 2012

Mar. 04, 2011

Mar. 31, 2011

Dec. 31, 2011

Dec. 31, 2011

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Onyx Pharmaceuticals, Inc. [Member]

Onyx Pharmaceuticals, Inc. [Member]

Onyx Pharmaceuticals, Inc. [Member]

Onyx Pharmaceuticals, Inc. [Member]

Onyx Pharmaceuticals, Inc. [Member]

Onyx Pharmaceuticals, Inc. [Member]

Onyx Pharmaceuticals, Inc. [Member]

Onyx Pharmaceuticals, Inc. [Member]

de CODE Genetics [Member]

de CODE Genetics [Member]

Mustafa Nevzat Pharmaceuticals [Member]

Mustafa Nevzat Pharmaceuticals [Member]

Micromet Inc. [Member]

Micromet Inc. [Member]

Micromet Inc. [Member]

Micromet Inc. [Member]

Biovex Group Inc [Member]

Biovex Group Inc [Member]

Other Acquisitions [Member]

Bergamo [Member]

Filgrastim and Pegfilgrastim Rights [Member]

Common Stockholders [Member]

Equity Award Holders for Services Rendered Prior to Date of Acquisition [Member]

oncology_assets

payment

Developed Product Technology Rights [Member]

Selling, General and Administrative Expense [Member]

Selling, General and Administrative Expense [Member]

Pro Forma [Member]

Pro Forma [Member]

Pro Forma [Member]

Developed Product Technology Rights [Member]

Developed Product Technology Rights [Member]

market

Onyx Pharmaceuticals, Inc. [Member]

Onyx Pharmaceuticals, Inc. [Member]

Business Acquisition [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of partnered oncology assets

'

'

'

3

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cash payments

'

'

'

$9,515

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$407

'

'

'

$479

$9,184

$331

Share-based compensation expense

'

'

'

'

'

'

197

'

197

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Finite-lived intangible assets, estimated useful life (in years)

'

'

'

'

'

'12 years

'

'

'

'

'

'10 years

'

'8 years

'

'

'

'

'10 years

'

'

'

'

'

'

'

Number of separate milestone payments

'

'

'

'

2

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Contingent consideration obligations

'

'

'

'

150

'

'

'

'

'

'

'

'

'

'

'

'

'

'

575

575

'

'

'

'

'

Goodwill

14,968

12,662

11,750

2,526

'

'

'

'

'

'

'

'

'

380

'

'

'

247

'

170

'

265

'

'

'

'

Transaction related expenses

'

'

'

'

'

'

'

36

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Intangible asset amortization expense

642

397

380

'

'

'

'

'

'

488

412

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Impairment charge resulting from termination of a non-key program under an outlicensing arrangement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

19

'

'

'

'

'

'

'

'

'

'

Fair value of contingent consideration obligations

'

'

'

261

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

190

'

'

'

'

'

'

Increase in fair value of finite-lived intangible assets

'

'

'

'

'

'

'

'

'

'

'

'

64

'

'

'

'

'

'

'

'

'

'

'

'

'

Goodwill, purchase accounting adjustment

'

'

'

'

'

'

'

'

'

'

'

'

43

'

'

'

83

'

'

'

'

'

'

'

'

'

Aggregate acquisition date consideration for business combinations

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

453

'

'

'

'

Tax deductible portion of goodwill arising from a business combination

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

130

'

'

'

Property plant equipment acquired in business combinations

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

99

'

'

'

'

Finite-lived intangible assets

'

'

'

'

'

5,910

'

'

'

'

'

'

'

'

81

'

'

'

'

'

'

58

'

'

'

'

Other assets (liabilities), net

'

'

'

$142

'

'

'

'

'

'

'

($29)

'

$179

'

'

'

$170

'

($2)

'

$31

'

'

'

'

Number of markets holding acquired licenses

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100

'

'

Stockbased_compensation_Detail

Stock-based compensation (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Components of stock-based compensation expense [Abstract]	'	'	'
Total stock-based compensation expense, pre-tax	$403	$362	$341
Tax benefit from stock-based compensation expense	-149	-134	-124
Total stock-based compensation expense, net of tax	254	228	217
RSUs [Member]	'	'	'
Components of stock-based compensation expense [Abstract]	'	'	'
Total stock-based compensation expense, pre-tax	206	186	188
Performance units [Member]	'	'	'
Components of stock-based compensation expense [Abstract]	'	'	'
Total stock-based compensation expense, pre-tax	163	117	68
Stock options [Member]	'	'	'
Components of stock-based compensation expense [Abstract]	'	'	'
Total stock-based compensation expense, pre-tax	$34	$59	$85

Stockbased_compensation_Detail1

Stock-based compensation (Details 1) (Restricted Stock Units [Member], USD $)	12 Months Ended
In Millions, except Per Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Restricted Stock Units [Member]	'	'	'
Restricted Stock Units, Nonvested, Number of Shares [Roll Forward]	'	'	'
Nonvested units, beginning balance (in shares)	9.4	'	'
Units granted (in shares)	2.8	'	'
Units, vested (in shares)	-2.7	'	'
Units, forfeited (in shares)	-0.7	'	'
Nonvested units, ending balance (in shares)	8.8	9.4	'
Restricted Stock Units, Nonvested, Weighted Average Grant Date Fair Value [Roll Forward]	'	'	'
Weighted average grant date fair value of units, beginning balance (in usd per share)	$61.14	'	'
Weighted average grant date fair value, granted (in usd per share)	$107.01	$72.99	$51.83
Weighted average grant date fair value, vested (in usd per share)	$54.74	'	'
Weighted average grant date fair value, forfeited (in usd per share)	$69.84	'	'
Weighted average grant date fair value of nonvested units, end of period (in usd per share)	$76.75	$61.14	'

Stockbased_compensation_Detail2

Stock-based compensation (Details 2) (Stock Options [Member], USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Stock Options [Member]	'	'	'
Weighted-average assumptions and resulting weighted-average grant date fair values [Abstract]	'	'	'
Closing price of our common stock on grant date	$85.59	$74.56	$54.66
Expected volatility	23.10%	22.20%	23.50%
Expected life (in years)	'8 years 1 month 6 days	'8 years 1 month 6 days	'5 years 10 months 24 days
Risk-free interest rate	1.70%	1.60%	2.50%
Expected dividend yield	2.20%	2.10%	2.00%
Fair value of stock options granted	$17.43	$14.65	$11.39

Stockbased_compensation_Detail3

Stock-based compensation (Details 3) (Stock Options [Member], USD $)	12 Months Ended
In Millions, except Per Share data, unless otherwise specified	Dec. 31, 2013
Stock Options [Member]	'
Stock Options [Roll Forward]	'
Stock options unexercised, beginning balance (in shares)	12.3
Stock options, granted (in shares)	0.1
Stock options, exercised (in shares)	-4.7
Stock options, expired/forfeited (in shares)	-0.3
Stock options unexercised, ending balance (in shares)	7.4
Stock Options, Weighted Average Exercise Price [Roll Forward]	'
Weighted-average exercise price, unexercised beginning balance (in usd per share)	$56.09
Weighted-average exercise price, granted (in usd per share)	$85.59
Weighted-average exercise price, exercised (in usd per share)	$58.05
Weighted-average exercise price, expired/forfeited (in usd per share)	$56.93
Weighted-average exercise price, unexercised ending balance (in usd per share)	$54.91
Stock options information [Abstract]	'
Vested or expected to vest (in shares)	7.3
Exercisable (in shares)	4.8
Weighted-average exercise price, vested or expected to vest (in usd per share)	$54.91
Weighted-average exercise price, exercisable (in usd per share)	$53.95
Weighted-average remaining contractual life (years), unexercised	'4 years 9 months 18 days
Weighted-average remaining contractual life (years), vested or expected to vest	'4 years 9 months 18 days
Weighted-average remaining contractual life (years), exercisable	'3 years 8 months 12 days
Aggregate intrinsic value, unexercised	$436
Aggregate intrinsic value, vested or expected to vest	434
Aggregate intrinsic value, exercisable	$291

Stockbased_compensation_Detail4

Stock-based compensation (Details 4) (Performance Units [Member], USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Performance Units [Member]	'	'	'
Weighted-average assumptions and resulting weighted-average grant date fair values [Abstract]	'	'	'
Closing price of our common stock on grant date	$92.03	$68.75	$51.67
Expected volatility	21.00%	22.90%	32.80%
Risk-free interest rate	0.40%	0.50%	1.20%
Fair value of unit (in usd per share)	$102.73	$78.21	$49.50

Stockbased_compensation_Detail5

Stock-based compensation (Details Textual) (USD $)

12 Months Ended

In Millions, except Share data, unless otherwise specified

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2011

Dec. 31, 2010

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2009

22-May-13

Restricted Stock Units [Member]

Restricted Stock Units [Member]

Restricted Stock Units [Member]

Stock Options [Member]

Stock Options [Member]

Stock Options [Member]

Stock Option and Restricted Stock Units [Member]

Performance Units [Member]

Performance Units [Member]

Performance Units [Member]

Granted Prior to April 25, 2011 [Member]

Granted Prior to April 25, 2011 [Member]

Granted Prior to April 25, 2011 [Member]

Granted Prior to April 25, 2011 [Member]

Granted on April 25, 2011 through April 26, 2012 [Member]

Granted on and After April 26, 2010 [Member]

Granted on and After April 26, 2010 [Member]

Granted on and After April 26, 2010 [Member]

Granted Prior to April 26, 2010 [Member]

the Amended 2009 Plan [Member]

Restricted Stock Units [Member]

Restricted Stock Units [Member]

Stock Options [Member]

Stock Options [Member]

Restricted Stock Units [Member]

Stock Options [Member]

Stock Options [Member]

Stock Options [Member]

Stock Options [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of shares of common stock authorized for issuance

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

104,000,000

Amount by which the pool of available shares will be reduced for each stock option granted

1

1

1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

The number of shares by which the pool of available shares will be reduced for other types of awards granted

'

'

'

1.9

1.9

1.9

'

'

'

'

1.9

1.9

1.9

'

'

'

'

'

'

'

'

'

'

The amount of common stock available under the plan for future grants and/or issuances (in shares)

58,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Period over which the grants of equity instruments vest

'

'

'

'

'

'

'

'

'

'

'3 years

'3 years

'3 years

'4 years

'4 years

'4 years

'4 years

'

'

'

'

'

'

Description of vesting of restricted stock units and stock options

'Stock options and RSUs granted on and after April 25, 2011, generally vest in approximately equal amounts on the second, third and fourth anniversaries of the grant date.

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Expected dividend yield

'

'

'

'

'

'

2.20%

2.10%

2.00%

'

'

'

'

'

'

'

'

2.00%

'

'

'

'

'

Weighted-average risk-free interest rate

'

'

'

'

'

'

1.70%

1.60%

2.50%

'

0.40%

0.50%

1.20%

'

'

'

'

1.00%

'

'

'

'

'

Weighted average grant date fair value, granted (in usd per share)

'

'

'

$107.01

$72.99

$51.83

'

'

'

'

$102.73

$78.21

$49.50

'

'

'

'

'

'

'

'

'

'

Total fair value of units that vested during the year

'

'

'

$145

$139

$176

'

'

'

'

$270

$100

$25

'

'

'

'

'

'

'

'

'

'

Total unrecognized compensation cost related to nonvested awards

'

'

'

'

'

'

'

'

'

394

173

'

'

'

'

'

'

'

'

'

'

'

'

Weighted average number of years over which compensation cost related to nonvested awards is expected to be recognized

'

'

'

'

'

'

'

'

'

'1 year 9 months 18 days

'10 months 24 days

'

'

'

'

'

'

'

'

'

'

'

'

Expiration period of stock options from date of grant

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'10 years

'10 years

'10 years

'7 years

'

Total intrinsic value of stock options exercised during the year

'

'

'

'

'

'

210

320

47

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Actual tax benefits realized from tax deductions from option exercises

$77

$117

$14

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Units outstanding (in shares)

'

'

'

8,800,000

9,400,000

'

'

'

'

'

6,600,000

5,800,000

'

'

'

'

'

'

'

'

'

'

'

Weighted average grant date fair value of units, outstanding

'

'

'

'

'

'

'

'

'

'

$76.95

$65.15

'

'

'

'

'

'

'

'

'

'

'

Units granted (in shares)

'

'

'

2,800,000

'

'

'

'

'

'

2,100,000

'

'

'

'

'

'

'

'

'

'

'

'

Units, vested (in shares)

'

'

'

2,700,000

'

'

'

'

'

'

2,400,000

'

'

'

'

'

'

'

'

'

'

'

'

Weighted average grant date fair value, vested (in usd per share)

'

'

'

$54.74

'

'

'

'

'

'

$49.33

'

'

'

'

'

'

'

'

'

'

'

'

Units, forfeited (in shares)

'

'

'

700,000

'

'

'

'

'

'

500,000

'

'

'

'

'

'

'

'

'

'

'

'

Weighted average grant date fair value, forfeited (in usd per share)

'

'

'

$69.84

'

'

'

'

'

'

$73.13

'

'

'

'

'

'

'

'

'

'

'

'

Number of common shares issued for each performance unit earned

1

1

1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Income_taxes_Details

Income taxes (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Current provision:	'	'	'
Federal	$54	$438	$551
State	26	47	54
Foreign	191	158	148
Total current provision	271	643	753
Deferred provision (benefit):	'	'	'
Federal	-86	83	-273
State	19	-43	-12
Foreign	-20	-19	-1
Total deferred provision (benefit)	-87	21	-286
Total provision	$184	$664	$467

Income_taxes_Details_1

Income taxes (Details 1) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Millions, unless otherwise specified
Deferred income tax assets:	'	'
NOL and credit carryforwards	$1,017	$427
Expense accruals	697	805
Expenses capitalized for tax	196	195
Stock-based compensation	211	115
Deferred revenue	40	40
Other	104	83
Total deferred income tax assets	2,265	1,665
Valuation allowance	-314	-273
Net deferred income tax assets	1,951	1,392
Deferred income tax liabilities:	'	'
Acquired intangibles	-4,430	-1,249
Fixed assets	-8	-117
Unremitted foreign earnings	-55	-106
Other	-200	-145
Total deferred income tax liabilities	-4,693	-1,617
Total deferred income taxes, net	($2,742)	($225)

Income_taxes_Details_2

Income taxes (Details 2) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Reconciliation of total gross amounts of unrecognized tax benefits (excluding interest, penalties, foreign tax credits and the federal tax benefit of state taxes related to unrecognized tax benefits)	'	'	'
Balance at beginning of year	$1,200	$975	$920
Additions based on tax positions related to the current year	335	300	283
Additions based on tax positions related to prior years	96	5	1
Reductions for tax positions of prior years	-192	-50	-8
Settlements	-24	-30	-221
Balance at end of year	$1,415	$1,200	$975

Income_taxes_Details_3

Income taxes (Details 3)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Reconciliation between the federal statutory tax rate applied to income before income taxes and effective tax rate [Abstract]	'	'	'
Federal statutory tax rate	35.00%	35.00%	35.00%
Foreign earnings, including earnings invested indefinitely	-21.30%	-17.80%	-19.40%
Credits, Puerto Rico Excise Tax	-4.70%	-5.20%	-6.50%
Credits, primarily federal R&D	-3.00%	0.00%	-1.50%
State taxes	0.80%	0.60%	0.70%
Audit settlements (federal, state, foreign)	-3.70%	0.30%	0.00%
Legal settlements	0.00%	-0.20%	2.20%
Other, net	0.40%	0.60%	0.80%
Effective tax rate	3.50%	13.30%	11.30%

Income_taxes_Details_Textual

Income taxes (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Taxes (Textual) [Abstract]	'	'	'
Increase in valuation allowance for deferred tax assets	$41,000,000	$147,000,000	'
Interest and penalties related to unrecognized tax benefits recognized in income tax provision	32,000,000	30,000,000	23,000,000
Accrued interest and penalties associated with unrecognized tax benefits	99,000,000	102,000,000	'
Total foreign income before income taxes	3,700,000,000	3,300,000,000	3,000,000,000
Income taxes paid	321,000,000	502,000,000	595,000,000
Tax Credit Carryforward [Line Items]	'	'	'
Net noncurrent deferred tax liabilities	3,500,000,000	900,000,000	'
Decrease in unrecognized tax benefits that is reasonably possible within the succeeding twelve months due to potential tax settlements	70,000,000	'	'
Undistributed earnings of our foreign operations that are intended to be invested indefinitely outside of the United States	25,500,000,000	'	'
Additional income taxes required to be accrued and paid if earnings of foreign operations that are intended to be indefinitely invested outside of the United States were repatriated	9,100,000,000	'	'
Research Tax Credit Carryforward [Member]	'	'	'
Tax Credit Carryforward [Line Items]	'	'	'
Tax benefit of the retroactive extension of the 2012 R&D tax credit	70,000,000	'	'
Puerto Rico Excise Tax [Member]	'	'	'
Excise Tax Rate [Abstract]	'	'	'
Effective excise tax rate for 2011	4.00%	'	'
Effective excise tax rate for 2012	3.75%	'	'
Effective excise tax rate for first half of 2013	2.75%	'	'
Excise tax rate effective July 1, 2013 through 2017	4.00%	'	'
State [Member]	'	'	'
Tax Credit Carryforward [Line Items]	'	'	'
Tax credit carryforwards available to reduce income taxes	313,000,000	'	'
Tax credit carryforwards for which a full valuation allowance has been provided	202,000,000	'	'
NOL carryforwards	883,000,000	'	'
Operating loss carryforwards, valuation allowance	266,000,000	'	'
Federal [Member]	'	'	'
Tax Credit Carryforward [Line Items]	'	'	'
Tax credit carryforwards available to reduce income taxes	341,000,000	'	'
Tax credit carryforwards for which a full valuation allowance has been provided	4,000,000	'	'
NOL carryforwards	425,000,000	'	'
Operating loss carryforwards, valuation allowance	80,000,000	'	'
Foreign Tax Authority [Member]	'	'	'
Tax Credit Carryforward [Line Items]	'	'	'
NOL carryforwards	1,300,000,000	'	'
Operating loss carryforwards, valuation allowance	$770,000,000	'	'

Earnings_per_share_Details

Earnings per share (Details) (USD $)	3 Months Ended								12 Months Ended
In Millions, except Per Share data, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income (Numerator):	'	'	'	'	'	'	'	'	'	'	'
Net income for basic and diluted EPS	$1,021	$1,368	$1,258	$1,434	$788	$1,107	$1,266	$1,184	$5,081	$4,345	$3,683
Shares (Denominator):	'	'	'	'	'	'	'	'	'	'	'
Weighted-average shares for basic EPS	'	'	'	'	'	'	'	'	753	775	905
Effect of dilutive securities	'	'	'	'	'	'	'	'	12	12	7
Weighted-average shares for diluted EPS	'	'	'	'	'	'	'	'	765	787	912
Basic EPS (in usd per share)	$1.35	$1.81	$1.67	$1.91	$1.03	$1.44	$1.63	$1.50	$6.75	$5.61	$4.07
Diluted EPS (in usd per share)	$1.33	$1.79	$1.65	$1.88	$1.01	$1.41	$1.61	$1.48	$6.64	$5.52	$4.04

Earnings_per_share_Details_Tex

Earnings per share (Details Textual)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2012	Dec. 31, 2011
Earnings Per Share [Abstract]	'	'
Antidilutive securities excluded from computation of diluted earnings per share, amount	6	33

Collaborative_arrangements_Tex

Collaborative arrangements (Textuals) (Details) (USD $)	3 Months Ended								12 Months Ended
	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'	'	'	'	'	'	'	'	'	'
ENBREL sales	$4,799,000,000	$4,647,000,000	$4,595,000,000	$4,151,000,000	$4,337,000,000	$4,201,000,000	$4,200,000,000	$3,901,000,000	$18,192,000,000	$16,639,000,000	$15,295,000,000
Pfizer Inc [Member]	'	'	'	'	'	'	'	'	'	'	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Period required to pay percentage of net sales, after expiration of agreement in years	'	'	'	'	'	'	'	'	'3 years	'	'
Maximum percentage of annual net ENBREL sales payable to Pfizer for three years after expiration of the collaboration agreement in the fourth quarter of 2013	12.00%	'	'	'	'	'	'	'	12.00%	'	'
Minimum percentage of annual net ENBREL sales payable to Pfizer for three years after expiration of the collaboration agreement in the fourth quarter of 2013	10.00%	'	'	'	'	'	'	'	10.00%	'	'
ENBREL sales	'	'	'	'	'	'	'	'	4,600,000,000	4,200,000,000	3,700,000,000
Pfizer Inc [Member] | Selling, General and Administrative [Member]	'	'	'	'	'	'	'	'	'	'	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Profit share and royalty expense, net of partner portion of selling and marketing expense	'	'	'	'	'	'	'	'	$1,300,000,000	$1,300,000,000	$1,100,000,000

Collaborative_arrangements_Tex1

Collaborative arrangements (Textuals 1) (Details) (USD $)	3 Months Ended								12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Product sales	$4,799	$4,647	$4,595	$4,151	$4,337	$4,201	$4,200	$3,901	$18,192	$16,639	$15,295
Glaxo Group Limited [Member] | Selling, General and Administrative [Member]	'	'	'	'	'	'	'	'	'	'	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Cost recoveries	'	'	'	'	'	'	'	'	-16	10	30
Glaxo Group Limited [Member] | Primary Territories [Member]	'	'	'	'	'	'	'	'	'	'	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Product sales	'	'	'	'	'	'	'	'	$219	$139	$62

Collaborative_arrangements_Tex2

Collaborative arrangements (Textuals 2) (Details) (Astrazeneca Plc. [Member], USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'
Percentage of related development costs for the 2012-2014 period will be funded by partner	65.00%	'
Other Revenues [Member]	'	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'
Milestone payments received	'	$50
Research and development expense [Member]	'	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'
Cost recoveries	$194	$28

Collaborative_arrangements_Tex3

Collaborative arrangements (Textuals 3) (Details) (USD $)	6 Months Ended		12 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2012	Jun. 30, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2008	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
	License arrangement for Motesanib with Takeda Pharmaceutical Company Limited [Member]	Takeda Pharmaceutical Company Limited [Member]	Takeda Pharmaceutical Company Limited [Member]	Takeda Pharmaceutical Company Limited [Member]	Takeda Pharmaceutical Company Limited [Member]	Takeda Pharmaceutical Company Limited [Member]	Takeda Pharmaceutical Company Limited [Member]	Takeda Pharmaceutical Company Limited [Member]	Takeda Pharmaceutical Company Limited [Member]
			Research and development expense [Member]	Research and development expense [Member]	Research and development expense [Member]	Japanese Market Products [Member]	Vectibix [Member]	Vectibix [Member]	Vectibix [Member]
						Molecule	Other Revenues [Member]	Other Revenues [Member]	Other Revenues [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'	'	'	'	'	'	'	'
Number of molecules developed and commercialized as per collaborations	'	'	'	'	'	12	'	'	'
Milestone payments received under arrangements	$3	'	'	'	'	'	'	'	'
Incremental cost to be recovered	21	'	'	'	'	'	'	'	'
Deferred revenue as of the date of modification of the original arrangement	'	230	'	'	'	'	'	'	'
Cost recoveries	'	'	34	74	83	'	'	'	'
Royalties received on sales	'	'	'	'	'	'	$18	$21	$20

Collaborative_arrangements_Tex4

Collaborative arrangements (Textuals 4) (Details) (UCB [Member], Research and development expense [Member], USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
UCB [Member] | Research and development expense [Member]	'	'	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'	'
Cost recoveries	$66	$71	$35

Collaborative_arrangements_Col

Collaborative arrangements Collaborative arrangements (Textuals 5) (Details) (Bayer HealthCare Pharmaceuticals Inc. [Member], Nexavar [Member], USD $)	3 Months Ended	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2013
		country
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'
Number of countries product is marketed and sold	'	100
Percentage of development costs funded by Company	'	50.00%
Percentage of net profits after deducting certain partner related costs	'	50.00%
Collaboration, net R&D expenses	$13	'
Other Revenues [Member]	'	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'
Collaboration profit	$78	'

Related_party_transactions_Det

Related party transactions (Details Textual) (Kirin-Amgen [Member], USD $)

12 Months Ended

12 Months Ended

Dec. 31, 2013

Dec. 31, 2011

Dec. 31, 2010

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Selling, General and Administrative [Member]

Selling, General and Administrative [Member]

Selling, General and Administrative [Member]

Cost of Sales [Member]

Cost of Sales [Member]

Cost of Sales [Member]

Other Revenues [Member]

Other Revenues [Member]

Other Revenues [Member]

Research and Development Expense [Member]

Research and Development Expense [Member]

Research and Development Expense [Member]

Noncurrent Other Assets [Member]

Noncurrent Other Assets [Member]

Other Current Assets [Member]

Accrued Liabilities [Member]

Related Party Transaction [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Ownership interest (in percent) in related party

50.00%

50.00%

50.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Company's share of profits (losses) of related party

'

'

'

($6,000,000)

($24,000,000)

$47,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Approximate carrying value of the company's equity method investment net of dividends received

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

300,000,000

400,000,000

'

'

Royalties earned by related party from Amgen

'

'

'

'

'

'

272,000,000

274,000,000

298,000,000

'

'

'

'

'

'

'

'

'

'

Revenues earned by Amgen from related party

'

'

'

'

'

'

'

'

'

117,000,000

115,000,000

130,000,000

'

'

'

'

'

'

'

Payments that may be received upon the achievement of various substantive success-based development and regulatory approval milestones

85,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cost recoveries by Amgen from related party

'

'

'

'

'

'

'

'

'

'

'

'

218,000,000

142,000,000

85,000,000

'

'

'

'

Amount due from related party

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

22,000,000

'

Amount owed to related party

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$31,000,000

Other_charges_Details_Textual

Other charges (Details Textual) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Cost of Sales [Member] | Manufacturing operations optimization [Member]	'	'	'
Cost Savings Initiatives (Textuals) [Line Items]	'	'	'
Incremental depreciation in excess of what otherwise would have been recorded	'	$42	$42
Charges related to lease period beyond supply period	'	'	23
Manufacturing operations optimization	'	'	'
Impairment of fixed assets to be disposed of	'	118	'
Other operating expense [Member]	'	'	'
Legal settlement	'	'	'
Loss accrual	'	'	780
Other operating expense [Member] | Other cost savings initiative [Member]	'	'	'
Cost Savings Initiatives (Textuals) [Line Items]	'	'	'
Severance and lease termination costs	$71	$175	$109

Availableforsale_investments_D

Available-for-sale investments (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Millions, unless otherwise specified
Amortized cost, gross unrealized gains, gross unrealized losses and estimated fair values of available-for-sale investments by type of security	'	'
Amortized cost	$22,432	$23,455
Gross unrealized gains	97	312
Gross unrealized losses	-166	-22
Total available-for-sale investments, fair value	22,363	23,745
U.S. Treasury securities [Member]	'	'
Amortized cost, gross unrealized gains, gross unrealized losses and estimated fair values of available-for-sale investments by type of security	'	'
Amortized cost	4,737	4,443
Gross unrealized gains	2	15
Gross unrealized losses	-9	0
Total available-for-sale investments, fair value	4,730	4,458
Other government-related debt securities - U.S. [Member]	'	'
Amortized cost, gross unrealized gains, gross unrealized losses and estimated fair values of available-for-sale investments by type of security	'	'
Amortized cost	1,087	1,018
Gross unrealized gains	0	12
Gross unrealized losses	-8	0
Total available-for-sale investments, fair value	1,079	1,030
Other government-related debt securities - Foreign and other [Member]	'	'
Amortized cost, gross unrealized gains, gross unrealized losses and estimated fair values of available-for-sale investments by type of security	'	'
Amortized cost	1,574	1,549
Gross unrealized gains	13	60
Gross unrealized losses	-41	-1
Total available-for-sale investments, fair value	1,546	1,608
Corporate debt securities - Financial [Member]	'	'
Amortized cost, gross unrealized gains, gross unrealized losses and estimated fair values of available-for-sale investments by type of security	'	'
Amortized cost	3,667	3,266
Gross unrealized gains	28	96
Gross unrealized losses	-19	-1
Total available-for-sale investments, fair value	3,676	3,361
Corporate debt securities - Industrial [Member]	'	'
Amortized cost, gross unrealized gains, gross unrealized losses and estimated fair values of available-for-sale investments by type of security	'	'
Amortized cost	3,745	4,283
Gross unrealized gains	36	100
Gross unrealized losses	-21	-3
Total available-for-sale investments, fair value	3,760	4,380
Corporate debt securities - Other [Member]	'	'
Amortized cost, gross unrealized gains, gross unrealized losses and estimated fair values of available-for-sale investments by type of security	'	'
Amortized cost	388	441
Gross unrealized gains	4	11
Gross unrealized losses	-2	0
Total available-for-sale investments, fair value	390	452
Residential mortgage-backed securities [Member]	'	'
Amortized cost, gross unrealized gains, gross unrealized losses and estimated fair values of available-for-sale investments by type of security	'	'
Amortized cost	1,478	1,828
Gross unrealized gains	3	9
Gross unrealized losses	-21	-8
Total available-for-sale investments, fair value	1,460	1,829
Other mortgage- and asset-backed securities [Member]	'	'
Amortized cost, gross unrealized gains, gross unrealized losses and estimated fair values of available-for-sale investments by type of security	'	'
Amortized cost	1,555	1,769
Gross unrealized gains	1	7
Gross unrealized losses	-45	-9
Total available-for-sale investments, fair value	1,511	1,767
Money market mutual funds [Member]	'	'
Amortized cost, gross unrealized gains, gross unrealized losses and estimated fair values of available-for-sale investments by type of security	'	'
Amortized cost	3,366	2,620
Gross unrealized gains	0	0
Gross unrealized losses	0	0
Total available-for-sale investments, fair value	3,366	2,620
Other short-term interest-bearing securities [Member]	'	'
Amortized cost, gross unrealized gains, gross unrealized losses and estimated fair values of available-for-sale investments by type of security	'	'
Amortized cost	750	2,186
Gross unrealized gains	0	0
Gross unrealized losses	0	0
Total available-for-sale investments, fair value	750	2,186
Total interest-bearing securities [Member]	'	'
Amortized cost, gross unrealized gains, gross unrealized losses and estimated fair values of available-for-sale investments by type of security	'	'
Amortized cost	22,347	23,403
Gross unrealized gains	87	310
Gross unrealized losses	-166	-22
Total available-for-sale investments, fair value	22,268	23,691
Equity securities [Member]	'	'
Amortized cost, gross unrealized gains, gross unrealized losses and estimated fair values of available-for-sale investments by type of security	'	'
Amortized cost	85	52
Gross unrealized gains	10	2
Gross unrealized losses	0	0
Total available-for-sale investments, fair value	$95	$54

Availableforsale_investments_D1

Available-for-sale investments (Details 1) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
In Millions, unless otherwise specified
Fair values of available-for-sale investments by classification in the Consolidated Balance Sheets	'	'	'	'
Cash and cash equivalents	$3,805	$3,257	$6,946	$3,287
Marketable securities	15,596	20,804	'	'
Other assets - noncurrent	1,767	1,133	'	'
Restricted investments	3,412	0	'	'
Total available-for-sale investments, fair value	22,363	23,745	'	'
Available-for-sale investments [Member]	'	'	'	'
Fair values of available-for-sale investments by classification in the Consolidated Balance Sheets	'	'	'	'
Cash and cash equivalents	3,266	2,887	'	'
Other assets - noncurrent	95	54	'	'
ATL Holdings [Member] | Available-for-sale investments [Member]	'	'	'	'
Fair values of available-for-sale investments by classification in the Consolidated Balance Sheets	'	'	'	'
Restricted investments	$3,406	$0	'	'

Availableforsale_investments_D2

Available-for-sale investments (Details 2) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Millions, unless otherwise specified
Fair values of available-for-sale debt security investments by contractual maturity	'	'
Maturing in one year or less	$6,799	$7,175
Maturing after one year through three years	4,785	5,014
Maturing after three years through five years	6,057	6,286
Maturing after five years through ten years	1,656	1,620
Mortgage- and asset-backed securities	2,971	3,596
Total available-for-sale investments, fair value	22,363	23,745
Total interest-bearing securities [Member]	'	'
Fair values of available-for-sale debt security investments by contractual maturity	'	'
Total available-for-sale investments, fair value	$22,268	$23,691

Availableforsale_investments_D3

Available-for-sale investments (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013	Sep. 30, 2013
				ATL Holdings [Member]	Reclassified to Restricted Investments [Member]
Schedule of Equity Method Investments [Line Items]	'	'	'	'	'
Interest receivable	'	'	'	$6,000,000	$4,000,000
Available for sale securities gross unrealized loss accumulated in investments	166,000,000	22,000,000	'	'	'
Fair value of investments in continuous unrealized loss position, less than 12 months	10,000,000,000	'	'	'	'
Available-for-sale investments (Textual) [Abstract]	'	'	'	'	'
Cash	539,000,000	370,000,000	'	'	526,000,000
Marketable securities	15,596,000,000	20,804,000,000	'	'	2,881,000,000
Total realized gains	158,000,000	186,000,000	191,000,000	'	'
Total realized losses	$83,000,000	$54,000,000	$37,000,000	'	'

Inventories_Details

Inventories (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Millions, unless otherwise specified
Inventories	'	'
Raw materials	$217	$192
Work in process	2,064	1,723
Finished goods	738	829
Total inventories	$3,019	$2,744

Property_plant_and_equipment_D

Property, plant and equipment (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013
In Millions, unless otherwise specified			Building and Improvements [Member]	Building and Improvements [Member]	Manufacturing Equipment [Member]	Manufacturing Equipment [Member]	Laboratory Equipment [Member]	Laboratory Equipment [Member]	Other [Member]	Other [Member]
			Minimum [Member]	Maximum [Member]	Minimum [Member]	Maximum [Member]	Minimum [Member]	Maximum [Member]	Minimum [Member]	Maximum [Member]
Property, Plant and Equipment [Line Items]	'	'	'	'	'	'	'	'	'	'
Useful life	'	'	'10 years	'40 years	'8 years	'12 years	'8 years	'12 years	'3 years	'15 years
Property, plant and equipment [Abstract]	'	'	'	'	'	'	'	'	'	'
Land	$408	$412	'	'	'	'	'	'	'	'
Buildings and improvements	3,467	3,510	'	'	'	'	'	'	'	'
Manufacturing equipment	2,024	2,007	'	'	'	'	'	'	'	'
Laboratory equipment	1,165	1,056	'	'	'	'	'	'	'	'
Other	4,107	3,891	'	'	'	'	'	'	'	'
Construction in progress	1,120	1,071	'	'	'	'	'	'	'	'
Property, plant and equipment, gross	12,291	11,947	'	'	'	'	'	'	'	'
Less accumulated depreciation and amortization	-6,942	-6,621	'	'	'	'	'	'	'	'
Property, plant and equipment, net	$5,349	$5,326	'	'	'	'	'	'	'	'

Property_plant_and_equipment_D1

Property, plant and equipment (Details Textual) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Property, Plant and Equipment [Abstract]	'	'	'
Depreciation and amortization charges associated with property, plant and equipment	$644	$689	$679

Goodwill_and_intangible_assets2

Goodwill and intangible assets (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Goodwill [Roll Forward]	'	'
Beginning balance	$12,662	$11,750
Goodwill resulting from acquisitions of businesses	2,526	928
Currency translation and other adjustments	-220	-16
Ending balance	$14,968	$12,662

Goodwill_and_intangible_assets3

Goodwill and intangible assets (Details 1) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Millions, unless otherwise specified
Finite-lived intangible assets:	'	'
Gross carrying amount	$15,197	$6,443
Accumulated amortization	-4,575	-3,934
Intangible assets, net	10,622	2,509
Indefinite-lived intangible assets:	'	'
Identifiable intangible assets	17,837	7,902
Accumulated amortization	-4,575	-3,934
Identifiable intangible assets, net	13,262	3,968
IPR&D [Member]	'	'
Indefinite-lived intangible assets:	'	'
Indefinite-lived intangible assets	2,640	1,459
Developed Product Technology Rights [Member]	'	'
Finite-lived intangible assets:	'	'
Gross carrying amount	10,130	4,220
Accumulated amortization	-3,347	-2,942
Intangible assets, net	6,783	1,278
Licensing Rights [Member]	'	'
Finite-lived intangible assets:	'	'
Gross carrying amount	3,241	445
Accumulated amortization	-366	-268
Intangible assets, net	2,875	177
R&D Technology Rights [Member]	'	'
Finite-lived intangible assets:	'	'
Gross carrying amount	1,207	1,130
Accumulated amortization	-496	-411
Intangible assets, net	711	719
Marketing-related Rights [Member]	'	'
Finite-lived intangible assets:	'	'
Gross carrying amount	619	648
Accumulated amortization	-366	-313
Intangible assets, net	$253	$335

Goodwill_and_intangible_assets4

Goodwill and intangible assets (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]	'	'	'
Amortization charges associated with finite-lived intangible assets	$642,000,000	$397,000,000	$380,000,000
Total estimated amortization of finite- lived intangible assets for 2014	1,200,000,000	'	'
Total estimated amortization of finite- lived intangible assets for 2015	1,200,000,000	'	'
Total estimated amortization of finite- lived intangible assets for 2016	1,200,000,000	'	'
Total estimated amortization of finite-lived intangible assets for 2017	1,100,000,000	'	'
Total estimated amortization of finite-lived intangible assets for 2018	$902,000,000	'	'

Accrued_liabilites_Details

Accrued liabilites (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Millions, unless otherwise specified
Accrued liabilities [Abstract]	'	'
Sales deductions	$1,248	$1,129
Employee compensation and benefits	1,003	1,010
Clinical development costs	522	361
Dividends payable	460	355
Sales returns reserve	295	346
Other	1,127	1,590
Total accrued liabilities	$4,655	$4,791

Financing_arrangements_Details

Financing arrangements (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Millions, unless otherwise specified
Carrying values of long-term borrowings	'	'
Other notes, including our zero- coupon convertible notes	$105	$109
Total debt	32,128	26,529
Less current portion	-2,505	-2,495
Total noncurrent debt	29,623	24,034
0.375% convertible notes due 2013 (0.375% 2013 Convertible Notes) [Member]	'	'
Carrying values of long-term borrowings	'	'
Convertible notes, current	'	2,488
1.875% notes due 2014 (1.875% 2014 Notes) [Member]	'	'
Carrying values of long-term borrowings	'	'
Total noncurrent debt	1,000	1,000
4.85% notes due 2014 (4.85% 2014 Notes) [Member]	'	'
Carrying values of long-term borrowings	'	'
Total noncurrent debt	1,000	1,000
2.30% notes due 2016 (2.30% 2016 Notes) [Member]	'	'
Carrying values of long-term borrowings	'	'
Total noncurrent debt	749	749
2.50% notes due 2016 (2.50% 2016 Notes) [Member]	'	'
Carrying values of long-term borrowings	'	'
Total noncurrent debt	999	999
2.125% notes due 2017 (2.125% 2017 Notes) [Member]	'	'
Carrying values of long-term borrowings	'	'
Total noncurrent debt	1,248	1,248
5.85% notes due 2017 (5.85% 2017 Notes) [Member]	'	'
Carrying values of long-term borrowings	'	'
Total noncurrent debt	1,099	1,099
6.15% notes due 2018 (6.15% 2018 Notes) [Member]	'	'
Carrying values of long-term borrowings	'	'
Total noncurrent debt	500	499
Master Repurchase Agreement Obligation Due 2018 [Member]	'	'
Carrying values of long-term borrowings	'	'
Loans payable to bank, noncurrent	3,100	'
Term Loan Due 2018 [Member]	'	'
Carrying values of long-term borrowings	'	'
Loans payable to bank, noncurrent	4,875	'
4.375% euro denominated notes due 2018 (4.375% 2018 euro Notes) [Member]	'	'
Carrying values of long-term borrowings	'	'
Total noncurrent debt	751	723
5.70% notes due 2019 (5.70% 2019 Notes) [Member]	'	'
Carrying values of long-term borrowings	'	'
Total noncurrent debt	999	999
2.125% euro denominated notes due 2019 (2.125% 2019 euro Notes) [Member]	'	'
Carrying values of long-term borrowings	'	'
Total noncurrent debt	925	887
4.50% notes due 2020 (4.50% 2020 Notes) [Member]	'	'
Carrying values of long-term borrowings	'	'
Total noncurrent debt	300	300
3.45% notes due 2020 (3.45% 2020 Notes) [Member]	'	'
Carrying values of long-term borrowings	'	'
Total noncurrent debt	898	897
4.10% notes due 2021 (4.10% 2021 Notes) [Member]	'	'
Carrying values of long-term borrowings	'	'
Total noncurrent debt	998	998
3.875% notes due 2021 (3.875% 2021 Notes) [Member]	'	'
Carrying values of long-term borrowings	'	'
Total noncurrent debt	1,746	1,745
3.625% notes due 2022 (3.625% 2022 Notes) [Member]	'	'
Carrying values of long-term borrowings	'	'
Total noncurrent debt	747	747
5.50% pound sterling denominated notes due 2026 (5.50% 2026 pound sterling Notes) [Member]	'	'
Carrying values of long-term borrowings	'	'
Total noncurrent debt	781	763
4.00% pound sterling denominated notes due 2029 (4.00% 2029 pound sterling Notes) [Member]	'	'
Carrying values of long-term borrowings	'	'
Total noncurrent debt	1,144	1,117
6.375% notes due 2037 (6.375% 2037 Notes) [Member]	'	'
Carrying values of long-term borrowings	'	'
Total noncurrent debt	899	899
6.90% notes due 2038 (6.90% 2038 Notes) [Member]	'	'
Carrying values of long-term borrowings	'	'
Total noncurrent debt	499	499
6.40% notes due 2039 (6.40% 2039 Notes) [Member]	'	'
Carrying values of long-term borrowings	'	'
Total noncurrent debt	996	996
5.75% notes due 2040 (5.75% 2040 Notes) [Member]	'	'
Carrying values of long-term borrowings	'	'
Total noncurrent debt	697	697
4.95% notes due 2041 (4.95% 2041 Notes) [Member]	'	'
Carrying values of long-term borrowings	'	'
Total noncurrent debt	596	595
5.15% notes due 2041 (5.15% 2041 Notes) [Member]	'	'
Carrying values of long-term borrowings	'	'
Total noncurrent debt	2,233	2,232
5.65% notes due 2042 (5.65% 2042 Notes) [Member]	'	'
Carrying values of long-term borrowings	'	'
Total noncurrent debt	1,244	1,244
5.375% notes due 2043 (5.375% 2043 Notes) [Member]	'	'
Carrying values of long-term borrowings	'	'
Total noncurrent debt	$1,000	$1,000

Financing_arrangements_Details1

Financing arrangements (Details 1) (Interest rate swap [Member], USD $)	Dec. 31, 2013	Dec. 31, 2011	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013
In Millions, unless otherwise specified			3.45% notes due 2020 (3.45% 2020 Notes) [Member]	4.10% notes due 2021 (4.10% 2021 Notes) [Member]	3.875% notes due 2021 (3.875% 2021 Notes) [Member]	3.625% notes due 2022 (3.625% 2022 Notes) [Member]
Debt Instrument [Line Items]	'	'	'	'	'	'
Derivative, description of variable rate basis	'	'	'LIBOR	'LIBOR	'LIBOR	'LIBOR
Derivative, effective interest rate	'	'	1.10%	1.70%	2.00%	1.60%
Notional amount	$4,400	$3,600	$900	$1,000	$1,750	$750

Financing_arrangements_Details2

Financing arrangements (Details 2) (USD $)	Dec. 31, 2013
In Millions, unless otherwise specified
Maturities of Long-term Debt [Abstract]	'
2014	$2,505
2015	500
2016	2,250
2017	2,850
2018	7,228
Thereafter	16,873
Total	$32,206

Financing_arrangements_Details3

Financing arrangements (Details Textual)

12 Months Ended

12 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

1 Months Ended

1 Months Ended

12 Months Ended

9 Months Ended

3 Months Ended

3 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2011

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

1-May-13

Feb. 28, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2006

Feb. 28, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Feb. 28, 2011

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 1997

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Sep. 30, 2013

Sep. 30, 2013

Dec. 31, 2013

Sep. 30, 2013

Dec. 31, 2013

USD ($)

USD ($)

USD ($)

Rate Adjustment to LIBOR on Interest Rate Swap Agreements [Member]

Rate Adjustment to LIBOR on Interest Rate Swap Agreements [Member]

Interest rate swap [Member]

Interest rate swap [Member]

Interest rate swap [Member]

Derivatives designated as hedging instrument [Member]

Derivatives designated as hedging instrument [Member]

Onyx Pharmaceuticals, Inc. [Member]

MN [Member]

MN [Member]

0.375% convertible notes due 2013 (0.375% 2013 Convertible Notes) [Member]

0.375% convertible notes due 2013 (0.375% 2013 Convertible Notes) [Member]

0.375% convertible notes due 2013 (0.375% 2013 Convertible Notes) [Member]

0.375% convertible notes due 2013 (0.375% 2013 Convertible Notes) [Member]

0.375% convertible notes due 2013 (0.375% 2013 Convertible Notes) [Member]

0.375% convertible notes due 2013 (0.375% 2013 Convertible Notes) [Member]

0.375% convertible notes due 2013 (0.375% 2013 Convertible Notes) [Member]

1.875% notes due 2014 (1.875% 2014 Notes) [Member]

1.875% notes due 2014 (1.875% 2014 Notes) [Member]

4.85% notes due 2014 (4.85% 2014 Notes) [Member]

4.85% notes due 2014 (4.85% 2014 Notes) [Member]

2.30% notes due 2016 (2.30% 2016 Notes) [Member]

2.30% notes due 2016 (2.30% 2016 Notes) [Member]

2.50% notes due 2016 (2.50% 2016 Notes) [Member]

2.50% notes due 2016 (2.50% 2016 Notes) [Member]

2.125% notes due 2017 (2.125% 2017 Notes) [Member]

2.125% notes due 2017 (2.125% 2017 Notes) [Member]

5.85% notes due 2017 (5.85% 2017 Notes) [Member]

5.85% notes due 2017 (5.85% 2017 Notes) [Member]

6.15% notes due 2018 (6.15% 2018 Notes) [Member]

6.15% notes due 2018 (6.15% 2018 Notes) [Member]

4.375% euro denominated notes due 2018 (4.375% 2018 euro Notes) [Member]

4.375% euro denominated notes due 2018 (4.375% 2018 euro Notes) [Member]

4.375% euro denominated notes due 2018 (4.375% 2018 euro Notes) [Member]

5.70% notes due 2019 (5.70% 2019 Notes) [Member]

5.70% notes due 2019 (5.70% 2019 Notes) [Member]

2.125% euro denominated notes due 2019 (2.125% 2019 euro Notes) [Member]

2.125% euro denominated notes due 2019 (2.125% 2019 euro Notes) [Member]

2.125% euro denominated notes due 2019 (2.125% 2019 euro Notes) [Member]

4.50% notes due 2020 (4.50% 2020 Notes) [Member]

4.50% notes due 2020 (4.50% 2020 Notes) [Member]

3.45% notes due 2020 (3.45% 2020 Notes) [Member]

3.45% notes due 2020 (3.45% 2020 Notes) [Member]

3.45% notes due 2020 (3.45% 2020 Notes) [Member]

4.10% notes due 2021 (4.10% 2021 Notes) [Member]

4.10% notes due 2021 (4.10% 2021 Notes) [Member]

4.10% notes due 2021 (4.10% 2021 Notes) [Member]

3.875% notes due 2021 (3.875% 2021 Notes) [Member]

3.875% notes due 2021 (3.875% 2021 Notes) [Member]

3.875% notes due 2021 (3.875% 2021 Notes) [Member]

3.625% notes due 2022 (3.625% 2022 Notes) [Member]

3.625% notes due 2022 (3.625% 2022 Notes) [Member]

3.625% notes due 2022 (3.625% 2022 Notes) [Member]

5.50% pound sterling denominated notes due 2026 (5.50% 2026 pound sterling Notes) [Member]

5.50% pound sterling denominated notes due 2026 (5.50% 2026 pound sterling Notes) [Member]

5.50% pound sterling denominated notes due 2026 (5.50% 2026 pound sterling Notes) [Member]

4.00% pound sterling denominated notes due 2029 (4.00% 2029 pound sterling Notes) [Member]

4.00% pound sterling denominated notes due 2029 (4.00% 2029 pound sterling Notes) [Member]

4.00% pound sterling denominated notes due 2029 (4.00% 2029 pound sterling Notes) [Member]

6.375% notes due 2037 (6.375% 2037 Notes) [Member]

6.375% notes due 2037 (6.375% 2037 Notes) [Member]

6.90% notes due 2038 (6.90% 2038 Notes) [Member]

6.90% notes due 2038 (6.90% 2038 Notes) [Member]

6.40% notes due 2039 (6.40% 2039 Notes) [Member]

6.40% notes due 2039 (6.40% 2039 Notes) [Member]

5.75% notes due 2040 (5.75% 2040 Notes) [Member]

5.75% notes due 2040 (5.75% 2040 Notes) [Member]

4.95% notes due 2041 (4.95% 2041 Notes) [Member]

4.95% notes due 2041 (4.95% 2041 Notes) [Member]

5.15% notes due 2041 (5.15% 2041 Notes) [Member]

5.15% notes due 2041 (5.15% 2041 Notes) [Member]

5.65% notes due 2042 (5.65% 2042 Notes) [Member]

5.65% notes due 2042 (5.65% 2042 Notes) [Member]

5.375% notes due 2043 (5.375% 2043 Notes) [Member]

5.375% notes due 2043 (5.375% 2043 Notes) [Member]

0.125% convertible notes due 2011 (0.125% 2011 Convertible Notes) [Member]

0.125% convertible notes due 2011 (0.125% 2011 Convertible Notes) [Member]

Notes due 2097 (Other) [Member]

Notes due 2097 (Other) [Member]

Commercial Paper [Member]

Commercial Paper [Member]

Line of Credit [Member]

Line of Credit [Member]

Line of Credit [Member]

Medium-term Notes [Member]

Medium-term Notes [Member]

Medium-term Notes [Member]

Master Repurchase Agreement Obligation Due 2018 [Member]

Master Repurchase Agreement Obligation Due 2018 [Member]

Master Repurchase Agreement Obligation Due 2018 [Member]

Master Repurchase Agreement Obligation Due 2018 [Member]

Master Repurchase Agreement Obligation Due 2018 [Member]

Term Loan Credit Facility [Member]

Term Loan Credit Facility [Member]

Term Loan Credit Facility [Member]

USD ($)

USD ($)

USD ($)

Interest rate swap [Member]

Interest rate swap [Member]

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Excess Conversion Value [Member]

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

EUR (€)

USD ($)

USD ($)

USD ($)

USD ($)

EUR (€)

USD ($)

USD ($)

USD ($)

USD ($)

Interest rate swap [Member]

USD ($)

USD ($)

Interest rate swap [Member]

USD ($)

USD ($)

Interest rate swap [Member]

USD ($)

USD ($)

Interest rate swap [Member]

USD ($)

USD ($)

GBP (£)

USD ($)

USD ($)

GBP (£)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Shelf Registration Statement [Member]

Shelf Registration Statement [Member]

Shelf Registration Statement [Member]

USD ($)

London Interbank Offered Rate (LIBOR) [Member]

ATL Holdings [Member]

ATL Holdings [Member]

ATL Holdings [Member]

USD ($)

USD ($)

London Interbank Offered Rate (LIBOR) [Member]

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

extension

USD ($)

USD ($)

USD ($)

USD ($)

subsidiary

Preferred Class A [Member]

Financing arrangements (Textual) [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stated contractual interest rate on note

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.38%

'

0.38%

'

'

'

1.88%

1.88%

4.85%

4.85%

2.30%

2.30%

2.50%

2.50%

2.13%

2.13%

5.85%

5.85%

6.15%

6.15%

4.38%

4.38%

'

5.70%

5.70%

2.13%

2.13%

2.13%

4.50%

4.50%

3.45%

3.45%

'

4.10%

4.10%

'

3.88%

3.88%

'

3.63%

3.63%

'

5.50%

5.50%

'

4.00%

4.00%

4.00%

6.38%

6.38%

6.90%

6.90%

6.40%

6.40%

5.75%

5.75%

4.95%

4.95%

5.15%

5.15%

5.65%

5.65%

5.38%

5.38%

'

0.13%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Repayments of convertible notes

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$2,500,000,000

'

'

'

'

$99,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$2,500,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Repayment of debt

3,371,000,000

123,000,000

2,500,000,000

'

'

'

'

'

'

'

742,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Repayment of principal amount

125,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Repayment of other notes

4,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Aggregate principal amount of notes issued

8,100,000,000

5,000,000,000

10,500,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,500,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

550,000,000

'

'

'

'

675,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

475,000,000

'

'

700,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total debt issuance costs

46,000,000

25,000,000

55,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Redemption price as a percentage of the principal amount of notes that may be required to be paid in the event of a change in control triggering event

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

101.00%

'

'

'

101.00%

'

101.00%

'

101.00%

'

101.00%

'

101.00%

'

101.00%

'

'

101.00%

'

101.00%

'

'

101.00%

'

101.00%

'

'

101.00%

'

'

101.00%

'

'

101.00%

'

'

101.00%

'

'

101.00%

'

'

101.00%

'

101.00%

'

101.00%

'

101.00%

'

101.00%

'

101.00%

'

101.00%

'

101.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Sale of stock, number of shares issued in transaction

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

34,097

'

'

'

Sale of stock, number of subsidiaries

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1

'

'

'

'

Preferred stock, liquidation preference per share (in usd per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$100,000

'

'

'

'

'

Loans payable to bank, noncurrent

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,100,000,000

'

'

'

'

'

5,000,000,000

'

Description of variable rate basis

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'London Interbank Offered Rate (LIBOR)

'

'

'

'

'LIBOR

'

'

Interest rate charged over LIBOR on any amounts borrowed under the facility

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.90%

'

'

'

'

'

'

1.10%

'

'

'

'

'

1.00%

Debt instrument, periodic payment, principal

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

125,000,000

'

'

Cash settlement of convertible bond hedge

'

'

'

'

'

'

'

'

'

'

'

'

'

'

99,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Class of warrant or right, number of securities called by warrants or rights

'

'

'

'

'

'

'

'

'

'

'

'

'

32,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise price of warrants

'

'

'

'

'

'

'

'

'

'

'

'

'

104.8

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Payments for repurchase of warrants

'

'

'

'

'

'

'

'

'

'

'

'

'

100,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Effective interest rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6.35%

6.35%

6.35%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Interest expense, net

1,022,000,000

1,053,000,000

610,000,000

'

'

'

'

'

'

'

'

'

'

'

'

13,000,000

151,000,000

143,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Non-cash interest expense

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

12,000,000

142,000,000

133,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Carrying amount of equity component of debt

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

829,000,000

829,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total noncurrent debt

29,623,000,000

24,034,000,000

'

'

'

'

'

'

'

'

'

5,000,000

9,000,000

'

'

'

'

'

'

'

1,000,000,000

1,000,000,000

1,000,000,000

1,000,000,000

749,000,000

749,000,000

999,000,000

999,000,000

1,248,000,000

1,248,000,000

1,099,000,000

1,099,000,000

500,000,000

499,000,000

751,000,000

723,000,000

'

999,000,000

999,000,000

925,000,000

887,000,000

'

300,000,000

300,000,000

898,000,000

897,000,000

'

998,000,000

998,000,000

'

1,746,000,000

1,745,000,000

'

747,000,000

747,000,000

'

781,000,000

763,000,000

'

1,144,000,000

1,117,000,000

'

899,000,000

899,000,000

499,000,000

499,000,000

996,000,000

996,000,000

697,000,000

697,000,000

596,000,000

595,000,000

2,233,000,000

2,232,000,000

1,244,000,000

1,244,000,000

1,000,000,000

1,000,000,000

'

'

100,000,000

100,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Interest rate swap contracts - fair value hedge - notional amounts

'

'

'

'

'

'

4,400,000,000

3,600,000,000

4,400,000,000

3,600,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

900,000,000

'

'

1,000,000,000

'

'

1,750,000,000

'

'

750,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Derivative lower range variable interest rate

'

'

'

1.10%

0.30%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Derivative higher range variable interest rate

'

'

'

2.00%

2.60%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Maximum borrowing capacity under commercial paper program

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,500,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amount outstanding under commercial paper program

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Maximum current borrowing capacity under a syndicated, unsecured, revolving credit agreement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,500,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Amount by which the borrowing capacity under a syndicated, unsecured, revolving credit agreement maybe increased upon our request at the discretion of the banks

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

500,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Initial commitment term of each bank which is a party to the agreement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'5 years

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of additional extensions

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2

'

'

'

'

'

'

'

'

'

'

'

'

'

Additional period for extension of commitment term

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'1 year

'

'

'

'

'

'

'

'

'

'

'

'

'

Annual commitment fees for syndicated, unsecured, revolving credit agreement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.10%

'

'

'

'

'

'

'

'

'

'

'

'

'

Amount outstanding under syndicated, unsecured, revolving credit facility

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

0

'

'

'

'

'

'

'

'

'

'

'

Amount that may be issued under a medium term note program established under the shelf registration statement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

400,000,000

'

'

'

'

'

'

'

'

Amount outstanding under medium term note program

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

0

'

'

'

'

'

'

'

'

'

Interest costs capitalized

18,000,000

26,000,000

22,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Interest paid, net of interest rate swaps

930,000,000

406,000,000

446,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Receipt from counterparties upon termination of interest rate swap contracts

'

'

'

'

'

$397,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stockholders_equity_Details

Stockholders' equity (Details) (USD $)

3 Months Ended

12 Months Ended

In Millions, unless otherwise specified

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2012

Sep. 30, 2012

Jun. 30, 2012

Mar. 31, 2012

Dec. 31, 2011

Sep. 30, 2011

Jun. 30, 2011

Mar. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Stock repurchase program

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock repurchases (in shares)

0

0

0

9.1

14.2

9.7

17.4

21

86

45.4

12.9

0

9.1

62.3

144.3

Stock Repurchase Program [Member]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock repurchase program

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock repurchases

0

0

0

771

1,233

797

1,203

1,429

5,154

[1]

2,421

732

0

771

4,662

8,307

[1]

Includes the repurchase of 83.3 million shares of our common stock at an average price paid per share of $60.08, including related expenses, for an aggregate cost of $5.0 billion, under a modified Dutch auction tender offer.

Stockholders_equity_Details_1

Stockholders' equity (Details 1) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Increase (Decrease) in Accumulated Other Comprehensive Income [Roll Forward]	'	'	'
Beginning balance, Foreign currency translation	$12	$21	$22
Beginning balance, Cash flow hedges	-35	43	3
Beginning balance, Available-for-sale securities	183	120	135
Beginning balance, Other	-14	-13	-7
Beginning balance, AOCI	146	171	153
Other Comprehensive Income (Loss), Net of Tax [Abstract]	'	'	'
Foreign currency translation adjustments	-71	-13	-6
Unrealized gains (losses), Cash flow hedges	88	15	-51
Unrealized gains (losses), Available-for-sale securities	-284	233	125
Unrealized gains (losses), Other	-1	-1	2
Unrealized gains (losses), AOCI	-197	247	76
Reclassification adjustments to income, Cash flow hedges	-85	134	112
Reclassification adjustments to income, Available-for-sale securities	-75	132	-154
Reclassification adjustments to income, AOCI	-160	266	-42
Other	-2	'	-8
Other, AOCI	-2	'	-8
Income taxes, Foreign currency translation	-9	4	5
Income taxes, Cash flow hedges	-1	41	-21
Income taxes, Available-for-sale securities	133	-38	14
Income taxes, Other	0	0	0
Income taxes, AOCI	123	7	-2
Ending balance, Foreign currency translation	-68	12	21
Ending balance, Cash flow hedges	-33	-35	43
Ending balance, Available-for-sale securities	-43	183	120
Ending balance, Other	-17	-14	-13
Ending balance, AOCI	($161)	$146	$171

Stockholders_equity_Details_2

Stockholders' equity (Details 2) (USD $)	3 Months Ended								12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Product sales	$4,799	$4,647	$4,595	$4,151	$4,337	$4,201	$4,200	$3,901	$18,192	$16,639	$15,295
Interest and other income, net	'	'	'	'	'	'	'	'	420	485	448
Interest expense, net	'	'	'	'	'	'	'	'	-1,022	-1,053	-610
Income before income taxes	'	'	'	'	'	'	'	'	5,265	5,009	4,150
Tax (expense)	'	'	'	'	'	'	'	'	-184	-664	-467
Net income	1,021	1,368	1,258	1,434	788	1,107	1,266	1,184	5,081	4,345	3,683
Cash flow hedges [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member]	'	'	'	'	'	'	'	'	'	'	'
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Product sales	'	'	'	'	'	'	'	'	4	'	'
Interest and other income, net	'	'	'	'	'	'	'	'	82	'	'
Interest expense, net	'	'	'	'	'	'	'	'	-1	'	'
Income before income taxes	'	'	'	'	'	'	'	'	85	'	'
Tax (expense)	'	'	'	'	'	'	'	'	-33	'	'
Net income	'	'	'	'	'	'	'	'	52	'	'
Available-for-sale securities [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member]	'	'	'	'	'	'	'	'	'	'	'
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Interest and other income, net	'	'	'	'	'	'	'	'	75	'	'
Tax (expense)	'	'	'	'	'	'	'	'	-28	'	'
Net income	'	'	'	'	'	'	'	'	$47	'	'

Stockholders_equity_Details_Te

Stockholders' equity (Details Textual) (USD $)

1 Months Ended

3 Months Ended

12 Months Ended

Dec. 13, 2013

Dec. 06, 2013

Oct. 16, 2013

Sep. 06, 2013

Jul. 26, 2013

Jun. 07, 2013

Mar. 07, 2013

Mar. 06, 2013

Dec. 13, 2012

Dec. 07, 2012

Oct. 10, 2012

Sep. 07, 2012

Jul. 19, 2012

Jun. 07, 2012

Mar. 15, 2012

Mar. 07, 2012

Dec. 15, 2011

Dec. 08, 2011

Oct. 13, 2011

Sep. 08, 2011

Jul. 28, 2011

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2012

Sep. 30, 2012

Jun. 30, 2012

Mar. 31, 2012

Dec. 31, 2011

Sep. 30, 2011

Jun. 30, 2011

Mar. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Stock Repurchase Program [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock repurchases (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

0

0

9,100,000

14,200,000

9,700,000

17,400,000

21,000,000

86,000,000

45,400,000

12,900,000

0

9,100,000

62,300,000

144,300,000

Amount available for stock repurchases under a board approved stock repurchase plan

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1,600,000,000

'

'

Common stock, dividends declared per share (in usd per share)

$0.61

'

$0.47

'

$0.47

'

'

$0.47

$0.47

'

$0.36

'

$0.36

'

$0.36

'

$0.36

'

$0.28

'

$0.28

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Dividends paid per share (in usd per share)

'

$0.47

'

$0.47

'

$0.47

$0.47

'

'

$0.36

'

$0.36

'

$0.36

'

$0.36

'

$0.28

'

$0.28

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Income taxes expense or (benefit) for unrealized gains and losses for cash flow hedges

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

34,000,000

8,000,000

-20,000,000

Income tax expense or (benefit) reclassification adjustments to income for cash flow hedges

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-33,000,000

-49,000,000

41,000,000

Income taxes expense or (benefit) for unrealized gains and losses for available-for-sale securities

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-105,000,000

87,000,000

45,000,000

Income tax expense or (benefit) for reclassification adjustments to income for available-for-sale securities

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-28,000,000

-49,000,000

-59,000,000

Preferred stock shares authorized (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,000,000

'

'

'

'

'

'

'

'

'

'

'

5,000,000

'

'

Preferred stock, par value (in usd per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.00

'

'

'

'

'

'

'

'

'

'

'

$0.00

'

'

Preferred stock, shares issued (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

0

'

'

'

'

'

'

'

0

0

'

Preferred stock, shares outstanding (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

0

'

'

'

'

'

'

'

0

0

'

Modified Dutch Auction Tender Offer [Member]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Repurchase Program [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock repurchases (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

83,300,000

Stock repurchased price per share (in usd per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$60.08

Stock repurchases

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$5,000,000,000

Fair_value_measurement_Details

Fair value measurement (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
In Millions, unless otherwise specified
Assets:	'	'	'
Total available-for-sale investments	$22,363	$23,745	'
Fair Value, Measurements, Recurring [Member]	'	'	'
Derivative Assets:	'	'	'
Total assets	22,609	23,856	'
Derivative Liabilities:	'	'	'
Contingent consideration obligations in connection with a business combination	595	221	'
Total liabilities	867	286	'
Fair Value, Measurements, Recurring [Member] | Foreign currency contracts [Member]	'	'	'
Derivative Assets:	'	'	'
Foreign currency contracts	53	46	'
Derivative Liabilities:	'	'	'
Foreign currency contracts	107	59	'
Fair Value, Measurements, Recurring [Member] | Cross currency swap contracts [Member]	'	'	'
Derivative Assets:	'	'	'
Foreign currency contracts	193	65	'
Derivative Liabilities:	'	'	'
Foreign currency contracts	4	6	'
Fair Value, Measurements, Recurring [Member] | Interest rate swap contracts [Member]	'	'	'
Derivative Liabilities:	'	'	'
Interest rate swap contracts	161	'	'
Fair Value, Measurements, Recurring [Member] | U.S. Treasury securities [Member]	'	'	'
Assets:	'	'	'
Total available-for-sale investments	4,730	4,458	'
Fair Value, Measurements, Recurring [Member] | Other government-related debt securities - U.S. [Member]	'	'	'
Assets:	'	'	'
Total available-for-sale investments	1,079	1,030	'
Fair Value, Measurements, Recurring [Member] | Other government-related debt securities - Foreign and other [Member]	'	'	'
Assets:	'	'	'
Total available-for-sale investments	1,546	1,608	'
Fair Value, Measurements, Recurring [Member] | Corporate debt securities - Financial [Member]	'	'	'
Assets:	'	'	'
Total available-for-sale investments	3,676	3,361	'
Fair Value, Measurements, Recurring [Member] | Corporate debt securities - Industrial [Member]	'	'	'
Assets:	'	'	'
Total available-for-sale investments	3,760	4,380	'
Fair Value, Measurements, Recurring [Member] | Corporate debt securities - Other [Member]	'	'	'
Assets:	'	'	'
Total available-for-sale investments	390	452	'
Fair Value, Measurements, Recurring [Member] | Residential mortgage-backed securities [Member]	'	'	'
Assets:	'	'	'
Total available-for-sale investments	1,460	1,829	'
Fair Value, Measurements, Recurring [Member] | Other mortgage- and asset-backed securities [Member]	'	'	'
Assets:	'	'	'
Total available-for-sale investments	1,511	1,767	'
Fair Value, Measurements, Recurring [Member] | Money market mutual funds [Member]	'	'	'
Assets:	'	'	'
Total available-for-sale investments	3,366	2,620	'
Fair Value, Measurements, Recurring [Member] | Other short-term interest-bearing securities [Member]	'	'	'
Assets:	'	'	'
Total available-for-sale investments	750	2,186	'
Fair Value, Measurements, Recurring [Member] | Equity securities [Member]	'	'	'
Assets:	'	'	'
Total available-for-sale investments	95	54	'
Fair Value, Measurements, Recurring [Member] | Quoted prices in active markets for identical assets (Level 1) [Member]	'	'	'
Derivative Assets:	'	'	'
Total assets	8,191	7,132	'
Derivative Liabilities:	'	'	'
Contingent consideration obligations in connection with a business combination	0	0	'
Total liabilities	0	0	'
Fair Value, Measurements, Recurring [Member] | Quoted prices in active markets for identical assets (Level 1) [Member] | Foreign currency contracts [Member]	'	'	'
Derivative Assets:	'	'	'
Foreign currency contracts	0	0	'
Derivative Liabilities:	'	'	'
Foreign currency contracts	0	0	'
Fair Value, Measurements, Recurring [Member] | Quoted prices in active markets for identical assets (Level 1) [Member] | Cross currency swap contracts [Member]	'	'	'
Derivative Assets:	'	'	'
Foreign currency contracts	0	0	'
Derivative Liabilities:	'	'	'
Foreign currency contracts	0	0	'
Fair Value, Measurements, Recurring [Member] | Quoted prices in active markets for identical assets (Level 1) [Member] | Interest rate swap contracts [Member]	'	'	'
Derivative Liabilities:	'	'	'
Interest rate swap contracts	0	'	'
Fair Value, Measurements, Recurring [Member] | Quoted prices in active markets for identical assets (Level 1) [Member] | U.S. Treasury securities [Member]	'	'	'
Assets:	'	'	'
Total available-for-sale investments	4,730	4,458	'
Fair Value, Measurements, Recurring [Member] | Quoted prices in active markets for identical assets (Level 1) [Member] | Other government-related debt securities - U.S. [Member]	'	'	'
Assets:	'	'	'
Total available-for-sale investments	0	0	'
Fair Value, Measurements, Recurring [Member] | Quoted prices in active markets for identical assets (Level 1) [Member] | Other government-related debt securities - Foreign and other [Member]	'	'	'
Assets:	'	'	'
Total available-for-sale investments	0	0	'
Fair Value, Measurements, Recurring [Member] | Quoted prices in active markets for identical assets (Level 1) [Member] | Corporate debt securities - Financial [Member]	'	'	'
Assets:	'	'	'
Total available-for-sale investments	0	0	'
Fair Value, Measurements, Recurring [Member] | Quoted prices in active markets for identical assets (Level 1) [Member] | Corporate debt securities - Industrial [Member]	'	'	'
Assets:	'	'	'
Total available-for-sale investments	0	0	'
Fair Value, Measurements, Recurring [Member] | Quoted prices in active markets for identical assets (Level 1) [Member] | Corporate debt securities - Other [Member]	'	'	'
Assets:	'	'	'
Total available-for-sale investments	0	0	'
Fair Value, Measurements, Recurring [Member] | Quoted prices in active markets for identical assets (Level 1) [Member] | Residential mortgage-backed securities [Member]	'	'	'
Assets:	'	'	'
Total available-for-sale investments	0	0	'
Fair Value, Measurements, Recurring [Member] | Quoted prices in active markets for identical assets (Level 1) [Member] | Other mortgage- and asset-backed securities [Member]	'	'	'
Assets:	'	'	'
Total available-for-sale investments	0	0	'
Fair Value, Measurements, Recurring [Member] | Quoted prices in active markets for identical assets (Level 1) [Member] | Money market mutual funds [Member]	'	'	'
Assets:	'	'	'
Total available-for-sale investments	3,366	2,620	'
Fair Value, Measurements, Recurring [Member] | Quoted prices in active markets for identical assets (Level 1) [Member] | Other short-term interest-bearing securities [Member]	'	'	'
Assets:	'	'	'
Total available-for-sale investments	0	0	'
Fair Value, Measurements, Recurring [Member] | Quoted prices in active markets for identical assets (Level 1) [Member] | Equity securities [Member]	'	'	'
Assets:	'	'	'
Total available-for-sale investments	95	54	'
Fair Value, Measurements, Recurring [Member] | Significant other observable inputs (Level 2) [Member]	'	'	'
Derivative Assets:	'	'	'
Total assets	14,418	16,724	'
Derivative Liabilities:	'	'	'
Contingent consideration obligations in connection with a business combination	0	0	'
Total liabilities	272	65	'
Fair Value, Measurements, Recurring [Member] | Significant other observable inputs (Level 2) [Member] | Foreign currency contracts [Member]	'	'	'
Derivative Assets:	'	'	'
Foreign currency contracts	53	46	'
Derivative Liabilities:	'	'	'
Foreign currency contracts	107	59	'
Fair Value, Measurements, Recurring [Member] | Significant other observable inputs (Level 2) [Member] | Cross currency swap contracts [Member]	'	'	'
Derivative Assets:	'	'	'
Foreign currency contracts	193	65	'
Derivative Liabilities:	'	'	'
Foreign currency contracts	4	6	'
Fair Value, Measurements, Recurring [Member] | Significant other observable inputs (Level 2) [Member] | Interest rate swap contracts [Member]	'	'	'
Derivative Liabilities:	'	'	'
Interest rate swap contracts	161	'	'
Fair Value, Measurements, Recurring [Member] | Significant other observable inputs (Level 2) [Member] | U.S. Treasury securities [Member]	'	'	'
Assets:	'	'	'
Total available-for-sale investments	0	0	'
Fair Value, Measurements, Recurring [Member] | Significant other observable inputs (Level 2) [Member] | Other government-related debt securities - U.S. [Member]	'	'	'
Assets:	'	'	'
Total available-for-sale investments	1,079	1,030	'
Fair Value, Measurements, Recurring [Member] | Significant other observable inputs (Level 2) [Member] | Other government-related debt securities - Foreign and other [Member]	'	'	'
Assets:	'	'	'
Total available-for-sale investments	1,546	1,608	'
Fair Value, Measurements, Recurring [Member] | Significant other observable inputs (Level 2) [Member] | Corporate debt securities - Financial [Member]	'	'	'
Assets:	'	'	'
Total available-for-sale investments	3,676	3,361	'
Fair Value, Measurements, Recurring [Member] | Significant other observable inputs (Level 2) [Member] | Corporate debt securities - Industrial [Member]	'	'	'
Assets:	'	'	'
Total available-for-sale investments	3,760	4,380	'
Fair Value, Measurements, Recurring [Member] | Significant other observable inputs (Level 2) [Member] | Corporate debt securities - Other [Member]	'	'	'
Assets:	'	'	'
Total available-for-sale investments	390	452	'
Fair Value, Measurements, Recurring [Member] | Significant other observable inputs (Level 2) [Member] | Residential mortgage-backed securities [Member]	'	'	'
Assets:	'	'	'
Total available-for-sale investments	1,460	1,829	'
Fair Value, Measurements, Recurring [Member] | Significant other observable inputs (Level 2) [Member] | Other mortgage- and asset-backed securities [Member]	'	'	'
Assets:	'	'	'
Total available-for-sale investments	1,511	1,767	'
Fair Value, Measurements, Recurring [Member] | Significant other observable inputs (Level 2) [Member] | Money market mutual funds [Member]	'	'	'
Assets:	'	'	'
Total available-for-sale investments	0	0	'
Fair Value, Measurements, Recurring [Member] | Significant other observable inputs (Level 2) [Member] | Other short-term interest-bearing securities [Member]	'	'	'
Assets:	'	'	'
Total available-for-sale investments	750	2,186	'
Fair Value, Measurements, Recurring [Member] | Significant other observable inputs (Level 2) [Member] | Equity securities [Member]	'	'	'
Assets:	'	'	'
Total available-for-sale investments	0	0	'
Fair Value, Measurements, Recurring [Member] | Significant unobservable inputs (Level 3) [Member]	'	'	'
Derivative Assets:	'	'	'
Total assets	'	0	'
Derivative Liabilities:	'	'	'
Contingent consideration obligations in connection with a business combination	595	221	190
Total liabilities	595	221	'
Fair Value, Measurements, Recurring [Member] | Significant unobservable inputs (Level 3) [Member] | Foreign currency contracts [Member]	'	'	'
Derivative Assets:	'	'	'
Foreign currency contracts	0	0	'
Derivative Liabilities:	'	'	'
Foreign currency contracts	0	0	'
Fair Value, Measurements, Recurring [Member] | Significant unobservable inputs (Level 3) [Member] | Cross currency swap contracts [Member]	'	'	'
Derivative Assets:	'	'	'
Foreign currency contracts	0	0	'
Derivative Liabilities:	'	'	'
Foreign currency contracts	0	0	'
Fair Value, Measurements, Recurring [Member] | Significant unobservable inputs (Level 3) [Member] | Interest rate swap contracts [Member]	'	'	'
Derivative Liabilities:	'	'	'
Interest rate swap contracts	0	'	'
Fair Value, Measurements, Recurring [Member] | Significant unobservable inputs (Level 3) [Member] | U.S. Treasury securities [Member]	'	'	'
Assets:	'	'	'
Total available-for-sale investments	0	0	'
Fair Value, Measurements, Recurring [Member] | Significant unobservable inputs (Level 3) [Member] | Other government-related debt securities - U.S. [Member]	'	'	'
Assets:	'	'	'
Total available-for-sale investments	0	0	'
Fair Value, Measurements, Recurring [Member] | Significant unobservable inputs (Level 3) [Member] | Other government-related debt securities - Foreign and other [Member]	'	'	'
Assets:	'	'	'
Total available-for-sale investments	0	0	'
Fair Value, Measurements, Recurring [Member] | Significant unobservable inputs (Level 3) [Member] | Corporate debt securities - Financial [Member]	'	'	'
Assets:	'	'	'
Total available-for-sale investments	0	0	'
Fair Value, Measurements, Recurring [Member] | Significant unobservable inputs (Level 3) [Member] | Corporate debt securities - Industrial [Member]	'	'	'
Assets:	'	'	'
Total available-for-sale investments	0	0	'
Fair Value, Measurements, Recurring [Member] | Significant unobservable inputs (Level 3) [Member] | Corporate debt securities - Other [Member]	'	'	'
Assets:	'	'	'
Total available-for-sale investments	0	0	'
Fair Value, Measurements, Recurring [Member] | Significant unobservable inputs (Level 3) [Member] | Residential mortgage-backed securities [Member]	'	'	'
Assets:	'	'	'
Total available-for-sale investments	0	0	'
Fair Value, Measurements, Recurring [Member] | Significant unobservable inputs (Level 3) [Member] | Other mortgage- and asset-backed securities [Member]	'	'	'
Assets:	'	'	'
Total available-for-sale investments	0	0	'
Fair Value, Measurements, Recurring [Member] | Significant unobservable inputs (Level 3) [Member] | Money market mutual funds [Member]	'	'	'
Assets:	'	'	'
Total available-for-sale investments	0	0	'
Fair Value, Measurements, Recurring [Member] | Significant unobservable inputs (Level 3) [Member] | Other short-term interest-bearing securities [Member]	'	'	'
Assets:	'	'	'
Total available-for-sale investments	0	0	'
Fair Value, Measurements, Recurring [Member] | Significant unobservable inputs (Level 3) [Member] | Equity securities [Member]	'	'	'
Assets:	'	'	'
Total available-for-sale investments	$0	$0	'

Fair_value_measurement_Fair_va

Fair value measurement Fair value measurement (Details 1) (Fair Value, Measurements, Recurring [Member], USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Ending balance	$595	$221
Significant unobservable inputs (Level 3) [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Beginning balance	221	190
Additions from Onyx acquisition	261	0
Net changes in valuation	113	31
Ending balance	$595	$221

Fair_value_measurement_Details1

Fair value measurement (Details Textual) (USD $)	12 Months Ended		1 Months Ended	12 Months Ended					12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Mar. 31, 2011	Dec. 31, 2013	Dec. 31, 2012	Mar. 04, 2011	Dec. 31, 2013	Sep. 30, 2013	Dec. 31, 2013	Dec. 31, 2013
			Biovex Group Inc [Member]	Biovex Group Inc [Member]	Biovex Group Inc [Member]	Biovex Group Inc [Member]	Onyx Pharmaceuticals, Inc. [Member]	Onyx Pharmaceuticals, Inc. [Member]	Other government-related debt securities [Member]	Corporate debt securities [Member]
			ContingentConsideration				payment
Fair Value Measurement (Textual) [Abstract]	'	'	'	'	'	'	'	'	'	'
Investment maturity period	'	'	'	'	'	'	'	'	'5 years	'5 years
Length of time hedged in foreign currency contracts	'3 years	'	'	'	'	'	'	'	'	'
Maximum additional consideration due contingent on certain milestones	'	'	$575,000,000	'	'	$575,000,000	$150,000,000	'	'	'
Maximum number of contingent consideration payments for achieving regulatory and sales related milestones	'	'	8	'	'	'	'	'	'	'
The number of payments that will potentially be made that each equal the largest potential contingent consideration payment	'	'	3	'	'	'	'	'	'	'
Largest potential contingent consideration payments	'	'	125,000,000	'	'	'	'	'	'	'
Change in fair values of contingent consideration obligations	'	'	'	113,000,000	31,000,000	'	'	'	'	'
Assumed contingent consideration obligation	'	'	'	'	'	'	'	261,000,000	'	'
Number of milestone payments	'	'	'	'	'	'	2	'	'	'
Aggregate fair value of long-term debt, including current portion	33,500,000,000	29,900,000,000	'	'	'	'	'	'	'	'
Carrying value of long-term debt, including current portion	$32,128,000,000	$26,529,000,000	'	'	'	'	'	'	'	'

Derivative_Instruments_Details

Derivative Instruments (Details) (Cash flow hedge [Member], Cross currency swap contracts [Member])

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

In Millions, unless otherwise specified

2.125% euro denominated notes due 2019 (2.125% 2019 euro Notes) [Member]

2.125% euro denominated notes due 2019 (2.125% 2019 euro Notes) [Member]

5.50% pound sterling denominated notes due 2026 (5.50% 2026 pound sterling Notes) [Member]

5.50% pound sterling denominated notes due 2026 (5.50% 2026 pound sterling Notes) [Member]

4.00% pound sterling denominated notes due 2029 (4.00% 2029 pound sterling Notes) [Member]

4.00% pound sterling denominated notes due 2029 (4.00% 2029 pound sterling Notes) [Member]

Interest rate received [Member]

Interest rate received [Member]

Interest rate received [Member]

Interest rate paid [Member]

Interest rate paid [Member]

Interest rate paid [Member]

USD ($)

EUR (€)

USD ($)

GBP (£)

USD ($)

GBP (£)

2.125% euro denominated notes due 2019 (2.125% 2019 euro Notes) [Member]

5.50% pound sterling denominated notes due 2026 (5.50% 2026 pound sterling Notes) [Member]

4.00% pound sterling denominated notes due 2029 (4.00% 2029 pound sterling Notes) [Member]

2.125% euro denominated notes due 2019 (2.125% 2019 euro Notes) [Member]

5.50% pound sterling denominated notes due 2026 (5.50% 2026 pound sterling Notes) [Member]

4.00% pound sterling denominated notes due 2029 (4.00% 2029 pound sterling Notes) [Member]

Derivative [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Notional Amount

$864

€ 675

$748

£ 475

$1,122

£ 700

'

'

'

'

'

'

Fixed Interest Rate

'

'

'

'

'

'

2.13%

5.50%

4.00%

2.60%

5.80%

4.30%

Derivative_Instruments_Details1

Derivative Instruments (Details 1) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Effective portion of the unrealized gain (loss) recognized in Other Comprehensive Income for our derivative instruments designated as cash flow hedges contracts [Abstract]	'	'	'
Unrealized gain (loss) on derivative instruments recognized in Other Comprehensive Income, effective portion, net	$88	$15	($51)
Foreign currency contracts [Member]	'	'	'
Effective portion of the unrealized gain (loss) recognized in Other Comprehensive Income for our derivative instruments designated as cash flow hedges contracts [Abstract]	'	'	'
Unrealized gain (loss) on derivative instruments recognized in Other Comprehensive Income, effective portion, net	-44	-63	-25
Cross currency swap contracts [Member]	'	'	'
Effective portion of the unrealized gain (loss) recognized in Other Comprehensive Income for our derivative instruments designated as cash flow hedges contracts [Abstract]	'	'	'
Unrealized gain (loss) on derivative instruments recognized in Other Comprehensive Income, effective portion, net	132	85	-26
Forward interest rate contracts [Member]	'	'	'
Effective portion of the unrealized gain (loss) recognized in Other Comprehensive Income for our derivative instruments designated as cash flow hedges contracts [Abstract]	'	'	'
Unrealized gain (loss) on derivative instruments recognized in Other Comprehensive Income, effective portion, net	$0	($7)	$0

Recovered_Sheet1

Derivative instruments (Details 2) (USD $)	3 Months Ended								12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Location in the Consolidated Statements of Income and the effective portion of gain/(loss) reclassified from Accumulated Other Comprehensive Income into earnings for our derivative instruments designated as cash flow hedges contracts [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Product sales	$4,799	$4,647	$4,595	$4,151	$4,337	$4,201	$4,200	$3,901	$18,192	$16,639	$15,295
Derivatives in cash flow hedging relationships [Member]	'	'	'	'	'	'	'	'	'	'	'
Location in the Consolidated Statements of Income and the effective portion of gain/(loss) reclassified from Accumulated Other Comprehensive Income into earnings for our derivative instruments designated as cash flow hedges contracts [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Total	'	'	'	'	'	'	'	'	85	134	-112
Derivatives in cash flow hedging relationships [Member] | Foreign currency contracts [Member]	'	'	'	'	'	'	'	'	'	'	'
Location in the Consolidated Statements of Income and the effective portion of gain/(loss) reclassified from Accumulated Other Comprehensive Income into earnings for our derivative instruments designated as cash flow hedges contracts [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Product sales	'	'	'	'	'	'	'	'	4	74	-108
Derivatives in cash flow hedging relationships [Member] | Cross currency swap contracts [Member]	'	'	'	'	'	'	'	'	'	'	'
Location in the Consolidated Statements of Income and the effective portion of gain/(loss) reclassified from Accumulated Other Comprehensive Income into earnings for our derivative instruments designated as cash flow hedges contracts [Abstract]	'	'	'	'	'	'	'	'	'	'	'
The amount of gain (loss) recognized in interest and other income, net	'	'	'	'	'	'	'	'	82	61	-3
Derivatives in cash flow hedging relationships [Member] | Forward interest rate contracts [Member]	'	'	'	'	'	'	'	'	'	'	'
Location in the Consolidated Statements of Income and the effective portion of gain/(loss) reclassified from Accumulated Other Comprehensive Income into earnings for our derivative instruments designated as cash flow hedges contracts [Abstract]	'	'	'	'	'	'	'	'	'	'	'
The amount of gain (loss) recognized in interest expense, net	'	'	'	'	'	'	'	'	($1)	($1)	($1)

Recovered_Sheet2

Derivative instruments (Details 3) (Foreign currency contracts [Member], Interest and other income, net [Member], USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Foreign currency contracts [Member] | Interest and other income, net [Member]	'	'	'
Location in the Condensed Consolidated Statements of Income and the amount of gain (loss) recognized in earnings for our derivative instruments not designated as hedging instruments	'	'	'
Derivatives not designated as hedging instruments	$15	$19	($1)

Derivative_instruments_Details2

Derivative instruments (Details 4) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Millions, unless otherwise specified
Assets	'	'
Total derivative assets, fair value	$246	$111
Liabilities	'	'
Total derivative liabilities, fair value	272	65
Derivatives designated as hedging instrument [Member]	'	'
Assets	'	'
Total derivative assets, fair value	246	110
Liabilities	'	'
Total derivative liabilities, fair value	269	64
Derivatives not designated as hedging instrument [Member]	'	'
Assets	'	'
Total derivative assets, fair value	0	1
Liabilities	'	'
Total derivative liabilities, fair value	3	1
Cross currency swap contracts [Member] | Other current assets/Other noncurrent assets [Member] | Derivatives designated as hedging instrument [Member]	'	'
Assets	'	'
Total derivative assets, fair value	193	65
Cross currency swap contracts [Member] | Accrued liabilities/Other noncurrent liabilities [Member] | Derivatives designated as hedging instrument [Member]	'	'
Liabilities	'	'
Total derivative liabilities, fair value	4	6
Foreign currency contracts [Member] | Other current assets/Other noncurrent assets [Member] | Derivatives designated as hedging instrument [Member]	'	'
Assets	'	'
Total derivative assets, fair value	53	45
Foreign currency contracts [Member] | Other current assets [Member] | Derivatives not designated as hedging instrument [Member]	'	'
Assets	'	'
Total derivative assets, fair value	0	1
Foreign currency contracts [Member] | Accrued liabilities/Other noncurrent liabilities [Member] | Derivatives designated as hedging instrument [Member]	'	'
Liabilities	'	'
Total derivative liabilities, fair value	104	58
Foreign currency contracts [Member] | Accrued liabilities [Member] | Derivatives not designated as hedging instrument [Member]	'	'
Liabilities	'	'
Total derivative liabilities, fair value	3	1
Interest rate swap contracts [Member] | Other current assets/Other noncurrent assets [Member] | Derivatives designated as hedging instrument [Member]	'	'
Assets	'	'
Total derivative assets, fair value	0	'
Interest rate swap contracts [Member] | Accrued liabilities/Other noncurrent liabilities [Member] | Derivatives designated as hedging instrument [Member]	'	'
Liabilities	'	'
Total derivative liabilities, fair value	$161	'

Derivative_instruments_Details3

Derivative instruments (Details Textual) (USD $)

12 Months Ended

12 Months Ended

3 Months Ended

In Millions, unless otherwise specified

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2011

Jun. 30, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Interest expense, net [Member]

Interest expense, net [Member]

Interest expense, net [Member]

Foreign currency and cross currency swap contracts [Member]

Forward interest rate contracts [Member]

Interest rate swap [Member]

Interest rate swap [Member]

Interest rate swap [Member]

Rate adjustment to LIBOR on Interest Rate Swap Agreements [Member]

Rate adjustment to LIBOR on Interest Rate Swap Agreements [Member]

Net cash provided by operating activities [Member]

Derivatives designated as hedging instrument [Member]

Derivatives designated as hedging instrument [Member]

Derivatives designated as hedging instrument [Member]

Derivatives designated as hedging instrument [Member]

Derivatives designated as hedging instrument [Member]

Derivatives designated as hedging instrument [Member]

Derivatives designated as hedging instrument [Member]

Derivatives designated as hedging instrument [Member]

Derivatives not designated as hedging instrument [Member]

Derivatives not designated as hedging instrument [Member]

Derivatives not designated as hedging instrument [Member]

Foreign currency option contracts [Member]

Foreign currency option contracts [Member]

Foreign currency option contracts [Member]

Interest rate swap [Member]

Interest rate swap [Member]

Foreign currency forward contracts [Member]

Foreign currency forward contracts [Member]

Foreign currency forward contracts [Member]

Foreign currency forward contracts [Member]

Foreign currency forward contracts [Member]

Foreign currency forward contracts [Member]

Derivative instruments (Textual) [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Length of time hedged in foreign currency contracts

'3 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Notional amount

'

'

'

'

'

'

'

$4,400

$3,600

'

'

'

$516

$200

$292

$4,400

$3,600

$4,000

$3,700

$3,500

$999

$629

$389

Amounts expected to be reclassified from accumulated other comprehensive income into earnings over the next 12 months - gains on foreign currency and cross currency swap

'

'

'

'

-51

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amounts expected to be reclassified from accumulated other comprehensive income into earnings over the next 12 months - gain (loss)

'

'

'

'

'

-1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Derivative lower range variable interest rate

'

'

'

'

'

'

'

'

'

1.10%

0.30%

'

'

'

'

'

'

'

'

'

'

'

'

Derivative higher range variable interest rate

'

'

'

'

'

'

'

'

'

2.00%

2.60%

'

'

'

'

'

'

'

'

'

'

'

'

Receipt from counterparties upon termination of interest rate swap contracts

'

'

'

'

'

'

397

'

'

'

'

397

'

'

'

'

'

'

'

'

'

'

'

Unrealized gain (loss) on the hedged debt

'

161

-20

-182

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Offsetting unrealized gain (loss) on related interest rate swaps

'

($161)

$20

$182

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Contingencies_and_commitments_1

Contingencies and commitments (Details) (USD $)	Dec. 31, 2013
In Millions, unless otherwise specified
Minimum future rental commitments under non-cancelable operating leases	'
2014	$140
2015	125
2016	114
2017	95
2018	86
Thereafter	345
Total minimum operating lease commitments	$905

Contingencies_and_commitments_2

Contingencies and commitments (Details Textual) (USD $)	12 Months Ended								1 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Sep. 16, 2013	Sep. 16, 2013
				In re Amgen Inc. Securities Litigation [Member]	Larson v. Sharer, et al [Member]	Federal Derivative Litigation [Member]	Ramos v. Amgen Inc., et al. [Member]	Harris, et. al. v. Amgen Inc. [Member]	Onyx Pharmaceuticals, Inc. [Member]	Onyx Pharmaceuticals, Inc. [Member]
				complaints	complaints		defendants	plaintiffs	plaintiffs	Superior Court State of California [Member]
										plaintiffs
Loss Contingencies [Line Items]	'	'	'	'	'	'	'	'	'	'
Loss Contingency, Number of Plaintiffs	'	'	'	'	'	'	'	'	9	7
Number of stockholder complaints	'	'	'	6	3	'	'	'	'	'
Length of time Federal Derivative Litigation cases stayed after Amgen Inc. Securities Litigation	'	'	'	'	'	'30 days	'	'	'	'
Number of defendants	'	'	'	'	'	'	4	'	'	'
Number of plaintiffs	'	'	'	'	'	'	'	2	'	'
Future rental commitments for abandoned leases	$293	'	'	'	'	'	'	'	'	'
Rental expense on operating leases	$125	$117	$131	'	'	'	'	'	'	'

Segment_information_Details

Segment information (Details) (USD $)	3 Months Ended								12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Revenues [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Product sales	$4,799	$4,647	$4,595	$4,151	$4,337	$4,201	$4,200	$3,901	$18,192	$16,639	$15,295
Other revenues	'	'	'	'	'	'	'	'	484	626	287
Total revenues	'	'	'	'	'	'	'	'	18,676	17,265	15,582
Neulasta [Member]	'	'	'	'	'	'	'	'	'	'	'
Revenues [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Product sales	'	'	'	'	'	'	'	'	4,392	4,092	3,952
NEUPOGEN [Member]	'	'	'	'	'	'	'	'	'	'	'
Revenues [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Product sales	'	'	'	'	'	'	'	'	1,398	1,260	1,260
ENBREL [Member]	'	'	'	'	'	'	'	'	'	'	'
Revenues [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Product sales	'	'	'	'	'	'	'	'	4,551	4,236	3,701
Aranesp [Member]	'	'	'	'	'	'	'	'	'	'	'
Revenues [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Product sales	'	'	'	'	'	'	'	'	1,911	2,040	2,303
EPOGEN [Member]	'	'	'	'	'	'	'	'	'	'	'
Revenues [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Product sales	'	'	'	'	'	'	'	'	1,953	1,941	2,040
Sensipar Mimpara [Member]	'	'	'	'	'	'	'	'	'	'	'
Revenues [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Product sales	'	'	'	'	'	'	'	'	1,089	950	808
Vectibix [Member]	'	'	'	'	'	'	'	'	'	'	'
Revenues [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Product sales	'	'	'	'	'	'	'	'	389	359	322
Nplate [Member]	'	'	'	'	'	'	'	'	'	'	'
Revenues [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Product sales	'	'	'	'	'	'	'	'	427	368	297
XGEVA [Member]	'	'	'	'	'	'	'	'	'	'	'
Revenues [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Product sales	'	'	'	'	'	'	'	'	1,019	748	351
Prolia [Member]	'	'	'	'	'	'	'	'	'	'	'
Revenues [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Product sales	'	'	'	'	'	'	'	'	744	472	203
Kyprolis [Member]	'	'	'	'	'	'	'	'	'	'	'
Revenues [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Product sales	'	'	'	'	'	'	'	'	73	0	0
Other [Member]	'	'	'	'	'	'	'	'	'	'	'
Revenues [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Product sales	'	'	'	'	'	'	'	'	$246	$173	$58

Segment_information_Details_1

Segment information (Details 1) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Geographical Information With Respect To Revenues [Abstract]	'	'	'
Revenues	$18,676	$17,265	$15,582
United States [Member]	'	'	'
Geographical Information With Respect To Revenues [Abstract]	'	'	'
Revenues	14,480	13,415	11,985
Rest of the world (ROW) [Member]	'	'	'
Geographical Information With Respect To Revenues [Abstract]	'	'	'
Revenues	$4,196	$3,850	$3,597

Segment_information_Details_2

Segment information (Details 2) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Millions, unless otherwise specified
Long Lived Assets [Abstract]	'	'
Total long-lived assets	$5,349	$5,326
United States [Member]	'	'
Long Lived Assets [Abstract]	'	'
Total long-lived assets	2,772	2,906
Puerto Rico [Member]	'	'
Long Lived Assets [Abstract]	'	'
Total long-lived assets	1,822	1,908
Rest of the world (ROW) [Member]	'	'
Long Lived Assets [Abstract]	'	'
Total long-lived assets	$755	$512

Segment_information_Details_3

Segment information (Details 3) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Revenues Earned from Major Customers [Abstract]	'	'	'
Revenues	$18,676	$17,265	$15,582
AmerisourceBergen Corporation [Member]	'	'	'
Revenues Earned from Major Customers [Abstract]	'	'	'
Revenues	8,527	7,556	7,574
Gross product sales to major customer (as defined) as a percentage of total gross revenues	35.00%	34.00%	36.00%
Gross product sales to major customer (as defined) as a percentage of U.S. gross product sales	44.00%	43.00%	45.00%
McKesson Corporation [Member]	'	'	'
Revenues Earned from Major Customers [Abstract]	'	'	'
Revenues	6,440	5,898	4,591
Gross product sales to major customer (as defined) as a percentage of total gross revenues	27.00%	27.00%	22.00%
Gross product sales to major customer (as defined) as a percentage of U.S. gross product sales	32.00%	32.00%	27.00%
Cardinal Health, Inc. [Member]	'	'	'
Revenues Earned from Major Customers [Abstract]	'	'	'
Revenues	$3,209	$3,245	$3,021
Gross product sales to major customer (as defined) as a percentage of total gross revenues	13.00%	15.00%	14.00%
Gross product sales to major customer (as defined) as a percentage of U.S. gross product sales	17.00%	19.00%	18.00%

Segment_information_Details_Te

Segment information (Details Textual)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
	customer	customer	customer
	segment
Segment Reporting Information [Line Items]	'	'	'
Number of business segment	1	'	'
Number of major customers (as defined) accounting for more than 10% of total revenue	3	3	3
Threshold as a percentage of total revenues for determining a major customer for additional disclosures	10.00%	10.00%	10.00%
Percentage of worldwide gross revenues derived from major customers (as defined) on a combined basis	75.00%	'	'
Percentage of United States gross product sales derived from major customers (as defined) on a combined basis	93.00%	'	'
Major customers (as defined) accounting for more than 10% of gross trade receivables	3	3	'
Combined trade receivables for all major customers (as defined) as a percentage of net trade receivables	63.00%	61.00%	'
Percentage of net trade receivables due from customers located outside the United States, primarily in Europe	35.00%	36.00%	'
AmerisourceBergen Corporation [Member]	'	'	'
Segment Reporting Information [Line Items]	'	'	'
Amount due from major customer (as defined) as a percentage of gross trade receivables	'exceeded 10%	'exceeded 10%	'
McKesson Corporation [Member]	'	'	'
Segment Reporting Information [Line Items]	'	'	'
Amount due from major customer (as defined) as a percentage of gross trade receivables	'exceeded 10%	'exceeded 10%	'
Cardinal Health, Inc. [Member]	'	'	'
Segment Reporting Information [Line Items]	'	'	'
Amount due from major customer (as defined) as a percentage of gross trade receivables	'exceeded 10%	'exceeded 10%	'

Quarterly_financial_data_Detai

Quarterly financial data (Details) (USD $)	3 Months Ended												12 Months Ended
In Millions, except Per Share data, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012		Sep. 30, 2012		Jun. 30, 2012		Mar. 31, 2012		Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Quarterly Financial Information Disclosure [Abstract]	'	'	'	'	'		'		'		'		'	'	'
Product sales	$4,799	$4,647	$4,595	$4,151	$4,337		$4,201		$4,200		$3,901		$18,192	$16,639	$15,295
Gross profit from product sales	3,770	3,859	3,810	3,407	3,415	[1]	3,426	[1]	3,448	[1]	3,151	[1]	'	'	'
Net income	$1,021	$1,368	$1,258	$1,434	$788		$1,107		$1,266		$1,184		$5,081	$4,345	$3,683
Earnings per share:	'	'	'	'	'		'		'		'		'	'	'
Basic (in usd per share)	$1.35	$1.81	$1.67	$1.91	$1.03		$1.44		$1.63		$1.50		$6.75	$5.61	$4.07
Diluted (in usd per share)	$1.33	$1.79	$1.65	$1.88	$1.01		$1.41		$1.61		$1.48		$6.64	$5.52	$4.04
[1]	Includes the impact of prior-period amounts for amortization of certain acquired intangible assets that have been reclassified within Operating expenses in our Consolidated Statements of Income to conform to the current-period presentation.

SCHEDULE_II_VALUATION_AND_QUAL1

SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Allowance for doubtful accounts [Roll Forward]	'	'	'
Balance at beginning of period	$61	$54	$42
Additions charged to costs and expenses	5	7	17
Other additions	0	0	0
Deductions	7	0	5
Balance at end of period	$59	$61	$54